Multiple Sclerosis

On this page

Quick Reference

RxDrug of choiceHigh-efficacy anti-CD20 monoclonal antibody: ocrelizumab 600 mg IV every 24 weeks (300 mg day 0 and day 15 initially), ofatumumab 20 mg SC every 4 weeks, or ublituximab 450 mg IV every 24 weeks for active relapsing-remitting MS. Ocrelizumab is also approved for primary progressive MS. Tolebrutinib 60 mg once daily for nonrelapsing secondary progressive MS.

AltAlternativesNatalizumab 300 mg IV every 4 weeks (JCV serology required), cladribine 3.5 mg/kg oral cumulative over 2 years, alemtuzumab 12 mg IV induction (reserved for highly active RRMS after failure), fingolimod 0.5 mg daily, siponimod 2 mg daily (active SPMS), dimethyl fumarate 240 mg twice daily, teriflunomide 14 mg daily (moderate-efficacy for mild disease).

⊘AvoidNon-dihydropyridine calcium channel blockers (diltiazem, verapamil); atacicept (increases relapse rate); high-dose biotin (MD1003, failed phase 3); live-attenuated vaccines during immunosuppressive DMT; fingolimod, cladribine, and alemtuzumab in pregnancy (except special circumstances).

DxTest of choiceBrain MRI with 3D-FLAIR, pre- and post-gadolinium T1-weighted imaging, and T2* susceptibility sequences (SWI/T2*-GRE) to assess dissemination in space and time. Lumbar puncture for CSF oligoclonal bands or κ-free light chain index. Serum neurofilament light chain (sNfL) and glial fibrillary acidic protein (sGFAP) for prognosis and treatment stratification.

ScKey scoreExpanded Disability Status Scale (EDSS) for disability staging (0-10); No Evidence of Disease Activity-3 (NEDA-3) as treatment target (no relapses, no sustained progression, no new MRI lesions); Symbol Digit Modalities Test (SDMT) for cognitive screening; Multiple Sclerosis Functional Composite (MSFC) including Timed 25-Foot Walk, 9-Hole Peg Test, and PASAT.

→When to referRefer to MS specialist for diagnostic uncertainty (atypical presentation, inconclusive MRI/CSF), breakthrough disease on moderate-efficacy DMT requiring escalation, consideration of high-efficacy therapy in pregnancy/breastfeeding, aggressive MS variants (Marburg, tumefactive), evaluation for aHSCT, or when multidisciplinary rehabilitation needed for significant disability.

Multiple sclerosis is a treatable CNS demyelinating disease; early diagnosis using 2024 McDonald criteria and initiation of high-efficacy disease-modifying therapy (anti-CD20, cladribine, or natalizumab) in active relapsing disease reduces long-term disability. Acute relapses are managed with high-dose IV methylprednisolone 1 g daily × 3-5 days; steroid-refractory attacks require plasma exchange. For progressive MS, ocrelizumab (PPMS) and tolebrutinib (nonrelapsing SPMS) are evidence-based. Comprehensive care includes symptomatic therapy, rehabilitation, comorbidity management, and vaccination optimization.

Multiple sclerosis (MS) is a chronic immune-mediated demyelinating disease of the CNS, typically presenting in young adults with relapsing-remitting episodes. Early diagnosis using the 2024 McDonald criteria and prompt initiation of high-efficacy disease-modifying therapy are critical to prevent irreversible disability accumulation. Management includes acute attack abortion with high-dose corticosteroids, long-term immunotherapy tailored to disease activity, and comprehensive symptomatic and rehabilitative care. Key biomarkers such as serum neurofilament light chain and glial fibrillary acidic protein stratify risk and guide treatment intensity.

Overview and Recommendations

Background

•MS is a chronic immune-mediated demyelinating disease of the CNS with a global prevalence of 35.9 per 100,000 (2.8 million people), affecting young adults aged 18-40 years with a female-to-male ratio of 2.8:1. The clinical course is classified into relapsing-remitting MS (RRMS, ~85% at onset), secondary progressive MS (SPMS), primary progressive MS (PPMS), and clinically isolated syndrome (CIS). The 2024 McDonald criteria expanded diagnostic options by adding the optic nerve as a fifth anatomical region and incorporating biomarkers like the central vein sign, paramagnetic rim lesions, and CSF kappa free light chains, enabling earlier and more specific diagnosis.
•The paradigm of MS management has shifted from escalation therapy (starting with moderate-efficacy drugs) to early high-efficacy therapy (anti-CD20 antibodies, natalizumab, cladribine) based on evidence that early intensive treatment reduces long-term disability accrual. The concept of progression independent of relapse activity (PIRA) now dominates understanding of disability accumulation, accounting for 78-89% of confirmed disability worsening events in relapsing MS, driven by smoldering compartmentalized inflammation in chronic active lesions with microglial senescence and glymphatic failure.
•The immune pathogenesis involves peripheral dysregulation triggered by Epstein-Barr virus infection with molecular mimicry, followed by CNS-compartmentalized B-cell maturation and T-cell cooperation, leading to demyelination, neurodegeneration, and gray matter atrophy. Key effectors include autoantibodies against KIR4.1, complement activation, and activated microglia. Biomarkers such as serum neurofilament light chain (sNfL) and glial fibrillary acidic protein (sGFAP) stratify risk: patients with high levels of both have the highest risk of PIRA (HR 1.43) and benefit most from high-efficacy DMT.
•MS is one of the most common causes of neurological disability in young adults. Without treatment, the median time from diagnosis to needing a walking aid (EDSS 6) is approximately 18.5 years, but early high-efficacy therapy can reduce 10-year EDSS by 1 point or more. Modifiable risk factors include smoking, low vitamin D, and obesity; comorbidities (especially cardiometabolic) worsen outcomes. Vaccination is safe and recommended, with ECTRIMS/EAN 2023 consensus guidelines emphasizing optimization before immunosuppressive DMT.

Evaluation

•Suspect MS in any young-to-middle-aged adult (peak age 32) presenting with acute or subacute onset of a neurological deficit consistent with CNS demyelination: common presentations include optic neuritis (unilateral vision loss with painful eye movement), brainstem syndromes (diplopia, vertigo, internuclear ophthalmoplegia), transverse myelitis (symmetric or asymmetric weakness, sensory level, bladder dysfunction), or hemispheric syndromes. Also consider in patients with progressive neurologic decline without relapses (PPMS).
•Ask about prior episodes of similar deficits, even if completely resolved; symptoms of fatigue, depression, urinary urgency, or Lhermitte sign (electric shock on neck flexion) may precede diagnosis by years. Inquire about family history of autoimmune disease, EBV serostatus (especially infectious mononucleosis), smoking, and vitamin D exposure.
•Examine for pyramidal weakness (often asymmetric), spasticity, hyperreflexia, extensor plantar response, sensory loss with dorsal column involvement (vibration, proprioception), cerebellar signs (intention tremor, ataxic gait, dysarthria), and cranial nerve abnormalities including optic atrophy and internuclear ophthalmoplegia (INO). Assess for Lhermitte sign and Uhtoff phenomenon (worsening with heat).
•Order brain MRI with 3D-FLAIR, pre- and post-gadolinium T1-weighted images, and T2* susceptibility sequence (SWI/T2*-GRE) to assess for dissemination in space (DIS) and time (DIT). DIS requires T2-hyperintense lesions in at least two of four classic regions: periventricular, juxtacortical/cortical, infratentorial, spinal cord. The 2024 criteria add the optic nerve as a fifth region, assessable by fat-suppressed T2 MRI or optical coherence tomography (OCT) demonstrating ganglion cell-inner plexiform layer (GCIPL) thinning.
•DIT can be established by the simultaneous presence of gadolinium-enhancing and non-enhancing lesions on a single scan, or by a new T2 or gadolinium-enhancing lesion on follow-up MRI. The central vein sign (vein transecting ≥40% of lesions) and paramagnetic rim lesions (chronic active lesion marker) increase specificity for MS and are recommended when conventional findings are inconclusive.
•Perform lumbar puncture for CSF analysis when MRI is nondiagnostic or if atypical features appear. Test for CSF-specific oligoclonal bands (OCBs) by isoelectric focusing - present in >85% of MS. Alternatively, measure the κ-free light chain index (CSF κ-FLC/serum κ-FLC) with a cutoff of 6.1 (sensitivity 88%, specificity 89%), now accepted as a substitute for OCBs in the 2024 criteria. Also check CSF cell count (mild lymphocytic pleocytosis), protein, and IgG index.
•Obtain serum neurofilament light chain (sNfL) as a biomarker of neuroaxonal damage; levels correlate with gadolinium-enhancing lesions and predict future relapses and disability worsening (OR 2.41 for EDSS worsening when >97.5th percentile of healthy controls). Combined sNfL and sGFAP (glial fibrillary acidic protein) stratifies progression risk: high both indicates highest risk of PIRA (HR 1.43) and need for high-efficacy DMT; low both suggests a benign course.
•Apply the 2024 McDonald criteria: require demonstration of DIS and DIT, with no better explanation. In patients with a single clinical attack and DIS plus positive CSF (OCBs or κ-FLC), diagnosis can be made even without DIT. The criteria now allow diagnosis in radiologically isolated syndrome (RIS) if DIS plus DIT or positive CSF are met, enabling earlier detection.
•Also consider differential diagnoses: neuromyelitis optica spectrum disorder (NMOSD, test serum AQP4-IgG by cell-based assay), MOG antibody disease (MOG-IgG, titer ≥1:128), acute disseminated encephalomyelitis (ADEM with encephalopathy), progressive multifocal leukoencephalopathy (PML, CSF JC virus PCR), neurosarcoidosis (CSF cytokines, biopsy), Susac syndrome (triad of encephalopathy, hearing loss, retinopathy). Exclude cerebral small vessel disease/migraine and other mimics using clinical and imaging features (e.g., absence of central vein sign, lack of DIT).
•If initial workup is inconclusive, repeat MRI with contrast at 3-6 months, consider spinal cord MRI (cord lesions improve specificity), and refer to an MS specialist for additional testing such as visual evoked potentials (delayed P100 latency) or OCT with inter-eye GCIPL difference ≥4 μm. Evoked potentials and OCT can help confirm DIS when MRI is equivocal.

Management

•For acute relapse management, administer high-dose intravenous methylprednisolone 1 g daily for 3-5 days for moderate-to-severe attacks (motor, visual, brainstem, or coordination deficits that impair daily activities). An oral taper (prednisone 60 mg/day tapered over 2-4 weeks) is optional for incomplete responders. Monitor glucose, blood pressure, electrolytes, and neuropsychiatric effects (insomnia, mood changes).
•For steroid-refractory or fulminant attacks (severe myelitis, bilateral optic neuritis, brainstem compromise, or no improvement after 5-7 days of steroids), initiate plasma exchange (5-7 sessions over 10-14 days, 1-1.5 plasma volume per session) - early initiation (<20 days from symptom onset) improves likelihood of response. Plasma exchange is AAN Level B for steroid-resistant relapses.
•For aggressive MS variants (Marburg variant, tumefactive demyelination), escalate to cyclophosphamide 600-1000 mg/m² IV monthly or rituximab 1000 mg IV × 2 two weeks apart, in addition to corticosteroids and plasma exchange. For acute seizures in MS, treat the underlying attack with immunotherapy and start an antiseizure medication (e.g., levetiracetam) for symptomatic control.
•For long-term disease-modifying therapy (DMT), stratify risk at baseline using clinical relapse frequency, MRI activity (gadolinium-enhancing lesions, new/enlarging T2 lesions), and biomarkers (sNfL, sGFAP). The therapeutic goal is No Evidence of Disease Activity-3 (NEDA-3): no relapses, no sustained disability progression, and no new/enlarging T2 or gadolinium-enhancing lesions.
•Initiate early high-efficacy therapy in patients with active disease (frequent relapses, multiple MRI lesions, elevated sNfL): ocrelizumab 300 mg IV day 0 and day 15, then 600 mg IV every 24 weeks; ofatumumab 20 mg SC weeks 0, 1, 2, then every 4 weeks; or ublituximab 150 mg IV day 1 and day 15, then 450 mg IV every 24 weeks. Anti-CD20 therapies achieve low annualized relapse rates (0.02-0.08) and reduce disability progression.
•Alternative high-efficacy options include natalizumab 300 mg IV every 4 weeks (requires JC virus serology to stratify PML risk; extended-interval dosing 5-8 weeks considered), cladribine 3.5 mg/kg cumulative over 2 years (oral, 1.75 mg/kg per year in two courses), and alemtuzumab 12 mg IV daily for 5 days then 3 days at month 12 (reserved for highly active RRMS after failure of other therapies due to autoimmune adverse events including thyroid disease and immune thrombocytopenia).
•For nonrelapsing secondary progressive MS, initiate tolebrutinib 60 mg once daily (first therapy approved based on HERCULES trial: 22.6% vs 30.7% 6-month confirmed disability progression, HR 0.69). For SPMS with continued relapses, use anti-CD20 agents or siponimod 2 mg daily (after 5-day up-titration). No neuroprotective drug has demonstrated efficacy; do not use high-dose biotin (MD1003) or simvastatin for progression.
•For primary progressive MS, ocrelizumab 600 mg IV every 24 weeks is the only approved DMT - reduces 12-week confirmed disability progression by 24% (NNT=16). Provide comprehensive symptomatic management including spasticity (baclofen up to 80 mg/day, tizanidine, intrathecal baclofen for refractory cases), bladder dysfunction (botulinum toxin 200-300 U intradetrusor, clean intermittent catheterization), neuropathic pain (gabapentin 300-3600 mg/day, pregabalin 150-600 mg/day), and fatigue (modafinil 100-200 mg/day, cognitive behavioral therapy, aerobic exercise ≥150 min/week).
•Monitor DMT safety: for anti-CD20 agents, check baseline hepatitis B serology, VZV IgG, TB, immunoglobulins; monitor CBC and Ig levels every 3-6 months. For natalizumab, check JCV serology every 6 months if negative; if positive, consider switching after 24 months. For S1P modulators (fingolimod, siponimod), baseline ECG and first-dose cardiac monitoring; for teriflunomide, monthly LFTs and blood pressure; for dimethyl fumarate, monitor lymphocyte count (discontinue if <0.5 × 10⁹/L).
•Switch DMT if breakthrough disease occurs (relapse, new MRI lesion, or disability progression) despite adherence. Escalate to a high-efficacy agent with a different mechanism (e.g., from fumarate to anti-CD20). For failure of anti-CD20, consider cladribine or alemtuzumab. Refer to an MS specialist center for highly aggressive or treatment-refractory cases.
•Do not use non-dihydropyridine calcium channel blockers (diltiazem, verapamil) - they exacerbate fatigue and have negative inotropic effects. Do not use atacicept (increases relapse rate). Avoid high-dose biotin (MD1003) - phase 3 trial negative. Do not routinely discontinue DMT without shared decision-making: in patients ≥55 years with ≥5 years no activity, discontinuation carries a 7.5% absolute increase in recurrent disease activity over 2 years (DISCOMS); continue DMT unless risks outweigh benefits. For younger patients, the risk of rebound is higher (17.8% recurrence in DOT-MS).
•Refer for autologous hematopoietic stem cell transplantation (aHSCT) in selected patients <50 years with disease duration <10 years who have failed high-efficacy DMT and have aggressive disease; aHSCT achieves 69.6% activity-free survival at 3 years. National MS Society recommends aHSCT in this population.
•During pregnancy, discontinue high-risk DMTs: stop anti-CD20 3 months before conception; stop fingolimod, cladribine, alemtuzumab before pregnancy. Interferon beta and glatiramer acetate are considered safer. For highly active MS, continuing natalizumab into the third trimester may be considered with neonatal hematologic monitoring (thrombocytopenia, anemia). Resume DMT postpartum early to reduce relapse risk.
•Optimize vaccination status: administer inactivated vaccines (influenza, pneumococcal, Tdap, COVID-19) ≥4-6 weeks before starting immunosuppressive DMT. Live attenuated vaccines are contraindicated during therapy. Vaccination does not increase relapse risk (COVID-19 vaccine relapse rate 1.9% within 20 days). Screen for depression (PHQ-9), cognition (annual Symbol Digit Modalities Test), and osteoporosis (DXA scan if immobile or glucocorticoid exposure).

Board Review — High Yield

•Clinically Isolated Syndrome (CIS), First demyelinating event (optic neuritis, transverse myelitis, brainstem syndrome); 30-50% convert to clinically definite MS within 5 years; MRI lesions and CSF oligoclonal bands increase risk.
•McDonald Criteria 2024, Diagnosis requires dissemination in space (≥2 of 5 regions: periventricular, juxtacortical/cortical, infratentorial, spinal cord, optic nerve) and dissemination in time (simultaneous enhancing/non-enhancing lesions or new lesions on follow-up); optic nerve and CSF κ-free light chains added.
•Central Vein Sign (CVS), A vein coursing through ≥40% of white matter lesions on susceptibility-weighted MRI; highly specific for MS compared to mimics (small vessel disease, migraine).
•Progression Independent of Relapse Activity (PIRA), Dominant mechanism of disability worsening in RRMS (78-89% of confirmed disability accumulation); driven by smoldering inflammation; early PIRA predicts 26-fold higher risk of reaching EDSS 6.0.
•Early High-Efficacy Therapy, Starting anti-CD20 or natalizumab within 2 years of onset reduces 10-year EDSS by ~1 point compared with escalation; 5-year EDSS change 0.3 vs 1.2 (p=0.002).
•Serum Neurofilament Light Chain (sNfL), Biomarker of neuroaxonal damage; elevated in active MS; predicts future relapses and disability worsening (OR 2.41; higher risk if >97.5th percentile); combined with sGFAP stratifies PIRA risk.
•Ocrelizumab, First drug approved for both RRMS (ARR reduction 46-47%) and PPMS (ORATORIO: 24% reduction in 12-week confirmed disability progression; NNT=16).
•Tolebrutinib, First therapy to show benefit in nonrelapsing SPMS (HERCULES: HR 0.69 for 6-month confirmed disability progression); brain-penetrant BTK inhibitor; requires ALT monitoring.
•Pregnancy and DMT, Interferon beta and glatiramer acetate are safe; anti-CD20 stopped 3 months before conception; natalizumab continuation into third trimester may be considered with neonatal monitoring; postpartum relapse risk increases significantly.
•DMT Discontinuation Risks, Patients ≥55 years with ≥5 years stability: 12.2% vs 4.7% disease activity over 2 years (DISCOMS, noninferiority not met); discontinuation of natalizumab or fingolimod carries high rebound risk.

Deep Dive — Evidence Details

Definition, Classification & Nomenclature

▸MS is defined by dissemination of CNS lesions in space and time, with four primary clinical phenotypes: RRMS, SPMS, PPMS, and aggressive MS.
▸PIRA (progression independent of relapse activity) accounts for ≥50% of disability accrual in RRMS; a harmonized 12-month confirmed definition improves study comparability.
▸The 2024 McDonald criteria incorporate optic nerve as a fifth location and introduce central vein sign, paramagnetic rim lesions, and CSF κ-FLCs to enhance specificity.

HY High Yield: The 2024 McDonald criteria unify the diagnosis of RRMS and PPMS, eliminating the need for separate diagnostic algorithms. The optic nerve now counts as a fifth anatomical region for dissemination in space [12].

Multiple sclerosis (MS) is an autoimmune disease where the immune system attacks myelin, the insulating cover of nerve cells in the human body, causing damage to one's own central nervous system. It is a type of demyelin — Multiple sclerosis — Multiple sclerosis (MS) is an autoimmune disease where the immune system attacks myelin, the insulating cover of nerve cells in the human body, causin...Wikipedia ↗

Multiple sclerosis (MS) is a chronic immune-mediated inflammatory demyelinating disease of the central nervous system (CNS) characterized by dissemination of lesions in space and time, leading to heterogeneous neurological disability ^[21]^D5^[22]^D5.

Also Called / Synonyms: MS, disseminated sclerosis, encephalomyelitis disseminata (historical), relapsing-remitting MS (RRMS), secondary progressive MS (SPMS), primary progressive MS (PPMS), clinically isolated syndrome (CIS), radiologically isolated syndrome (RIS).

Disease Phases and Stages

The clinical course of MS is defined by distinct phases. Clinically isolated syndrome (CIS) represents the first episode of neurological symptoms suggestive of demyelination without meeting full dissemination in time criteria ^[12]^A1c. Radiologically isolated syndrome (RIS) describes individuals with incidentally identified MRI lesions typical of MS who have never experienced clinical symptoms; the 2024 McDonald criteria now allow RIS to fulfill the diagnosis in certain cases ^[12]^A1c^[29]^D5. Relapsing-remitting MS (RRMS) is characterized by acute relapses followed by partial or complete recovery. Progression independent of relapse activity (PIRA) is now recognized as the dominant contributor to disability accumulation in RRMS, accounting for at least 50% of all disability accrual events and occurring in approximately 5% of patients per year ^[8]^B2a^[18]^B2b. A harmonized definition of PIRA requires a significant disability worsening compared with a baseline (reset after each PIRA event, relapse, or EDSS improvement), in the absence of relapses, confirmed for at least 12 months ^[18]^B2b. Smouldering-associated worsening (SAW) is a broader conceptual framework capturing subtle physical and cognitive deterioration driven by chronic active lesions beyond relapse-related activity ^[34]^A1c.

Classification of MS Types

Type	Key distinguishing feature	Associated marker/subtype
Relapsing-remitting MS (RRMS)	Clear relapses with recovery, no progressive phase	~85% of cases at onset ^[21]^D5
Secondary progressive MS (SPMS)	Gradual disability accumulation after initial RRMS phase	Defined objectively by a 3-strata progression magnitude, confirmed at 3 months, with EDSS ≥4 and pyramidal score ≥2 ^[31]^B2b
Primary progressive MS (PPMS)	Progressive disability from onset without relapses	Can be diagnosed using unified criteria with RRMS dissemination in space criteria; optic nerve or ≥2 spinal cord lesions improve sensitivity ^[36]^B3b
Aggressive MS	Frequent, severe relapses with incomplete recovery early in disease	Narrow therapeutic window; high-efficacy therapy recommended from onset ^[42]^D5

Clinical Significance

MS is one of the most common causes of neurological disability in young adults aged 18-40 years, with a global prevalence that continues to rise ^[22]^D5. The 2024 McDonald criteria have expanded diagnostic options, including the optic nerve as a fifth anatomical location and novel biomarkers such as the central vein sign, paramagnetic rim lesions, and CSF kappa free light chains, enabling earlier and more specific diagnosis ^[12]^A1c^[16]^A1c^[41]^A1c.

Pearl: When evaluating a patient with suspected MS, remember that the 2024 McDonald criteria now allow diagnosis in RIS and older individuals (≥50 years) using the same unified framework, so do not dismiss asymptomatic MRI findings or age alone as exclusionary ^[12]^A1c.

Pathophysiology & Mechanism (Neuroanatomic Localization)

▸The MS pathogenic cascade progresses from EBV-triggered peripheral B- and T-cell dysregulation to intrathecal B-cell maturation, complement-mediated demyelination, and KIR4.1 autoantibody-driven injury.
▸Cortical demyelination, meningeal inflammation, and smoldering rims on microglial activation are present early and drive progression independent of relapse activity.
▸Glymphatic impairment, trans-synaptic degeneration, and accelerated cellular senescence represent converging mechanisms of irreversible neurodegeneration.

HY High Yield: Chronic active lesions, identified on MRI by a paramagnetic rim, are the imaging correlate of smoldering inflammation and predict disability worsening more reliably than gadolinium-enhancing lesions [37, 72].

The pathogenic cascade begins with peripheral immune dysregulation, centered on the interplay between genetic susceptibility and (EBV) infection, followed by CNS-compartmentalized inflammation that drives demyelination and neurodegeneration ^[64]^D5^[96]^B3b.

The Immune Cascade: From Periphery to CNS

Step 1 - Priming of autoreactive lymphocytes. EBV infection, likely a prerequisite for MS, triggers a humoral immune response against Epstein-Barr nuclear antigen 1 (EBNA-1) that cross-reacts with CNS antigens via molecular mimicry ^[64]^D5^[96]^B3b. The risk allele of a variant (encoding BAFF) escapes microRNA inhibition, producing higher levels of soluble BAFF that amplify B-cell survival and antibody production ^[57]^B3b. Mendelian randomization studies identify genetically determined increases in CSF (OR 5.03) and decreases in (OR 0.83) and (OR 0.42) as causal for MS risk ^[91]^B2b.

Step 2 - Intrathecal B-cell maturation and T-cell co-operation. Within the CNS, B cells differentiate into antibody-producing plasmablasts and plasma cells, supported by CD4+ T helper (Th1 and Th17) cells ^[78]^D5. The CD40-CD40L costimulatory pathway, targeted by frexalimab, regulates this adaptive response ^[49]^A1b. Oligoclonal bands in CSF reflect intrathecal IgG synthesis, a hallmark of MS.

Step 3 - Effector mechanisms of tissue injury. Autoantibodies against the potassium channel KIR4.1, found in 46.9% of patients, bind to the first extracellular loop of the channel on glial cells, activate complement, and disrupt KIR4.1 expression ^[59]^B3b. Complement activation and macrophage/microglial phagocytosis strip myelin. Matrix metalloprotease-9 (MMP-9) facilitates leukocyte infiltration and myelin breakdown, though MMP-9 deficiency paradoxically delays remyelination in murine models by altering microglial responses ^[115]^D5.

Neuroanatomic Localization of Injury

White matter lesions. Perivenular inflammatory demyelination preferentially involves periventricular, juxtacortical, infratentorial, and spinal cord regions. The serves as a gateway for immune cell entry; its volume increases early in disease and correlates with inflammatory activity ^[107]^D5. In progressive MS, chronic active lesions show a rim of activated microglia (paramagnetic rim lesions on MRI) that expand slowly over years, driving tissue loss ^[37]^B2b^[72]^D5.

Cortical demyelination. Inflammatory cortical demyelination occurs early - 38% of biopsied patients already had cortical lesions at diagnosis - and is topographically associated with meningeal inflammation ^[58]^C4. Subpial lesions are linked to B-cell-rich tertiary lymphoid follicles in the leptomeninges ^[82]^D5. imaging reveals that even non-enhancing white-matter lesions harbour a smoldering innate immune component that predicts cortical atrophy and disability progression over 2 years ^[37]^B2b^[97]^B2b.

Gray matter atrophy and trans-synaptic degeneration. Neuronal loss in the thalamus, cortex, and deep gray nuclei occurs from disease onset. Following acute , anterograde trans-synaptic degeneration accelerates atrophy of the occipital gray matter (-0.76%/year vs -0.22%/year) and thalamus, correlating with persistent visual dysfunction ^[101]^B2b. Cortical atrophy in MS maps to genes enriched in microglia, astrocytes, and oligodendrocytes, distinguishing it from ^[95]^B2b.

Glymphatic and vascular dysfunction. The glymphatic system, a perivascular waste clearance pathway, is impaired in MS: the diffusion along perivascular space index is reduced versus healthy controls (estimated mean difference -0.09, P=0.01) and declines further in progressive disease ^[93]^B2b. Lower values associate with higher lesion volume and gray matter atrophy. Cerebrovascular reactivity is diffusely decreased, suggesting a vascular component to neurodegeneration ^[79]^B3b.

Accelerated Aging and Cellular Senescence

A senescent cell burden accumulates in demyelinated lesions: p16+ and 53BP1+ cells are significantly more abundant in active white-matter and gray-matter lesions than in chronic inactive lesions, and higher senescent cell density correlates with faster disability progression and earlier death ^[100]^B3b. Biological aging - measured by DNA methylation clocks - is accelerated in MS beyond chronological age, potentially explaining the age-dependent shift from relapsing to progressive disease ^[104]^D5.

Pearl: The transition from relapsing to progressive MS reflects a shift from peripheral immune-driven focal inflammation to CNS-compartmentalized smoldering inflammation, microglial senescence, and glymphatic failure - mechanisms largely resistant to current B-cell-depleting therapies.

Epidemiology, Etiology & Risk Factors

▸Global MS prevalence is 2.8 million (35.9 per 100,000), with a 2.8:1 female predominance and a strong latitudinal gradient.
▸Age at immigration before 15 years modifies risk, indicating that childhood/adolescent environmental exposures are critical.

HY High Yield: Anti-EBNA IgG seropositivity carries the highest odds ratio (4.46) among all modifiable risk factors; consider EBV serology in atypical presentations.

From the neuroanatomic substrate of demyelination, the epidemiological profile of multiple sclerosis reveals a disease shaped by latitude, genetics, and modifiable exposures. An estimated 2.8 million people live with MS worldwide, a global prevalence of 35.9 per 100,000 and a pooled incidence of 2.1 per 100,000 persons per year ^[159]^C4. Prevalence follows a striking latitudinal gradient: highest in high-income North America (164.6 per 100,000), western Europe (127.0), and Australasia (91.1), and lowest in sub-Saharan Africa and Oceania (2.0-3.3 per 100,000) ^[137]^B2c. In the United States, the age-standardized prevalence is 309.2 per 100,000 (727,344 cases), with a female-to-male ratio of 2.8:1 and a persistent north-south gradient ^[142]^B2c. China, though low-risk (2.32 per 100,000), has seen its prevalent cases double since 1990 ^[141]^B2c. Mean age at diagnosis is 32 years ^[159]^C4. Age-standardized prevalence increased 10.4% globally from 1990 to 2016, while age-standardized death rates declined 11.5% ^[137]^B2c.

Established Risk Factors

Factor	Odds Ratio / Relative Risk	Evidence Level
HLA-DRB1*15:01 carrier	OR ~3.0	GWAS ^[133]^B3b
IL2RA / IL7RA risk alleles	OR ~1.2-1.3	GWAS ^[133]^B3b
Depression polygenic score (per SD)	OR 1.29-1.38 for comorbid depression	Cohort ^[7]^B2b
Low sun exposure / vitamin D insufficiency	HR ~1.5-2.0 (qualitative)	Cohort ^[173]^B2b
Obesity (adolescent BMI)	RR ~1.5-2.0	Review ^[21]^D5

Epstein-Barr virus stands as the strongest infectious risk factor: anti-EBNA-1 peptide IgG carries an OR of 3.13, with risk increasing monotonically with antibody titer ^[96]^B3b. Infectious mononucleosis in adolescence or young adulthood confers a 2.3-fold increased risk (95% CI 1.7-3.0) ^[10]^B2a. Smoking is consistently associated with a 52% increased odds ^[125]^B2a, and the effect is amplified in Black and Asian populations (OR 1.71-2.83) ^[157]^B3b. Vitamin D deficiency is supported by ecological and Mendelian randomization studies, yet high-dose supplementation after a clinically isolated syndrome did not reduce conversion to MS ^[126]^B2b, and neonatal vitamin D levels show no association ^[169]^B2b. Obesity in adolescence is a recognized risk factor, possibly acting through low-grade inflammation and altered vitamin D metabolism ^[21]^D5.

Genetic susceptibility is polygenic, with the HLA class II region (particularly DRB1*15:01) contributing the largest effect, followed by variants in IL2RA and IL7RA ^[133]^B3b. A monogenic rare disease variant mimicking MS is found in 2.86% of patients diagnosed with MS in the UK Biobank ^[132]^B2b. Depression polygenic burden increases relapse rate by 23% per standard deviation (IRR 1.23, 95% CI 1.01-1.50) ^[155]^B2b.

Negative and Protective Factors

Living within 50 m of a major road does not increase MS risk (HR 1.00) ^[128]^B2b. Chronic cerebrospinal is not a valid etiologic factor ^[129]^B3b. The pandemic, which sharply reduced respiratory infections, did not alter MS incidence, arguing against a dominant role for common viral triggers ^[151]^B2c. High ultraviolet radiation exposure in the year before or after diagnosis of radiologically isolated syndrome reduces the risk of symptom onset by approximately 48% (HR 0.52-0.54) ^[144]^B2b.

Special Populations

First-generation immigrants from low-risk areas who arrive before age 15 acquire 69% of the MS risk of the host population, whereas those arriving later retain the lower risk of their birthplace ^[130]^B2b. Pediatric-onset MS (before age 18) accounts for up to 5% of cases and is associated with a lower cumulative incidence of progression independent of relapse activity (PIRA) compared with adult-onset disease ^[145]^B2b. Pregnancy does not increase long-term disability, but the postpartum period carries a transiently elevated relapse risk, especially in women with pre-pregnancy disease activity ^[171]^B2b.

Pearl: The triad of EBV seropositivity, smoking, and low vitamin D exposure accounts for a substantial fraction of MS risk; smoking cessation and vitamin D optimization are actionable prevention strategies, though supplementation after symptom onset has not been shown to alter disease course ^[126]^B2b.

Clinical Presentation

▸The first demyelinating event (CIS) typically has acute/subacute onset over days to weeks, reaching a nadir at 2-4 weeks [138].
▸Optic neuritis is the most common CIS (57.7% in pediatric MS); fatigue is a frequent prodromal symptom [211, 207, 210].
▸Phenotypic variants include RRMS, SPMS, PPMS, and age-related presentations (pediatric: higher relapse rate; late-onset: more PPMS, faster disability) [178, 180, 200].
▸Red flags requiring urgent action include acute myelitis with respiratory compromise (FVC < 15 mL/kg), encephalopathy, and rapidly progressive course [71, 69, 182].

HY High Yield: In a patient with a first demyelinating event, the presence of CSF-specific oligoclonal bands satisfies dissemination in time per the 2017 McDonald criteria, enabling an MS diagnosis even without a clinical relapse [179].

Following the identification of risk factors, the clinical presentation of multiple sclerosis (MS) emerges as a heterogeneous syndrome defined by the first demyelinating event, a clinically isolated syndrome (CIS), typically with acute or subacute onset of neurological deficits that evolve over days to weeks, reaching a nadir at 2-4 weeks ^[138]^D5. The symptoms depend on the location of the demyelinating lesion within the central nervous system, and early recognition of these patterns is critical for timely diagnosis and initiation of disease-modifying therapy.

Presenting Symptoms

is the most common CIS, presenting with unilateral subacute vision loss (often over hours to days), pain on eye movement, and decreased color perception ^[138]^D5. In pediatric MS, optic neuritis occurs in 57.7% of first events ^[211]^B2b. Brainstem or cerebellar CIS manifests as diplopia, vertigo, ataxia, or facial numbness; spinal cord CIS ( ) causes symmetric or asymmetric weakness, sensory loss, and bladder/bowel dysfunction ^[138]^D5^[71]^D5. Fatigue is a prominent early symptom, reported in 28.9% of patients in the year before MS diagnosis, and may herald the disease by years ^[207]^B3b. A prodromal phase characterized by migraine, depression, urinary leakage, and declining physical activity has been identified up to 9-10 years before the first demyelinating event ^[210]^B2b.

Neurological Examination Findings

Motor system: Pyramidal weakness (often asymmetric), spasticity (especially in hip flexors and adductors), hyperreflexia, and extensor plantar responses (Babinski sign) are common ^[176]^A1c. In progressive forms, spastic paraparesis predominates ^[180]^D5. Sensory: Loss of vibration and proprioception in the lower extremities, Lhermitte sign (electric shock sensation on neck flexion), and a sensory level in myelitis. Reflexes: Exaggerated deep tendon reflexes, clonus, and Hoffman sign. Cranial nerves: Optic atrophy (pallor of the optic disc) after optic neuritis; internuclear ophthalmoplegia (INO) due to medial longitudinal fasciculus lesion; nystagmus; facial weakness (central or peripheral). Autonomic: Bladder dysfunction (urgency, frequency, retention), (21% of males in MOGAD, but also in MS) ^[192]^B2b, and occasionally orthostatic hypotension. Cerebellar: Intention tremor, dysmetria, ataxic gait, and dysarthria.

Phenotypic Variants

Variant	Key Features	Frequency
Relapsing-remitting MS (RRMS)	Acute exacerbations with partial or full recovery; stable between relapses	84-85% of initial cases ^[184]^D5
Secondary progressive MS (SPMS)	Initial RRMS followed by gradual worsening with or without relapses; median conversion time 28 years from onset ^[178]^B2b	50% of RRMS progress to SPMS by 15-20 years ^[138]^D5
Primary progressive MS (PPMS)	Steady progression from onset without relapses; older age at onset, lower sex ratio ^[180]^D5	10-15% of MS patients ^[180]^D5
Clinically isolated syndrome (CIS)	First monophasic episode (optic neuritis, brainstem, or spinal cord) without dissemination in time ^[138]^D5	30-50% convert to MS within 5 years
Pediatric-onset MS	Higher relapse frequency early; brainstem attacks portend worse disability; median time to secondary progression 28 years, but 10 years younger than adult-onset ^[178]^B2b^[184]^D5	2-10% of MS cases ^[186]^D5
Late-onset MS (≥50 years)	Higher proportion of PPMS, gait disability at onset, less inflammatory MRI activity, but faster disability accrual ^[200]^B2b	9.4% of MS cases ^[200]^B2b

Red Flags

Certain symptoms require urgent evaluation: acute myelitis with respiratory compromise (FVC < 15 mL/kg suggests need for intubation) ^[71]^D5; brainstem syndrome with dysphagia or dysarthria; severe bilateral optic neuritis (may indicate neuromyelitis optica spectrum disorder rather than MS) ^[185]^C4; rapidly progressive course over weeks (consider tumefactive demyelination, progressive multifocal leukoencephalopathy, or other mimics) ^[182]^B3b^[69]^D5. Encephalopathy (confusion, seizures) is atypical for MS and should raise suspicion for acute disseminated encephalomyelitis (ADEM) or ^[67]^D5^[199]^C4. Seizures occur in a minority of MS patients (2-5%) but can be the presenting symptom ^[146]^D5^[89]^D5.

Atypical Presentations

Movement disorders (chorea, hemiballismus), neuropsychiatric symptoms (depression, mania, psychosis), and cognitive impairment (especially processing speed and memory) may occur, particularly in progressive disease ^[195]^B2b^[202]^B2b. Rarely, patients present with a tumor-like (tumefactive) demyelinating lesion, which can mimic brain tumor on MRI ^[182]^B3b. Genetic disorders such as adult polyglucosan body disease (GBE1 mutations) can present with relapsing-remitting episodes and white matter lesions, simulating MS ^[11]^C4. The combination of clinical features, MRI findings, and CSF oligoclonal bands (present in 93% of MS vs 5% in MOGAD) is essential for accurate diagnosis ^[182]^B3b^[179]^A1c.

These clinical patterns, when integrated with MRI and laboratory findings, guide the application of the McDonald diagnostic criteria (see Diagnosis & Workup).

Pearl: In a patient presenting with a first demyelinating event, the presence of CSF-specific oligoclonal bands allows a diagnosis of MS if dissemination in space is demonstrated on MRI, even without clinical dissemination in time ^[179]^A1c.

Diagnosis & Workup (Neuroimaging, CSF, Evoked Potentials)

▸The 2024 McDonald criteria add the optic nerve as a fifth CNS location for DIS and accept κ‑FLC as an alternative to oligoclonal bands.
▸Central vein sign and paramagnetic rim lesions on susceptibility‑weighted MRI increase specificity for MS vs. mimics.
▸OCT measurement of GCIPL thinning can now fulfill optic nerve DIS criteria, improving early diagnosis.

Dx Diagnostic Essentials: McDonald criteria (2024 revision), the gold standard for MS diagnosis, integrating clinical attacks, MRI DIS/DIT, CSF findings, and optic nerve assessment [12].

HY High Yield: Central vein sign (≥40% of lesions) and paramagnetic rim lesions on susceptibility‑weighted MRI are highly specific for MS and can help differentiate from NMOSD, MOGAD, and small vessel disease [16,30,238].

Confirming the diagnosis requires integration of clinical, imaging, and laboratory findings through the McDonald criteria, most recently updated in 2024 ^[12]^A1c. The 2024 revisions expand the role of the optic nerve as a fifth anatomic location, allow the central vein sign (CVS) and paramagnetic rim lesions (PRLs) on susceptibility‐sensitive MRI to support specificity, and recognize κ‑free light chains (κ‑FLC) in CSF as an alternative to oligoclonal bands for demonstrating intrathecal IgG synthesis ^[12]^A1c^[16]^A1c. The diagnosis rests on dissemination in space (DIS) and dissemination in time (DIT) of CNS demyelinating lesions, with no better explanation for the clinical presentation ^[179]^A1c.

MRI Protocol and Lesion Criteria

Brain MRI is the single most sensitive paraclinical test. The core sequence is 3D‐FLAIR, supplemented by pre‑ and post‑gadolinium T1‐weighted imaging, and a T2* susceptibility sequence (SWI or T2*‐GRE) to evaluate CVS and PRLs ^[15]^A1c^[16]^A1c. Spinal cord MRI is recommended in all patients at baseline because cord lesions increase diagnostic specificity ^[15]^A1c^[16]^A1c.

DIS is fulfilled when T2‑hyperintense lesions are present in at least two of four classic CNS regions: periventricular, juxtacortical/cortical, infratentorial, and spinal cord ^[179]^A1c. The 2024 criteria add the optic nerve as a fifth region; a symptomatic optic nerve lesion on fat‑suppressed T2‐weighted MRI or optical coherence tomography (OCT) evidence of ganglion cell-inner plexiform layer (GCIPL) thinning can now satisfy DIS ^[12]^A1c^[16]^A1c. DIT can be demonstrated by the simultaneous presence of gadolinium‑enhancing and non‑enhancing lesions on a single scan, or by a new T2 or gadolinium‑enhancing lesion on follow‑up MRI ^[179]^A1c.

CVS, a vein coursing through the center of a lesion, visible on T2* or FLAIR*, is present in ≥40% of lesions in MS but rarely in mimics ^[16]^A1c^[30]^D5. PRLs, a hypointense rim on susceptibility‐weighted images, mark chronic active lesions and correlate with more aggressive disease ^[238]^B2b. The 2024 criteria recommend using CVS and PRLs when conventional MRI findings are insufficient to confirm the diagnosis ^[12]^A1c.

Cerebrospinal Fluid Analysis

Lumbar puncture is performed when the clinical and MRI picture is not classic, or when alternative diagnoses are suspected. The gold standard for intrathecal IgG synthesis remains CSF‑restricted oligoclonal bands (OCBs), present in >85% of patients with MS ^[179]^A1c^[232]^A1a. OCBs are detected by isoelectric focusing and immunofixation; they are not specific for MS but are absent in most healthy individuals and many mimics ^[179]^A1c.

κ‑Free light chains (κ‑FLC) in CSF, measured as a κ‑FLC index (CSF κ‑FLC / serum κ‑FLC), have a weighted diagnostic sensitivity of 88% and specificity of 89%, comparable to OCBs (85% and 92%) ^[232]^A1a. A κ‑FLC index cutoff of 6.1 is recommended ^[232]^A1a. The 2024 McDonald criteria accept κ‑FLC as an alternative to OCBs for establishing DIT or DIS ^[12]^A1c^[41]^A1c.

Serum neurofilament light chain (sNfL) is a sensitive biomarker of neuroaxonal damage. Levels are elevated in active MS, correlate with gadolinium‑enhancing lesions (β = 1.461, p = 0.005), and predict future relapses and disability worsening (OR = 2.41 for EDSS worsening at 97.5th percentile) ^[152]^B2b. sNfL is not yet incorporated into diagnostic criteria because of overlap with other neurologic conditions, but it aids in monitoring disease activity and treatment response ^[34]^A1c^[152]^B2b.

Evoked Potentials and Optical Coherence Tomography

Visual evoked potentials (VEPs) detect delayed P100 latency, indicating demyelination of the anterior visual pathway even without a history of . VEPs can support DIS when MRI is equivocal ^[236]^B2b.

Optical coherence tomography (OCT) measures retinal layer thickness. In MS, the peripapillary retinal nerve fiber layer (RNFL) is thinned by a mean of -7.41 μm (95% CI -8.98 to -5.83) in eyes without optic neuritis and -20.10 μm (95% CI -22.76 to -17.44) after optic neuritis compared with controls ^[228]^A1a. The GCIPL complex shows even greater atrophy: -6.31 μm (95% CI -7.75 to -4.87) in non‑optic neuritis eyes ^[228]^A1a. An inter‑eye difference in GCIPL thickness ≥4 μm has a sensitivity of 52% and specificity of 83% for diagnosing MS in community settings ^[149]^B2c. The 2024 criteria accept OCT evidence of GCIPL thinning to fulfill optic nerve DIS ^[12]^A1c^[16]^A1c.

Diagnostic Algorithm

Step 1, Clinical presentation: Identify a typical clinically isolated syndrome (optic neuritis, brainstem syndrome, myelitis, or hemispheric syndrome) or progressive neurologic decline consistent with MS ^[12]^A1c^[179]^A1c.
Step 2, MRI brain and spinal cord: Assess for DIS and DIT using standard sequences. If DIS is not met, add optic nerve MRI or OCT ^[16]^A1c.
Step 3, CSF analysis: If MRI criteria are not fully met, or if DIT is not demonstrated, perform lumbar puncture for OCBs or κ‑FLC. Positive result allows diagnosis in patients with a single clinical attack and DIS ^[179]^A1c.
Step 4, Alternative diagnoses: Exclude mimics (see Table) using serologic testing for AQP4‑IgG, MOG‑IgG, and other relevant biomarkers ^[1]^A1c^[13]^A1c^[234]^A1c.
Step 5, Confirmatory features: CVS, PRLs, or sustained sNfL elevation can increase confidence in borderline cases ^[12]^A1c^[34]^A1c.

Differential Diagnosis

Condition	Key distinguishing features	Diagnostic test
Neuromyelitis optica spectrum disorder (NMOSD)	Longitudinally extensive (≥3 vertebral segments), area postrema syndrome, bilateral optic neuritis; MRI shows periaqueductal, hypothalamic lesions ^[1]^A1c^[256]^D5	Serum AQP4‑IgG (cell‑based assay) ^[1]^A1c
MOG antibody‑associated disease (MOGAD)	Acute disseminated encephalomyelitis (ADEM)‑like presentation, conus medullaris myelitis, optic neuritis with optic nerve swelling; MRI shows ill‑defined, fluffy lesions ^[13]^A1c^[182]^B3b	Serum MOG‑IgG (cell‑based assay, titer ≥1:128) ^[13]^A1c^[245]^B2b
Acute disseminated encephalomyelitis (ADEM)	Acute encephalopathy, multifocal deficits, preceding infection/vaccination; MRI shows bilateral asymmetric white matter lesions, often involving thalami and basal ganglia ^[67]^D5	Clinical diagnosis; CSF rarely shows OCBs ^[67]^D5
Progressive multifocal leukoencephalopathy (PML)	Subacute progressive neurologic deficits in immunocompromised patients; MRI shows large confluent subcortical lesions without enhancement ^[69]^D5	CSF JC virus DNA PCR ^[69]^D5
Cerebral small vessel disease / migraine	Deep white matter hyperintensities with basilar predominance, lacunar infarcts, microbleeds; periventricular and juxtacortical lesions are less specific ^[83]^B2b^[234]^A1c	Clinical history, absence of CVS, lack of DIT
Sarcoidosis ( )	Leptomeningeal enhancement, , hypothalamic involvement; CSF shows elevated IL‑2, IL‑6, CXCL9, CXCL10 ^[250]^B3b	Biopsy, serum ACE/lysozyme, CSF cytokine panel ^[250]^B3b
Susac syndrome	Triad of encephalopathy, hearing loss, retinal arteriolar occlusions; MRI shows callosal “snowball” lesions ^[234]^A1c	Fluorescein angiography, audiometry

Pearl: The 2024 McDonald criteria now permit diagnosis of MS in patients with radiologically isolated syndrome (RIS) if they meet DIS plus DIT or positive CSF, and they allow the optic nerve as a fifth DIS region, making early diagnosis more feasible while maintaining specificity ^[12]^A1c^[16]^A1c.

Controversies and Guideline Disagreement

The 2024 McDonald criteria have not yet been endorsed by all national regulatory agencies; some clinicians continue to rely on the 2017 criteria for clinical trials and insurance approvals. The role of sNfL and quantitative MRI metrics (e.g., brain atrophy) remains investigational for diagnosis, though they are increasingly used in prognosis ^[12]^A1c^[34]^A1c^[247]^D5.

Severity, Staging & Risk Stratification

▸PIRA accounts for 78-89% of confirmed disability accumulation in relapsing MS and is the dominant driver of long-term worsening, even in patients without apparent relapse activity.
▸Serum NfL and GFAP at disease onset stratify patients into distinct risk groups: low-risk patients may be candidates for escalation therapy, while high-risk patients require immediate high-efficacy DMTs.
▸EDSS remains the standard for staging disability but misses cognitive and upper-limb dysfunction; composite measures (MSFC, NEDA-3) are superior for trial endpoints and treatment monitoring.

Dx Diagnostic Essentials: The EDSS is the gold standard for disability staging but underestimates cognitive impairment; always supplement with MSFC and cognitive screening.

HY High Yield: PIRA is the dominant driver of disability accumulation even in relapsing MS. Early PIRA (within 5 years) carries a 26-fold increased risk of reaching EDSS 6.0.

A diagnosis of multiple sclerosis must be immediately followed by a formal severity assessment using validated scales that guide treatment intensity and prognosis. The Expanded Disability Status Scale (EDSS) remains the gold standard for staging disability, scored from 0 (normal) to 10 (death due to MS). A score of 4.0 marks the onset of significant gait limitation, 6.0 requires a unilateral walking aid, and 6.5 requires bilateral support ^[90]^B2b^[120]^A1b. However, EDSS is heavily weighted toward ambulation and underestimates cognitive impairment, upper-limb dysfunction, and fatigue. The Multiple Sclerosis Functional Composite (MSFC), which includes the Timed 25-Foot Walk (T25FW), 9-Hole Peg Test (9HPT), and Paced Auditory Serial Addition Test (PASAT), captures these domains and is the primary outcome in many modern trials ^[48]^A1b^[276]^A1b. A clinically meaningful improvement in T25FW is defined as a ≥20% increase in walking speed sustained over 12 weeks ^[276]^A1b.

Progression Independent of Relapse Activity (PIRA)

The concept of PIRA has revolutionized risk stratification. In pooled OPERA I/II data, 78-89% of confirmed disability accumulation (CDA) events were attributable to PIRA, not relapse-associated worsening (RAW) ^[272]^B2b. PIRA begins early in relapsing-remitting MS and is the dominant driver of long-term disability ^[90]^B2b^[283]^B2b. Standardized definitions require a significant EDSS worsening (e.g., ≥1.0 point if baseline EDSS <5.5) confirmed at ≥12 months, with no relapse within 90 days before or 30 days after the worsening event ^[18]^B2b. Patients who develop PIRA within the first 5 years of disease have a 26-fold greater risk of reaching EDSS 6.0 compared with those without early PIRA ^[283]^B2b.

Serum Biomarkers: sNfL and sGFAP

Serum neurofilament light chain (sNfL) is a sensitive marker of neuroaxonal damage. Levels are elevated in active MS, correlate with gadolinium-enhancing lesions, and predict future relapses and disability worsening (OR 2.41 for EDSS worsening when sNfL >97.5th percentile of healthy controls) ^[152]^B2b. Serum glial fibrillary acidic protein (sGFAP) reflects astrocytic injury and is more specific for progressive disease. At disease onset, patients with high sNfL and high sGFAP have the highest risk of PIRA (HR 1.43) and reaching EDSS 3.0 (HR 1.55); only high-efficacy DMTs (e.g., , ) mitigate these risks, whereas injectable or oral platform therapies do not ^[286]^B2b. Conversely, patients with low sNfL and low sGFAP have a very low risk of progression and may be candidates for escalation strategies ^[286]^B2b.

Imaging and Genetic Risk Factors

MRI measures of disease activity, T1 gadolinium-enhancing lesions, new/enlarging T2 lesions, and brain volume loss, are independent predictors of future disability ^[48]^A1b^[90]^B2b. The DTI-ALPS index, a noninvasive measure of glymphatic function, is significantly lower in patients with higher disability (EDSS ≥6.0) and correlates with brain atrophy and lesion load ^[291]^B3b. Genetic risk scores, including the MS severity variant rs10191329, are emerging but not yet incorporated into routine clinical practice ^[280]^D5.

Composite Stratification and Treatment Thresholds

A pragmatic approach divides patients into low-risk (low sNfL/sGFAP, no recent relapses, minimal MRI activity) and high-risk (high sNfL/sGFAP, early PIRA, frequent relapses, high lesion burden). The presence of ≥3 comorbidities, especially cardiometabolic conditions, further increases the hazard of evidence of disease activity (aHR 1.14) ^[239]^B2b. Early intensive therapy (EIT) with high-efficacy DMTs (e.g., ocrelizumab, , ) is associated with better long-term disability outcomes compared with escalation from moderate-efficacy agents (mean 5-year EDSS change 0.3 vs. 1.2; p=0.002) ^[282]^B2b. The No Evidence of Disease Activity-3 (NEDA-3) criterion, absence of relapses, 24-week CDA, and new MRI lesions, is a stringent treatment target achieved in 66.4% of early-stage RRMS patients treated with ocrelizumab at 4 years ^[6]^C4.

Table: Risk Stratification at Disease Onset

Risk Category	sNfL/sGFAP	Clinical Features	Recommended Strategy
Low	Both low	Low relapse rate, minimal MRI lesions	Escalation from moderate-efficacy DMT
Intermediate	High sNfL only	Recent relapses, active MRI	High-efficacy DMT
High	High sNfL + high sGFAP	Early PIRA, age >40, oligoclonal bands	Immediate high-efficacy DMT (e.g., ocrelizumab)

Pearl: The combination of sNfL and sGFAP at disease onset identifies patients with a markedly elevated risk of PIRA and disability progression; only high-efficacy DMTs mitigate this risk, supporting early intensive therapy in this subgroup ^[286]^B2b.

Acute Management: Neurologic Emergencies & Attack Abortion

▸Distinguish true relapse from pseudorelapse (e.g., UTI) before initiating immunotherapy.
▸High-dose IV methylprednisolone (1 g/day × 3-5 days) is the cornerstone of acute attack abortion.
▸Plasma exchange is second-line for steroid-refractory or severe fulminant attacks; avoid it in chronic progressive MS.

! Warning: Do not use plasma exchange for chronic progressive multiple sclerosis, it is established as ineffective (Level A) [308].

Once severity and risk are stratified, the immediate priority shifts to halting acute inflammation and stabilizing neurologic function. Acute relapse is a two-track engine: abort the current attack with anti-inflammatory therapy, then transition to long-term prophylaxis (covered in Section 9).

Step 1: Triage and Classification of the Acute Event

Distinguish a true relapse from a pseudorelapse, the most common mimic is a urinary tract infection, which should be screened with urinalysis and culture only if symptoms (fever, dysuria, change in neurologic status) are present ^[44]^D5. does not warrant treatment outside the context of an acute relapse ^[44]^D5. Classify severity:

Mild - purely sensory symptoms, no functional limitation; may be managed with oral corticosteroids or observation.
Moderate - motor, visual, or coordination deficits that impair daily activities; requires hospital-based therapy.
Severe - disabling motor weakness, brainstem syndromes, acute with cord compression, rapidly progressive deficits (Marburg variant, tumefactive demyelination, status epilepticus) ^[147]^D5^[301]^D5^[325]^C4; these warrant ICU admission.

Step 2: First-Line Attack Abortion, High-Dose Corticosteroids

Administer high-dose intravenous 1 g daily for 3-5 days ^[302]^A1c^[314]^A1c. This regimen accelerates clinical recovery, though it does not alter long-term disability accumulation. An oral taper (e.g., 60 mg/day tapered over 2-4 weeks) is optional and often reserved for incomplete responders. Monitor glucose, blood pressure, electrolytes, and neuropsychiatric effects (insomnia, mood changes).

Step 3: Second-Line Therapy, Plasma Exchange for Severe or Steroid-Refractory Attacks

When deficits do not improve after 5-7 days of corticosteroids, or when the presenting attack is devastating (complete myelitis, bilateral , brainstem involvement), initiate plasma exchange (5-7 sessions, 1-1.5 plasma volume per session over 10-14 days). The American Academy of Neurology rates plasma exchange as probably effective (Level B) for steroid-resistant exacerbations in relapsing MS and possibly effective (Level C) for acute fulminant CNS demyelinating disease ^[308]^A1c. Early initiation (<20 days from symptom onset) improves the likelihood of response. Monitor calcium, coagulation, and immunoglobulin levels during treatment.

Step 4: Escalation for Aggressive and Atypical Syndromes

For Marburg variant MS (fulminant, rapidly progressive), steroids ± plasma exchange are often inadequate; the best available evidence suggests adding or mitoxantrone (dual B- and T-cell cytotoxicity) and, in contemporary practice, a B-cell-depleting agent such as ^[325]^C4. For acute transverse myelitis with severe deficits, follow the same steroid-first strategy, then escalate to plasma exchange if no improvement ^[71]^D5^[309]^B2b. For acute seizures in the setting of demyelination, treat the underlying attack with immunotherapy (corticosteroids) and start an antiseizure medication (e.g., ) for symptomatic control ^[147]^D5. Takotsubo cardiomyopathy - acute left ventricular hypokinesis triggered by a brainstem relapse - resolves with corticosteroid treatment of the underlying MS attack ^[251]^C4.

Step 5: Transition to Maintenance Therapy

Once the acute event has stabilized (typically within 1-2 weeks), reassess clinical status and initiate or optimize disease-modifying therapy to prevent future relapses (see Section 9). For patients on anti-CD20 therapies (ocrelizumab, rituximab), note that humoral vaccine responses are attenuated; plan immunizations before starting B-cell depletion ^[319]^B2b.

Drug / Modality	Indication	Regimen	Evidence Level	Key Outcome
IV methylprednisolone	All moderate-severe relapses	1 g/day × 3-5 days	Guideline consensus ^[302]^A1c^[314]^A1c	Accelerates recovery
Plasma exchange	Steroid-refractory; severe fulminant	5-7 sessions	AAN Level B ^[308]^A1c	Improvement in ~50% of steroid-refractory cases
Cyclophosphamide	Marburg variant	600-1000 mg/m² IV monthly	Case series ^[325]^C4	Frequent improvement when combined with steroids
Rituximab	Refractory RRMS with breakthrough activity	1000 mg IV × 2, 2 weeks apart	Observational ^[321]^B2b	Reduced annualized relapse rate from 0.8 to 0.18

What NOT to Do

Do not treat asymptomatic bacteriuria in the setting of a relapse ^[44]^D5.
Do not use plasma exchange for chronic progressive MS - it is established as ineffective (Level A) ^[308]^A1c.
Do not delay corticosteroids for fear of side effects; the benefit of early attack abortion outweighs risks.

Controversies and Guideline Disagreement

Question	Position A	Position B	Strength	Implication
Oral vs. IV corticosteroids for mild relapses	Some experts advocate high-dose oral therapy	Standard practice is IV for moderate-severe attacks	Mild	For pure sensory relapses without disability, oral prednisone (e.g., 1250 mg × 1) is a reasonable alternative.
Role of IVIG in acute MS	AAN: insufficient evidence ^[308]^A1c	Case series in pediatric/atypical neuroinflammation suggest benefit ^[70]^D5	Moderate	Reserve IVIG for patients with contraindications to steroids or plasma exchange (e.g., pregnancy).

Pearl: Initiate high-dose IV methylprednisolone within days of relapse onset; escalate to plasma exchange if no improvement by day 5-7 or for severe motor/brainstem deficits - early plasma exchange (<20 days) maximizes recovery. ^[308]^A1c^[302]^A1c

Acute Treatment Options for MS Relapses

Drug / Modality	Indication	Regimen	Evidence Level	Key Outcome
IV methylprednisolone	All moderate-severe relapses	1 g/day × 3-5 days	Guideline consensus ^[302]^A1c^[314]^A1c	Accelerates clinical recovery
Plasma exchange	Steroid-refractory; severe fulminant	5-7 sessions over 10-14 days	AAN Level B (steroid-refractory) ^[308]^A1c	Improvement in ~50% of steroid-refractory cases
Cyclophosphamide	Marburg variant, aggressive MS	600-1000 mg/m² IV monthly	Case series ^[325]^C4	Frequent improvement when combined with corticosteroids
Rituximab	Refractory RRMS with breakthrough disease	1000 mg IV × 2, 2 weeks apart	Observational ^[321]^B2b	Reduced annualized relapse rate from 0.8 to 0.18

Long-term & Definitive Management (Evidence Ladder)

▸Early high-efficacy therapy reduces 5-year EDSS worsening by 0.85 points vs escalation (Harding 2019) [282].
▸Ocrelizumab is the only approved therapy for PPMS, reducing 12-week CDP by 24% (ORATORIO) [216]; tolebrutinib reduces 6-month CDP by 31% in nonrelapsing SPMS [331].
▸DMT discontinuation increases risk of inflammatory activity in stable patients >55 years (DISCOMS, DOT-MS) [335][222]; anti-CD20 may be safer to stop than natalizumab or fingolimod [240].

Rx Drug of Choice: For active RRMS, first-line high-efficacy DMT: ocrelizumab 600 mg IV every 24 weeks (ENSEMBLE ARR 0.020) [6] or ofatumumab 20 mg SC every 4 weeks (ARR reduction 50% vs teriflunomide) [358]. For nonrelapsing SPMS, tolebrutinib 60 mg once daily (HERCULES HR 0.69 for 6-month CDP) [331]. For PPMS, ocrelizumab 600 mg IV every 24 weeks (ORATORIO HR 0.76 for 12-week CDP) [216].

Having addressed acute attacks, the central decision for long-term is selecting a disease-modifying therapy (DMT) that matches the patient's disease activity, subtype, and prognosis. The evidence ladder ascends from moderate-efficacy oral agents (dimethyl fumarate, teriflunomide) to high-efficacy parenteral therapies (anti-CD20 monoclonal antibodies, cladribine, alemtuzumab, natalizumab) and, in selected aggressive cases, autologous haematopoietic stem cell transplantation (aHSCT). The guiding principle: early control of inflammation prevents irreversible disability accrual.

Step 1: Risk Stratification and Treatment Goal

Classify disease activity at baseline using clinical relapses and MRI (new T2 lesions, gadolinium-enhancing lesions). The goal is no evidence of disease activity (NEDA-3): no relapses, no sustained disability progression, and no new/enlarging T2 or gadolinium-enhancing lesions. Patients with high relapse frequency, multiple enhancing lesions, or early disability progression (Expanded Disability Status Scale [EDSS] score rapidly rising) warrant high-efficacy therapy from onset. The hazard of all-cause disability worsening increases by 31-48% in a year following a relapse compared with a year without (p<0.001) ^[90]^B2b.

Step 2: First-Line DMT Selection - Early High-Efficacy vs Escalation

Real-world cohort data from 592 patients show that an early intensive treatment (EIT) strategy, compared with escalation from moderate-efficacy DMT, yields a lower 5-year EDSS change (0.3 vs 1.2, adjusted β -0.85, 95% CI -1.38 to -0.32; p=0.002) ^[282]^B2b. Among escalation patients who later switched to high-efficacy DMT, 60% had already developed sustained disability while on the initial moderate-efficacy agent ^[282]^B2b. The DELIVER-MS pragmatic trial (816 patients) confirms that treatment-naive patients more often choose EIT (67%) than escalation, driven by higher education and relapse rate ^[377]^A1b. In the ULTIMATE I/II pooled analysis, ublituximab versus teriflunomide in treatment-naive patients reduced annualized relapse rate (ARR) from 0.188 to 0.081 (p<0.001) ^[375]^B2b.

First-line moderate-efficacy options (for mild disease, low lesion burden):

Teriflunomide 14 mg once daily - In TEMSO (1088 patients), ARR 0.37 vs placebo 0.54 (relative risk reduction 31.5%; p<0.001); 12-week confirmed disability progression (CDP) reduced at 14 mg only (20.2% vs 27.3%; p=0.03) ^[120]^A1b. TOWER confirmed these findings: ARR 0.32 vs 0.50; HR for disability 0.68 (95% CI 0.47-1.00; p=0.044) ^[341]^A1b.

First-line high-efficacy options (for active disease, poor prognostic features):

Ofatumumab 20 mg subcutaneously every 4 weeks - In the ASCLEPIOS I/II recently diagnosed treatment-naive (RDTN) subgroup (n=615), ARR reduction was 50% vs teriflunomide (rate ratio 0.50, 95% CI 0.33-0.74; p<0.001); 6-month CDP delayed by 46% (HR 0.54, 95% CI 0.30-0.98; p=0.044) ^[358]^B2b. Efficacy was consistent across non-Hispanic Black, Asian, Hispanic/Latino, and White subgroups ^[5]^B2b.
Ublituximab 450 mg IV every 24 weeks - In the ULTIMATE I/II open-label extension (5 years), ARR in the ublituximab-continuous group fell to 0.020 (year 5); 24-week CDP was 8.0% vs 14.3% for those who switched from teriflunomide (p=0.01) ^[123]^B2b.

Drug	Starting dose	Target / maintenance dose	Key trial	ARR vs comparator	NNT for relapse prevention (from trial data)
Ocrelizumab	300 mg IV, then 300 mg IV day 15	600 mg IV every 24 weeks ^[6]^C4	ENSEMBLE, OPERA I/II	0.020 at 4 years ^[6]^C4	NNT not calculable from reported data; absolute ARR 0.02 suggests very low number
Ofatumumab	20 mg SC week 0, 1, 2, then every 4 weeks	20 mg SC every 4 weeks ^[358]^B2b	ASCLEPIOS I/II	0.50 rate ratio vs teriflunomide ^[358]^B2b	NNT not provided; in RDTN subgroup, ARR 0.15 vs 0.29 (approximate)
Ublituximab	150 mg IV day 1, then 150 mg IV day 15	450 mg IV every 24 weeks ^[123]^B2b	ULTIMATE I/II	0.081 vs 0.188 in treatment-naive ^[375]^B2b	NNT = 10 (calculated from ARR difference in treatment-naive)
Teriflunomide	7 mg or 14 mg oral daily	14 mg daily ^[120]^A1b	TEMSO, TOWER	0.37 vs 0.54 ^[120]^A1b; 0.32 vs 0.50 ^[341]^A1b	NNT for 1 year ARR reduction ~11 (from absolute difference 0.13-0.18)
Dimethyl fumarate	120 mg twice daily for 7 days	240 mg twice daily ^[354]^A1b	ARISE (RIS), DEFINE/CONFIRM	In RIS: HR 0.18 ^[354]^A1b	NNT = 5 to prevent first clinical event over 96 weeks (from event rates 4.5% vs 22.5%)
Cladribine	1.75 mg/kg orally over 4-5 days (two courses year 1, two courses year 2)	3.5 mg/kg cumulative per year ^[219]^A1b	CLARITY	0.14 vs 0.33 (p<0.001) ^[219]^A1b	NNT = 6 (from relapse rate difference 0.19 events/year)
Fingolimod	0.5 mg oral once daily	0.5 mg daily ^[333]^A1b	FREEDOMS, TRANSFORMS	0.18 vs 0.40 (placebo) ^[333]^A1b; 0.16 vs 0.33 (IFN) ^[332]^A1b	NNT = 5 (from 24-month relapse rate 17.3% vs 38.5% ^[333]^A1b)
Ozanimod	0.5 mg once daily for 1 month up-titration	1.0 mg daily ^[338]^A1b	SUNBEAM, RADIANCE	0.18 vs 0.35 (IFN), rate ratio 0.52 ^[340]^A1b	NNT = 8 (from ARR difference 0.17 events/year)
Ponesimod	2 mg once daily up-titration over 14 days	20 mg daily ^[122]^A1b	OPTIMUM	0.202 vs 0.290 (teriflunomide), rate reduction 30.5% ^[122]^A1b	NNT = 12 (from ARR difference 0.088 events/year)

Step 3: Selecting Therapy by MS Subtype

Relapsing-remitting MS (RRMS): Any of the above high-efficacy agents can be used first-line. Alemtuzumab (12 mg IV daily for 5 days, then for 3 days at 12 months) is reserved for patients with highly active RRMS who have failed other therapies. In CARE-MS II, alemtuzumab reduced ARR by 49.4% vs interferon beta-1a (rate ratio 0.51, 95% CI 0.39-0.65; p<0.0001) and 6-month CDP by 42% (HR 0.58) ^[346]^A1b. However, autoimmune adverse events (thyroid 16%, immune thrombocytopenia 1%) require rigorous monitoring ^[353]^C4. Natalizumab (300 mg IV every 4 weeks; biosimilar PB006 confirmed equivalent ^[343]^A1b) is also highly effective but carries progressive multifocal leukoencephalopathy risk; JC virus antibody index must be checked. Cladribine (3.5 mg/kg cumulative over 2 years) reduces ARR by 58% vs placebo (0.14 vs 0.33, p<0.001) ^[219]^A1b; its CSF effects show reduced switched memory B cells and emergence of CD4 Tregs ^[380]^C4.

Secondary progressive MS (SPMS): For nonrelapsing SPMS (no recent relapses but ongoing disability progression), tolebrutinib (60 mg once daily) is the first therapy shown to reduce 6-month CDP (22.6% vs 30.7%; HR 0.69, 95% CI 0.55-0.88; p=0.003) (HERCULES trial, 1131 participants) ^[331]^A1b. For SPMS with continued clinical or MRI activity, high-efficacy DMTs approved for RRMS (especially anti-CD20 agents) remain appropriate. No neuroprotective drug has yet demonstrated efficacy in SPMS: in MS-SMART, amiloride, , and riluzole all failed to reduce brain volume loss ^[339]^A1b. 80 mg daily did not meet its primary endpoint in MS-STAT2 (35.9% vs with progression; negative) ^[285]^A1b. High-dose biotin (MD1003 100 mg three times daily) also failed (12% vs 9% improvement; not significant) ^[337]^A1b.

Primary progressive MS (PPMS): Ocrelizumab 600 mg IV every 24 weeks is the only approved DMT. In ORATORIO (732 patients), 12-week CDP was 32.9% vs 39.3% (HR 0.76, 95% CI 0.59-0.98; p=0.03); 24-week CDP was 29.6% vs 35.7% (HR 0.75, 95% CI 0.58-0.98; p=0.04) ^[216]^A1b. Timed 25-foot walk worsened by 38.9% vs 55.1% (p=0.04); brain volume loss was 0.90% vs 1.09% (p=0.02) ^[216]^A1b.

Step 4: Monitoring, Switching, and Treatment Failure

Assess NEDA-3 at 6-12 months. Breakthrough disease (≥1 relapse, new T2/ gadolinium-enhancing lesions, or confirmed disability progression) while on therapy signals treatment failure. When switching from one high-efficacy agent to another, consider the therapeutic lag: relapses plateau at 12-30 weeks after starting; disability progression stabilizes at 30-70 weeks ^[381]^B2b. For patients switching from natalizumab or fingolimod to avoid rebound, bridging with short-term pulse steroids or overlapping with a B-cell-depleting agent is sometimes used (though no controlled trial data in provided references).

Treatment failure protocol:

Confirm adherence (≥80% of doses taken; for IV agents, ensure no missed infusions).
Repeat MRI (brain ± spine) to assess subclinical activity.
For moderate-efficacy DMT failure → escalate to high-efficacy anti-CD20, cladribine, alemtuzumab, or natalizumab.
For high-efficacy DMT failure → switch to a different class (e.g., from anti-CD20 to cladribine or alemtuzumab; or from S1P modulator to anti-CD20).
For highly aggressive, treatment-refractory RRMS, consider aHSCT. A phase 2 trial showed activity-free survival of 69.6% at 3 years, no relapses up to 13 years, and 35% sustained EDSS improvement ^[225]^C4. The National MS Society recommends aHSCT for patients <50 years with disease duration <10 years who have failed high-efficacy DMT ^[369]^A1c.

Step 5: Discontinuation of DMT in Older, Stable Patients

The decision to stop therapy must balance diminishing inflammatory activity with age and the risk of rebound. The DISCOMS trial (259 patients ≥55 years, no relapse in 5 years, no new MRI in 3 years) failed to demonstrate non-inferiority of discontinuation: new disease events occurred in 12.2% of discontinuers vs 4.7% of continuers (difference 7.5%, 95% CI 0.6-15.0; outside the 8% non-inferiority margin) ^[335]^A1b. The extension (up to 40 months) showed no relapses but few new MRI lesions (1/30 continuers, 2/44 discontinuers) ^[359]^B2b. In the DOT-MS trial (median age 54, stable >5 years on first-line DMT), discontinuation led to inflammatory activity in 17.8% vs 0% (p<0.001), resulting in early termination ^[222]^A1b. For high-efficacy therapies (anti-CD20, natalizumab, fingolimod) in patients ≥50 years with nonactive MS, stopping anti-CD20 agents did not increase relapse risk (HR 1.1, 95% CI 0.3-4.8), whereas stopping natalizumab or fingolimod did (HR 7.2 and 4.5, respectively) ^[240]^B2b. Clinical practice: Consider discontinuation only in patients ≥55 years with long-term stability (≥5 years no activity) and on lower-efficacy DMT; anti-CD20 therapy may be continued longer.

Symptomatic and Adjunctive Therapies

Walking impairment: Dalfampridine extended-release (10 mg twice daily) improves walking speed; the proportion of timed walk responders was 42.9% vs 9.3% (p<0.0001), with a 24.7% average improvement in responders ^[357]^A1b. Fatigue: Cognitive behavioural therapy (CBT), modafinil, and their combination all produce clinically meaningful reductions (MFIS change -15 to -17 points at 12 weeks) with no difference between arms (N=336) ^[269]^A1b. Vitamin D supplementation: A network meta-analysis of 32 RCTs (2254 patients) shows that vitamin D reduces relapse risk (RR 0.80) and improves EDSS (MD -0.22) when used adjunctively; high-dose long-duration (≥6 months) was most effective for disability (MD -0.28, 95% CI -0.54 to -0.03) ^[371]^A1a. Resistance training: Programs exceeding 20 sessions improve walking speed, endurance, and quality of life (18 RCTs pooled) ^[372]^A1a. Depression: Tailored CBT for newly diagnosed patients with mild-moderate depression reduced BDI-II scores; primary endpoint (≥10-point reduction at 8 weeks) significantly favored CBT over supportive listening ^[379]^A1b.

Controversies and Guideline Disagreement

Question	Position A	Position B	Strength of disagreement	Implication for practice
First-line treatment strategy: early high-efficacy vs escalation	Real-world cohort data (Harding 2019, ^[282]^B2b) and DELIVER-MS (^[377]^A1b) support early high-efficacy for better 5-year disability outcomes.	AAN 2018 guidelines (^[368]^D5) find insufficient evidence to mandate a specific starting therapy; most recommendations are level B (should).	Moderate (observational vs consensus-based)	Many centres now adopt high-efficacy first-line for active RRMS ^[282]^B2b; escalation remains common in mild disease but may miss the window to prevent disability.
DMT discontinuation in older stable patients	DISCOMS (^[335]^A1b, ^[359]^B2b) and DOT-MS (^[222]^A1b) show increased (mostly MRI) activity with discontinuation.	Observational data (^[240]^B2b) suggest that discontinuing anti-CD20 therapy in patients ≥50 may be safe (HR 1.1, 95% CI 0.3-4.8).	Strong (trial vs observational)	Do not discontinue natalizumab, fingolimod, or lower-efficacy DMTs without careful MRI monitoring; anti-CD20 may be an exception, pending more data.

What NOT to do: Avoid agents that worsen MS. Atacicept, a B-cell function suppressor, increased relapse rate (-0.98 vs 0.38; trial terminated early) ^[336]^A1b. Do not use B-cell-depleting therapy without baseline immunoglobulin levels and monitoring for hypogammaglobulinemia; is associated with higher hospitalization and hypogammaglobulinemia risk than ocrelizumab (HR 2.72-4.79) ^[386]^B2b. Do not use high-dose biotin (MD1003) - phase 3 trial negative ^[337]^A1b.

Pearl: Choose high-efficacy DMT (anti-CD20, cladribine, alemtuzumab) first-line in active RRMS to maximize NEDA and delay disability; for nonrelapsing SPMS, tolebrutinib is now the first FDA-approved option (HR 0.69 for 6-month CDP) ^[331]^A1b.

History and Evolution of Treatment

▸The standard of care evolved from interferon/glatiramer (30% ARR reduction) to anti-CD20 therapies (ARR reduction 46-47%) and CNS-penetrant agents targeting progressive disease.
▸Ocrelizumab is the only DMT approved for both relapsing and primary progressive MS; tolebrutinib is the first to show benefit in nonrelapsing secondary progressive MS.
▸Discontinuation trials (DISCOMS, DOT-MS) show that DMT cessation carries a measurable risk of inflammatory rebound, even in older, stable patients.

HY High Yield: PIRA (progression independent of relapse activity) accounts for 78-89% of confirmed disability accumulation in relapsing MS, underscoring the need for therapies that target compartmentalized CNS inflammation [272].

The preceding sections outline the current evidence ladder for disease-modifying therapy (DMT) selection. Understanding how these standards emerged, and which earlier approaches were abandoned, grounds contemporary decision-making in four decades of clinical trials.

The Pre-DMT Era and Natural History

Before any approved therapies, long-term natural history studies documented a relentless trajectory: by 15 years from onset, 50% of patients required a cane to walk (Expanded Disability Status Scale [EDSS] 6.0) ^[416]^D5. Relapses contributed to short-term disability but were increasingly dissociated from long-term progression. In modern cohorts, relapse-independent worsening (termed "silent progression" or PIRA, progression independent of relapse activity) accounted for 78-89% of confirmed disability accumulation in the pooled OPERA I/II trials ^[272]^B2b^[287]^B2b. This dissociation shaped the recognition that effective therapy must suppress both relapses and the smoldering compartmentalized inflammation driving progression.

First Generation: Interferons and Glatiramer Acetate (1990s)

The first DMTs, interferon beta-1a, interferon beta-1b, and glatiramer acetate, reduced annualized relapse rates (ARR) by approximately 30% versus placebo but had modest or no effect on disability progression ^[393]^D5. These agents established the feasibility of immunomodulation in multiple sclerosis (MS) but left substantial residual disease activity, driving the search for more potent therapies.

Second Generation: Natalizumab, Oral Therapies, and Induction (2000s)

Natalizumab, an α4-integrin antagonist, redefined expectations: in the AFFIRM trial it reduced ARR by 68% and lowered the 2-year risk of sustained disability progression by 42% (HR 0.58) ^[218]^A1b. However, progressive multifocal leukoencephalopathy (PML) emerged in patients with John Cunningham virus (JCV) antibodies, mandating risk stratification algorithms ^[411]^D5.

Oral therapies followed. Cladribine tablets (CLARITY) achieved an ARR of 0.14 vs 0.33 with placebo and reduced 3-month disability progression risk by 33% (HR 0.67) ^[219]^A1b; lymphopenia and required monitoring. Teriflunomide and dimethyl fumarate offered moderate efficacy with better safety; notably, both were later tested in radiologically isolated syndrome (RIS), where teriflunomide delayed first clinical events by 63% (HR 0.37) and dimethyl fumarate by 82% (HR 0.18) ^[221]^A1b^[354]^A1b.

Third Generation: Anti-CD20 Therapies (2010s)

The recognition that B cells play a central role ^[50]^A1b culminated in anti-CD20 monoclonal antibodies. Ocrelizumab, in the OPERA I/II trials, reduced ARR by 46-47% versus interferon beta-1a and lowered 12-week confirmed disability progression by 40% (HR 0.60) in relapsing MS ^[48]^A1b. For primary progressive MS (PPMS), the ORATORIO trial demonstrated a 24% reduction in 12-week confirmed disability progression (32.9% vs 39.3%; HR 0.76), the first drug approved for PPMS ^[216]^A1b. The absolute risk reduction was, yielding a number needed to treat (NNT) of 16 to prevent one progression event. Long-term follow-up showed that 78.7% of patients remained free of 24-week disability progression over 9 years ^[4]^B2b. Ofatumumab, a subcutaneous anti-CD20 antibody (ASCLEPIOS I/II), also proved superior to teriflunomide (ARR 0.11 vs 0.22; HR for 3-month disability worsening 0.66; NNT = 24) ^[215]^A1b. Ublituximab (ULTIMATE I/II) showed similar ARR reductions but did not significantly reduce disability worsening ^[217]^A1b.

-to-head, was noninferior to ocrelizumab for MRI lesion suppression (92.2% vs 94.8% probability of no new/enlarging T2 lesions) in the phase 3 OVERLORD-MS trial ^[119]^A1b. However, real-world comparative data from MSBase suggested a higher relapse rate with rituximab (ARR 0.20 vs 0.09; rate ratio 1.8) ^[237]^B2b.

Targeting Progressive MS: Siponimod, Tolebrutinib, and Failed Candidates

Siponimod, a selective sphingosine-1-phosphate receptor modulator, was the first therapy to show benefit in active secondary progressive MS (SPMS) in the EXPAND trial: 3-month confirmed disability progression occurred in 26% vs 32% (; relative risk reduction 21%) ^[273]^A1b. It also reduced the risk of requiring a wheelchair (sustained EDSS ≥7.0) by 40% ^[428]^B2b.

Tolebrutinib, a brain-penetrant Bruton's tyrosine kinase (BTK) inhibitor, demonstrated the first positive trial in nonrelapsing SPMS (HERCULES): 22.6% vs 30.7% had 6-month confirmed disability progression (HR 0.69; NNT = 12) ^[331]^A1b. However, the GEMINI trials in relapsing MS showed tolebrutinib was not superior to teriflunomide for ARR ^[394]^A1b, and evobrutinib similarly failed to improve ARR versus teriflunomide in two phase 3 trials ^[2]^A1b.

Other agents did not succeed. Fingolimod failed to slow disability progression in PPMS (INFORMS) ^[226]^A1b. , despite promising phase 2 results, did not reduce 6-month confirmed disability progression in SPMS (MS-STAT2: adjusted HR 1.13) ^[224]^A1b. Intravenous immunoglobulin showed no benefit in SPMS ^[399]^A1b, and mitoxantrone, while effective, was abandoned due to cardiotoxicity ^[398]^A1b.

Emerging and Investigational Therapies

Frexalimab, a second-generation anti-CD40L antibody, reduced new gadolinium-enhancing T1 lesions at 12 weeks by 89% (rate ratio 0.11) in a phase 2 trial ^[49]^A1b. Fenebrutinib, a reversible BTK inhibitor, achieved a 69% relative reduction in new T1 gadolinium-enhancing lesions in a phase 2 study ^[267]^A1b. Remyelination remains a frontier: clemastine fumarate shortened P100 visual evoked potential latency by 1.7 ms/eye in the ReBUILD trial, the first demonstration of pharmacological remyelination in chronic demyelinating injury ^[223]^A1b.

Lessons on De-escalation and Personalization

Two discontinuation trials clarified when DMTs can be safely stopped. The DISCOMS trial, enrolling patients ≥55 years with no recent disease activity, found a 7.5% absolute increase in new events with discontinuation (noninferiority not met) ^[335]^A1b. The DOT-MS trial, in younger patients (median age 54) on first-line DMTs, was stopped early because 17.8% of the discontinuation group developed inflammatory activity versus 0% in the continuation group ^[222]^A1b. These data support maintaining DMT in most patients but inform shared decision-making in older, stable individuals.

Pearl: The evolution from moderate-efficacy platform therapies to highly effective B-cell depletion and CNS-penetrant BTK inhibition reflects the growing recognition that suppressing both relapses and relapse-independent progression (PIRA) is essential. Ocrelizumab remains the only agent approved for both relapsing and primary progressive MS (NNT for preventing CDP in PPMS = 16), while tolebrutinib has emerged as the first to slow disability in nonrelapsing SPMS (NNT = 12). The failure of BTK inhibitors in relapsing MS and the positive signals in progressive phenotypes underscore that efficacy must be matched to the compartment (peripheral vs central) of inflammation.

Landmark Trials Shaping MS Therapy

Trial (Year)	Drug	Population	Primary Endpoint	Key Result	NNT
AFFIRM (2006) ^[218]^A1b	Natalizumab	Relapsing MS	1-year ARR, 2-year CDP	ARR reduction 68%; CDP HR 0.58	~7 for CDP
OPERA I/II (2016) ^[48]^A1b	Ocrelizumab	Relapsing MS	ARR over 96 weeks	ARR 0.16 vs 0.29 (46% reduction); CDP HR 0.60	22 for 12-week CDP
ORATORIO (2016) ^[216]^A1b	Ocrelizumab	PPMS	12-week CDP	CDP 32.9% vs 39.3%; HR 0.76	16 for 12-week CDP
HERCULES (2025) ^[331]^A1b	Tolebrutinib	Nonrelapsing SPMS	6-month CDP	CDP 22.6% vs 30.7%; HR 0.69	12 for 6-month CDP
ASCLEPIOS I/II (2020) ^[215]^A1b	Ofatumumab	Relapsing MS	ARR	ARR 0.11 vs 0.22; 3-month CDW HR 0.66	24 for 3-month CDW
CLARITY (2010) ^[219]^A1b	Cladribine	Relapsing MS	ARR at 96 weeks	ARR 0.14 vs 0.33; CDP HR 0.67	5.3 for relapse-free
ULTIMATE I/II (2022) ^[217]^A1b	Ublituximab	Relapsing MS	ARR	ARR 0.08 vs 0.19; CDW HR 0.84	Not significant for CDW
GEMINI 1/2 (2025) ^[394]^A1b	Tolebrutinib	Relapsing MS	ARR	ARR 0.13 vs 0.12 (NS)	-
TERIS (2023) ^[221]^A1b	Teriflunomide	RIS	Time to first clinical event	HR 0.37	~3 for delaying conversion
ARISE (2023) ^[354]^A1b	Dimethyl fumarate	RIS	Time to first clinical event	HR 0.18	~4 for delaying conversion

Disease-Modifying & Immunotherapy Program: Sequencing, Safety Monitoring & De-escalation

▸Early initiation of high-efficacy disease-modifying therapy within 2 years of disease onset reduces long-term disability accrual compared with escalation strategies (MSBase/Swedish registry, MS-STAT2).
▸Safety monitoring is drug-specific: anti-JCV antibody testing every 6 months for natalizumab, hepatitis B screening for anti-CD20 therapies, and liver function tests for tolebrutinib and teriflunomide.
▸De-escalation or discontinuation of DMT can be considered in patients aged ≥55 years with no relapse or MRI activity for ≥5 years, but carries a 7.5-17.8% risk of recurrent inflammatory activity over 2 years (DISCOMS, DOT-MS).

Rx Drug of Choice: For patients with highly active relapsing-remitting MS, early high-efficacy therapy with ocrelizumab (600 mg IV every 6 months), natalizumab (300 mg IV every 4 weeks; extended-interval dosing every 5-8 weeks if JCV seropositive), or alemtuzumab (12 mg/day IV for 5 days at baseline, then 3 days at 12 months) is recommended based on Level 1b evidence [4, 265, 346].

! Warning: Do not discontinue natalizumab abruptly in JCV-seropositive patients without a washout plan; PML can occur up to 6 months after discontinuation, often with immune reconstitution inflammatory syndrome (IRIS) [454]. Extended-interval dosing (every 5-8 weeks) may reduce PML risk but carries a higher risk of gadolinium-enhancing lesions [168].

The expanding therapeutic armamentarium has shifted the central clinical question from which drug to start to how to sequence, monitor, and de-escalate therapy over a patient's lifetime. The AAN 2018 practice guideline emphasizes individualized decision-making, integrating patient engagement, comorbidity assessment, and adherence monitoring ^[435]^A1c. The ECTRIMS/EAN 2018 guideline similarly endorses a shared decision framework ^[457]^A1c.

Step 1: Initial Treatment Selection, Early High-Efficacy vs Escalation

Population-based cohort studies consistently favor early high-efficacy therapy (HET) over escalation. A retrospective analysis of the MSBase and Swedish registries found that starting HET ( , ocrelizumab, mitoxantrone, alemtuzumab, or natalizumab) within 2 years of disease onset reduced mean EDSS at 6-10 years by 0.98 points (95% CI -1.51 to -0.45) compared with starting 4-6 years after onset ^[438]^B2b (2b). Another population-based study (n=592) reported a 5-year EDSS change of 0.3 with early intensive therapy vs 1.2 with escalation (β=-0.85; P=0.002) ^[282]^B2b (2b). A Danish-Swedish comparison (n=4861) showed that the Swedish strategy of more frequent HET initiation was associated with a 29% reduction in 24-week confirmed disability worsening (HR 0.71; 95% CI 0.57-0.90) ^[446]^B2b (2b). In the OPERA open-label extension, ocrelizumab as first-line therapy maintained NEDA-3 in 48.2% of patients at 7 years vs 25.7% in the delayed-start group (OR 2.72) ^[4]^B2b (2b).

Biomarkers refine risk stratification. Serum neurofilament light chain (sNfL) Z score >1.5 is associated with a 3.15-fold increased odds of future disease activity ^[443]^B2b (2b). Combined high sNfL and sGFAP at disease onset identifies patients at highest risk of progression independent of relapse activity (PIRA) and Expanded Disability Status Scale score of 3, a risk that high-efficacy DMT may not fully mitigate ^[286]^B2b (2b).

Table 1: First-Line Treatment Strategies

Strategy	Description	Key evidence	Recommended patient profile
Early high-efficacy therapy	Initiate ocrelizumab, natalizumab, alemtuzumab, rituximab, or ofatumumab within 2 years of onset	MSBase/Swedish registry ^[438]^B2b; COMBAT-MS ^[278]^B2b; OPERA OLE ^[4]^B2b	Active disease (high relapse rate, MRI lesions, elevated sNfL), young age, no contraindications
Escalation (moderate-efficacy first)	Start with interferon, glatiramer acetate, teriflunomide, dimethyl fumarate, or fingolimod; switch to HET if breakthrough disease	AAN guideline ^[435]^A1c; Danish-Swedish comparison ^[446]^B2b	Mild disease, low relapse frequency, low biomarker levels, patient preference

In patients with radiologically isolated syndrome (RIS), dimethyl fumarate 240 mg twice daily reduced the risk of a first clinical demyelinating event by 82% (HR 0.18) over 96 weeks ^[354]^A1b (1b), supporting early intervention at the preclinical stage.

Step 2: Safety Monitoring Before and During Therapy

Before initiating any DMT, screen for latent infections, assess vaccination status, and perform baseline laboratory studies. The ECTRIMS/EAN 2023 vaccination consensus recommends updating immunizations at least 4-6 weeks before starting highly active DMTs, with special attention to live-attenuated vaccines ^[439]^A1c (1c).

Pre-treatment screening by drug class:

Sphingosine-1-phosphate receptor modulators (fingolimod, ponesimod): Baseline CBC, LFTs, ophthalmologic exam (risk of macular edema), ECG for first-dose cardiac monitoring (especially with fingolimod). Ponesimod requires a 14-day gradual dose up-titration starting at 2 mg ^[122]^A1b (1b).
Teriflunomide: Baseline CBC, LFTs, and blood pressure; exclude pregnancy (teratogenic). LFT monitoring every 3 months. Hair thinning and diarrhea are common ^[120]^A1b (1b).
Dimethyl fumarate: Baseline CBC, LFTs; monitor for lymphopenia (absolute lymphocyte count <0.5 × 10⁹/L warrants discontinuation). PML risk exists but is rare ^[435]^A1c.
Alemtuzumab: Baseline CBC, thyroid function, and tuberculosis screening; urine protein at baseline. Monitor for thyroid autoimmunity (16% in the phase 3 trial ^[346]^A1b (1b)), immune thrombocytopenia (1%), and infusion reactions (90%).
Tolebrutinib (Bruton's tyrosine kinase inhibitor): Baseline LFTs; monitor alanine aminotransferase (ALT) every 3-6 months. In the HERCULES trial, ALT >3× ULN occurred in 4.0% of tolebrutinib-treated patients vs 1.6% of placebo ^[331]^A1b (1b).

Table 2: Core Safety Monitoring Schedule

Drug	Baseline	Every 3-6 months	Annually	Special
Ocrelizumab / rituximab	HBsAg, HBcAb, HBsAb, HCV, VZV IgG, TB, CBC, Ig levels	CBC, LFTs, Ig levels	Vaccination status, JCV if switching	Infusion reaction monitoring
Natalizumab	JCV serology, CBC, LFTs	JCV serology (if seronegative), CBC, LFTs	Contrast MRI brain	PML vigilance; extended-interval dosing (5-8 wk) considered
Fingolimod	CBC, LFTs, ECG, ophthalmology	CBC, LFTs	Ophthalmology	First-dose monitoring
Teriflunomide	CBC, LFTs, BP, pregnancy test	LFTs monthly × 6, then q3mo	BP	Washout with cholestyramine if needed
Alemtuzumab	CBC, TFTs, TB, urinalysis	Monthly CBC, TFTs	Urinalysis, skin exam	Infusion premedication
Tolebrutinib	CBC, LFTs	LFTs, CBC	,	,

Step 3: Switching and Escalation for Breakthrough Disease

Breakthrough disease is defined as a clinical relapse or new/enlarging T2 or gadolinium-enhancing MRI lesions despite adequate adherence to a moderate-efficacy DMT ^[435]^A1c. The AAN guideline recommends switching to a higher-efficacy agent when breakthrough disease occurs ^[435]^A1c (1c).

Options for escalation:

From oral DMT to anti-CD20: In the ARTIOS study, patients switching from fingolimod or fumarates to ofatumumab after breakthrough disease achieved an annualized relapse rate of 0.06 (95% CI 0.05-0.08) and 90.9% no evidence of disease activity ^[253]^C4 (4).
Ublituximab: In the ULTIMATE I/II trials, ublituximab reduced the annualized relapse rate to 0.081 vs 0.188 for teriflunomide in treatment-naïve patients (P<0.001) ^[375]^B2b (2b).

Treatment Failure Protocol (Step 3a):

Confirm adherence (direct questioning, pharmacy records).
Assess for comorbidities that may blunt response (e.g., cardiometabolic conditions, psychiatric disorders ^[239]^B2b (2b)).
If breakthrough disease confirmed, switch to a higher-efficacy DMT with a different mechanism of action.
For patients on natalizumab with rising JCV index or duration >24 months in seropositive patients, consider switching to an anti-CD20 agent or other HET; extended-interval dosing (5-8 weeks) is an alternative but carries a risk of increased gadolinium-enhancing lesions ^[168]^A1a (1a).

Step 4: De-escalation and Discontinuation

The decision to de-escalate or discontinue DMT is driven by a change in the benefit-risk ratio, typically with advancing age, prolonged clinical stability, or emergence of safety concerns ^[449]^D5 (5). The AAN guideline recommends considering DMT discontinuation in patients with no relapses, no MRI activity, and stable disability for ≥5 years, particularly in those aged ≥55 years ^[435]^A1c (1c).

Evidence from randomized trials:

DISCOMS trial (n=259): Among patients aged ≥55 years with no relapse in 5 years and no new MRI lesion in 3 years, discontinuation of DMT resulted in a 7.5% higher rate of new disease activity over 2 years (12.2% vs 4.7%; 95% CI 0.6-15.0). The difference crossed the non-inferiority margin of 8%, meaning continuation was superior ^[335]^A1b (1b). However, the absolute risk of recurrence was low, and serious adverse events were similar between groups (16% vs 14%) ^[335]^A1b.
DOT-MS trial (n=89): In patients aged ≥18 years with relapse-onset MS and no disease activity for ≥5 years while on first-line DMT, discontinuation led to inflammatory disease activity in 17.8% vs 0% in the continuation group (median follow-up 15.3 months) ^[222]^A1b (1b). The trial was terminated early due to recurrence above the predefined limit. Notably, the median age was 54 years, and the recurrence rate was higher than in DISCOMS, possibly because the cohort included younger patients ^[222]^A1b (1b).

Practical guidance for de-escalation ^[449]^D5 (5):

Patient selection: Age ≥55 years, no relapse in ≥5 years, no new MRI activity in ≥3 years, stable disability (EDSS).
PML risk mitigation: For natalizumab, consider extended-interval dosing (every 5-8 weeks) rather than full discontinuation in seropositive patients; PML can occur up to 6 months after discontinuation, often with immune reconstitution inflammatory syndrome (IRIS) ^[454]^C4 (4).
Monitoring after discontinuation: Annual clinical evaluation and MRI for at least 2-3 years.
Re-initiation: If disease activity returns, restart a high-efficacy DMT promptly.

Controversies and Guideline Disagreement

Question	Position A	Position B	Strength of disagreement	Implication for practice
Early HET vs escalation for all patients	AAN 2018 recommends individualizing, but favors early HET in patients with high disease activity ^[435]^A1c	ECTRIMS/EAN 2018 recommends escalation as default for most patients ^[457]^A1c	Moderate (different emphasis on patient selection)	Shared decision-making; use biomarkers (sNfL, sGFAP) to identify high-risk patients who warrant early HET ^[286]^B2b
Age threshold for discontinuation	DISCOMS suggests age ≥55 years as a reasonable cutoff ^[335]^A1b	DOT-MS found recurrence in younger patients even after 5 years of stability ^[222]^A1b	Strong (different age cutoffs; DOT-MS enrolled younger patients)	Do not apply age ≥55 years rigidly; assess on a case-by-case basis; younger patients with longer life expectancy may still benefit from continuation
JCV testing before natalizumab	AAN 2018 recommends testing before starting and every 6 months ^[435]^A1c	Real-world data show low adherence to pre-treatment testing ^[172]^C4	Moderate (guideline vs practice gap)	Healthcare systems must ensure timely access to JCV serology; delayed results undermine risk stratification

Pearl: Early high-efficacy therapy reduces long-term disability accrual, but de-escalation in older stable patients carries a 12-18% risk of recurrent inflammatory activity over 2 years; the decision to stop or continue must balance the minimal absolute risk against the potential for irreversible disability.

Neurorehabilitation, Symptomatic & Supportive Care

▸A multidisciplinary MS Care Unit that coordinates neurologist, nursing, physiotherapy, occupational therapy, and psychological support is essential for delivering symptomatic and rehabilitative care across the disease spectrum [106].
▸Structured exercise (≥150 min/week), Pilates, and aquatic therapy improve mobility, balance, and fatigue; virtual-reality-based rehabilitation adds cognitive gains [481,295,484,483].
▸Symptomatic pharmacotherapy includes intrathecal baclofen for severe spasticity, botulinum toxin for bladder overactivity (mean duration 9.7 months), dextromethorphan/quinidine for pseudobulbar affect, and low-dose naltrexone (4.5 mg nightly) for mental health QoL [459,479,463,462].

Alongside disease-modifying therapy, a comprehensive, multidisciplinary program of symptomatic pharmacotherapy, rehabilitation, and lifestyle intervention is essential to maintain function and quality of life across all disease stages ^[21]^D5^[22]^D5. The MS Care Unit model, integrating neurologists, nurses, physiotherapists, occupational therapists, psychologists, and social workers, provides the coordinated infrastructure needed to implement this longitudinal layer of care ^[106]^D5.

Symptomatic Pharmacotherapy

Spasticity. Oral agents (baclofen, tizanidine, gabapentinoids) are first-line; when responses are inadequate, intrathecal baclofen via an implanted pump can substantially reduce spasticity and improve motor function ^[459]^D5. The patient-reported Multiple Sclerosis Spasticity Scale (MSSS-88) is a validated tool to capture the subjective impact of spasticity across eight domains including stiffness, pain, and psychosocial function ^[475]^D5.

Bladder dysfunction. Detrusor overactivity causing urgency and incontinence is highly prevalent. Intradetrusor injections of type A (typically 200-300 U) produce a mean duration of continence of 9.7 months; 98% of patients will need to perform clean intermittent self-catheterization afterward, but quality-of-life scores improve significantly and repeat injections maintain efficacy ^[479]^C4. Sacral neuromodulation and posterior tibial nerve stimulation are additional neuromodulatory options ^[459]^D5.

Neuropathic pain. Central neuropathic pain in MS involves mechanisms such as oxidative-stress-driven TRPA1 activation ^[473]^D5. First-line pharmacotherapy includes gabapentinoids, tricyclic antidepressants, and serotonin-noradrenaline reuptake inhibitors. For in MS, classification as secondary trigeminal neuralgia guides with carbamazepine or oxcarbazepine, though rigorous trial data specific to MS are lacking ^[139]^D5.

Pseudobulbar affect. Pathological laughing or crying can be treated with dextromethorphan/quinidine (DM/Q) 20 mg/10 mg twice daily, which reduced CNS-Lability Scale scores versus placebo at all visits over 12 weeks (p < 0.0001) and improved quality of life ^[463]^A1b.

Fatigue. Fatigue affects 95% of individuals with MS and has a major independent effect on utility ^[290]^B2c. A unified taxonomy distinguishes performance fatigability from perceived fatigue, guiding assessment and treatment ^[68]^D5. Dietary interventions, the , low-fat, and s, each produce large reductions in fatigue (standardized mean differences ranging from -0.89 to -1.27) in small, low-certainty trials ^[464]^A1a. Low-dose naltrexone (4.5 mg nightly) improved the Mental Component Summary of the SF-36 by 3.3 points and the Pain Effects Scale by 1.6 points in a pilot crossover trial ^[462]^B2b.

Rehabilitation: Exercise, Physical Therapy, and Virtual Reality

The National MS Society recommends that every person with MS engage in ≥150 min/week of exercise or lifestyle physical activity, with gradual progression tailored to disability level and comorbidities ^[481]^A1c. Structured Pilates-based interventions improve functional mobility by a mean -5.23 seconds on the Timed Up and Go test and balance by 8.58 points on the Berg Balance Scale compared with controls ^[295]^A1a. Aquatic therapy produces large reductions in fatigue (SMD ≈ -1.20) and moderate gains in mobility and physical function (SMD ≈ 0.70) ^[484]^A1a.

(VR)-based rehabilitation, both immersive and non-immersive, enhances processing speed, visuospatial memory, and executive function; adherence exceeds 80% and no serious adverse events are reported ^[483]^B2a. In progressive MS, task-oriented rehabilitation with VR improves upper limb function and induces functional connectivity changes on MRI that correlate with clinical gains (r = 0.54) ^[376]^A1b. Video-game-based training specifically improves attentional performance and quality of life compared with balance platform training alone ^[429]^A1b.

Cognitive Rehabilitation and Screening

Cognitive impairment affects 41% of patients with MS at baseline and worsens over time, particularly in progressive forms ^[474]^B2b. The National MS Society recommends annual screening with the (SDMT) beginning early in the disease course, with more comprehensive neuropsychological assessment for those who screen positive ^[320]^A1c. The CogEx trial, a 12-week, four-arm sham-controlled study, found that individualized computer-based cognitive rehabilitation plus aerobic exercise did not improve SDMT scores more than sham in progressive MS, underscoring the difficulty of reversing established cognitive deficits in this population ^[266]^A1b. Nonetheless, VR-based cognitive training shows promise for improving processing speed and memory (p < 0.05) ^[483]^B2a, and music-based interventions may support cognition, motor function, and emotional well-being ^[468]^D5.

Psychosocial Support and Mood

Depression is 2-3 times more frequent in MS than in the general population and substantially worsens quality of life ^[472]^D5^[162]^D5. Randomized trials support the efficacy of antidepressant medication, cognitive behavioral therapy, and mindfulness-based interventions, though psychotropic-specific trial data in MS remain scarce ^[162]^D5. Suicidal ideation must be screened regularly. Palliative care, outpatient or home-based, improves patient and caregiver outcomes in MS by addressing physical, psychosocial, and existential suffering ^[470]^D5.

Sexual Dysfunction

Non-pharmacological interventions, particularly structured psychosexual counseling based on the PLISSIT model, produce large pooled effects on sexual function (Hedges g = 2.1) in women with MS; however, trials are small, at high risk of bias, and lack generalizability ^[167]^A1a.

Pearl: The most evidence-supported non-pharmacological strategy for improving fatigue and mobility is achieving ≥150 min/week of moderate exercise per National MS Society guidelines, but for fatigued patients who cannot tolerate land-based exercise, aquatic therapy offers a comparable benefit with a lower fall risk ^[481]^A1c^[484]^A1a.

Rehabilitation Modalities with Evidence in MS

Intervention	Key Outcome	Effect Size / Finding	Reference
Pilates	Timed Up and Go (mobility)	MD -5.23 s (95% CI -6.39 to -4.06)	^[295]^A1a
Aquatic therapy	Fatigue	SMD ≈ -1.20	^[484]^A1a
Task-oriented VR (progressive MS)	Upper limb function (ABILHAND)	Improved post-treatment; connectivity r=0.54	^[376]^A1b
Video game training	Balance, reaction time, QoL	Improved over balance platform	^[429]^A1b
Cognitive rehab + exercise (CogEx)	Processing speed (SDMT)	No significant difference vs sham at 12 wk	^[266]^A1b
VR cognitive training	Processing speed, memory	p < 0.05; adherence >80%	^[483]^B2a

Complications

▸Advanced MS patients require systematic screening for respiratory muscle weakness using FVC; FVC < 50% predicted or PaCO₂ > 50 mm Hg are intubation thresholds.
▸Neurogenic bladder is present in up to 80% of patients; post-void residual > 150 mL should prompt clean intermittent catheterization.
▸All non-ambulatory hospitalized MS patients need enoxaparin 40 mg SC daily plus compression devices for DVT/PE prophylaxis.
▸Suicide risk is doubled in MS, especially in younger males; routine depression screening and prompt treatment are essential.

HY High Yield: FVC < 1.5 L or < 50% predicted in an MS patient with new dyspnea or cough should trigger immediate assessment for non-invasive ventilation.

Despite effective disease-modifying therapies, multiple sclerosis (MS) patients face a substantial burden of complications arising both from the disease itself and its treatments. Anticipating and intercepting these requires a systematic, multidisciplinary approach.

Respiratory Complications

Progressive weakness of respiratory muscles, particularly in secondary or primary progressive MS, leads to restrictive lung disease. Forced vital capacity (FVC) should be monitored serially; an FVC < 1.5 L or < 50% of predicted signals impending respiratory failure. Intubation criteria include hypercapnia (PaCO₂ > 50 mm Hg), hypoxia (PaO₂ < 60 mm Hg on room air), or inability to clear secretions. Non-invasive ventilation may delay progression, but the threshold for invasive support should be low in acute deteriorations.

Autonomic Dysfunction

Autonomic involvement manifests as orthostatic hypotension, cardiac arrhythmias, sweat disturbances, and /urinary dysmotility. , present in up to 80% of patients, requires post-void residual assessment. Residual volumes > 150 mL indicate incomplete emptying and necessitate clean intermittent catheterization or, in advanced cases, suprapubic catheter insertion. One retrospective series reported immediate complication rates of 16% and delayed complications of 27% with radiologically guided suprapubic catheters; 5-year survival was 73% ^[511]^B2b. Chronic constipation and fecal incontinence are managed with bowel programs including stimulant laxatives and digital rectal stimulation.

Venous Thromboembolism Prophylaxis

Patients with advanced MS who are non-ambulatory face significant risk of deep vein thrombosis and pulmonary embolism. All hospitalized patients with EDSS ≥ 7 should receive 40 mg subcutaneously once daily or unfractionated 5000 units subcutaneously twice daily, combined with intermittent pneumatic compression devices unless contraindicated. Early mobilization and adequate hydration complement pharmacologic prevention.

Pain

Pain in MS is heterogeneous: central neuropathic pain (e.g., dysesthetic extremity pain, ), musculoskeletal pain from spasticity or poor posture, and headache. First-line agents for neuropathic pain include gabapentin 300-3600 mg/day or pregabalin 150-600 mg/day. Cannabinoids, such as nabiximols (oromucosal spray; maximum 12 actuations per 24 h), improved spasticity-related symptoms in a phase 2 trial (Modified Ashworth Scale improvement -0.32; 95% CI -0.57 to -0.069; p=0.013) ^[487]^A1b. Dronabinol (up to 28 mg/day) did not slow disability progression but was well tolerated, with serious adverse events in 35% vs 28% placebo ^[270]^A1b. Tricyclic antidepressants or serotonin-norepinephrine reuptake inhibitors may benefit co-morbid depression and pain.

Falls and Fractures

Falls affect 50-70% of MS patients annually, resulting in fractures at rates higher than the general population. Bone mineral density is significantly reduced, driven by immobility, glucocorticoid use, and possibly disease-specific factors ^[160]^D5^[163]^D5. Screening with dual-energy X-ray absorptiometry is recommended for postmenopausal women and men aged ≥ 50 years. Supplementation with calcium 1000-1200 mg/day and vitamin D 800-1000 IU/day is standard; bisphosphonates (e.g., alendronate 70 mg once weekly) are indicated if T-score ≤ -2.5.

Hospital-Acquired Complications & Infection Prevention

Hospitalization in advanced MS carries high risk of , pressure injuries, and catheter-associated urinary tract infections. Daily skin inspection with pressure-redistribution surfaces, turning every 2 hours, and incontinence care are mandatory. vaccination is safe: a meta-analysis of 14,755 MS patients reported a relapse rate of 1.9% (95% CI 1.3%-2.6%) within 20 days post-vaccination, with serious adverse events in only 0.1% ^[493]^A1a. Smoking cessation slows motor disability progression, smokers who quit showed a median reduction of -2.91 points on the MSIS-29-Phys compared with continued smokers ^[498]^B2b.

Mortality and Suicide

All-cause mortality is increased in MS (standardized mortality ratio ~2.5). Suicide risk is roughly twice that of the general population, particularly in younger males within the first few years after diagnosis ^[161]^D5. Depression, social isolation, and alcohol abuse are key modifiable risk factors; screening with the Beck Depression Inventory and prompt referral for cognitive-behavioral therapy or pharmacotherapy is critical ^[162]^D5.

Complication	Frequency	Prevention	Management
Respiratory failure	10-20% in advanced MS	Serial FVC monitoring, smoking cessation	Non-invasive or invasive ventilation, secretion clearance
Neurogenic bladder	50-80%	Post-void residual checks	Clean intermittent catheterization, anticholinergics, suprapubic catheter ^[511]^B2b
DVT/PE	5-10% in non-ambulatory	Enoxaparin 40 mg SC daily, compression devices	Therapeutic anticoagulation
Falls/fractures	50-70% falls yearly	DXA screening, vitamin D/calcium, balance training	Bisphosphonates for T-score ≤ -2.5 ^[163]^D5
Pressure injuries	15-30% in EDSS ≥ 7	Turning schedules, pressure-redistribution surfaces	Wound care, debridement, infection control

Pearl: In hospitalized patients with advanced MS, a simple protocol of daily FVC checks, post-void residual ultrasound, and enoxaparin 40 mg SC can prevent the three most common preventable complications, respiratory failure, urosepsis, and pulmonary embolism.

Prognosis & Natural History

▸Untreated, median time from EDSS 1 to EDSS 6 is 18.48 years; DMT delays this by approximately 3 years.
▸Early high-efficacy therapy (within 2 years) yields a mean EDSS of 2.3 versus 3.5 at year 10 compared to delayed initiation.
▸PIRA is the dominant driver of long-term disability in relapsing MS, accounting for ~89% of confirmed disability accumulation on ocrelizumab.

HY High Yield: PIRA begins in relapsing-remitting MS, not just progressive forms, look for insidious EDSS worsening in the absence of relapses or MRI activity.

! Warning: DMT discontinuation in patients <55 years with stable disease still carries a 17.8% risk of recurrent inflammatory activity over 15 months (DOT-MS); do not assume stability equates to quiescent disease.

Untreated, a patient with newly diagnosed relapsing-remitting MS and minimal disability (EDSS 1) can expect to reach the need for a walking aid (EDSS 6) in a median 18.48 years, with the transition to substantial limitation in walking (EDSS 4) by 8.95 years ^[90]^B2b. Disease-modifying therapy delays these milestones by a mean 3.51 years to EDSS 4 and 3.09 years to EDSS 6 ^[90]^B2b. The timing of treatment initiation critically alters this trajectory. Patients who started high-efficacy therapy within 2 years of disease onset had a mean EDSS of 2.3 at year 10, versus 3.5 for those starting 4-6 years after onset, a difference of -0.98 (p < 0.0001) ^[438]^B2b. Similarly, early intensive therapy yielded a 5-year EDSS change of only 0.3 versus 1.2 with escalation therapy ^[282]^B2b.

Drivers of Disability Accumulation

Progression independent of relapse activity (PIRA) begins early and becomes the dominant mechanism of disability worsening across all MS phenotypes ^[90]^B2b. In the pooled OPERA trials of relapsing MS, PIRA accounted for 89.1% of confirmed disability accumulation events in the ocrelizumab group over 96 weeks ^[272]^B2b. Relapses increase the hazard of all-cause disability worsening by 31-48% in the year following a relapse ^[90]^B2b. Silent progression, insidious disability that accrues without clinical or radiographic activity, is common even in patients who achieve no evidence of disease activity ^[287]^B2b.

Predictors of Adverse Trajectory

Older age, higher baseline EDSS, and the presence of paramagnetic rim lesions on susceptibility-weighted MRI identify patients at risk for more rapid disability accrual ^[90]^B2b^[238]^B2b. The presence of spinal cord lesions and CSF oligoclonal bands in radiologically isolated syndrome increases the 5-year risk of a first clinical event to 38% ^[29]^D5.

De-escalation and Discontinuation Risk

In patients ≥55 years with no recent disease activity, discontinuation of DMT resulted in a 7.5 percentage-point higher event rate over 2 years (12.2% vs 4.7%) ^[335]^A1b. Among younger, stable patients on first-line therapy, discontinuation led to recurrent inflammatory activity in 17.8% versus 0% in continuers, the DOT-MS trial was terminated early for this excess risk ^[222]^A1b. These data anchor shared decision-making around long-term therapy choices and timing of de-escalation.

Pearl: The untreated trajectory from EDSS 1 to EDSS 6 spans roughly two decades; early high-efficacy DMT can preserve over a full EDSS point of difference at 10 years, underscoring the therapeutic window in relapsing-remitting MS ^[90]^B2b^[438]^B2b.

Controversies and Guideline Disagreement

A key unresolved question is when and how to de-escalate or discontinue DMT in older, stable patients. The DISCOMS trial supported cautious discontinuation after age 55 (non-inferiority margin of 8% was missed, but event rates were low), while DOT-MS found that even in younger patients with long-term stability, discontinuation caused rebound inflammation ^[335]^A1b^[222]^A1b. ECTRIMS guidelines recommend individualised assessment, weighing age, disease activity, and DMT risk profile, but no consensus exists on a specific age or protocol ^[449]^D5.

Natural History Milestones in Untreated Relapsing-Remitting MS

Milestone	Median Time (years)	Source
EDSS 4 (limited walking)	8.95	^[90]^B2b
EDSS 6 (cane/walker)	18.48	^[90]^B2b
Delay to EDSS 4 with DMT	+3.51 years	^[90]^B2b
Delay to EDSS 6 with DMT	+3.09 years	^[90]^B2b

Special Populations & Pregnancy

▸Pediatric-onset MS often requires early high-efficacy therapy: fingolimod (0.5 mg/day, 0.25 mg/day if ≤40 kg) reduced ARR by 82% vs interferon beta-1a [220]; initial HET reduced first relapse risk by 54% [525], and natalizumab improved ARR and EDSS [540].
▸Pregnancy DMT management critically affects relapse risk: prolonged natalizumab interruption (cRR 2.18) and fingolimod cessation (cRR 2.15) double the risk, whereas anti-CD20 interruption 3 months preconception is most protective (cRR 0.38) [523].
▸Elderly patients experience a steep rise in PIRA after age 40 (78.7% at 70 years), warranting careful de-escalation of DMTs and management of comorbidities [145].

must be tailored to the physiologic and immunologic contexts of pediatric, pregnant, elderly, and immunocompromised patients, where the disease's biology and therapeutic risk-benefit balance fundamentally shift.

Pediatrics

Pediatric-onset MS (POMS) before age 11 years shows distinct features: a higher proportion of males, isolated brainstem involvement, and longer time between first and second relapse ^[434]^B2b. Early onset also carries a longer time to disability milestones but eventual accumulation of fixed deficits ^[434]^B2b. Diagnosis follows International Pediatric MS Study Group criteria ^[395]^D5; however, MOG-IgG is positive in 6% of children initially labeled POMS, most of whom ultimately meet criteria for MOG antibody disease ^[38]^B3b. Neuroimaging should avoid routine gadolinium where possible ^[15]^A1c. Treatment increasingly favors high-efficacy therapies (HET). Fingolimod at 0.5 mg/day (0.25 mg/day if ≤40 kg) reduced the annualized relapse rate to 0.12 versus 0.67 with interferon beta-1a - an 82% relative reduction (P<0.001) ^[220]^A1b; NNT not calculable from rate-based outcome. A 5-year cohort observed that initial HET (vs moderately effective therapy) reduced first relapse risk by 54% (HR 0.46, 95% CI 0.31-0.67); NNT not reported ^[525]^B2b. Natalizumab also demonstrates efficacy in POMS, with a mean ARR reduction of 1.962 relapses per patient-year from baseline ^[540]^A1a. PIRA can occur even in pediatric patients but increases steeply after age 20 ^[145]^B2b. Socioeconomic outcomes are worse: POMS patients are less likely to attend university (OR 0.80) and have lower lifetime earnings ^[524]^B2b.

Pregnancy

Disease activity typically declines during pregnancy, especially in the third trimester, driven partly by estriol and prolactin ^[521]^A1b^[56]^B2a. However, postpartum relapse risk rises, and DMT management during gestation significantly influences outcomes ^[523]^B2b. Interruption of natalizumab before the second trimester or resumption >3 months after delivery doubles the relapse rate (causal rate ratio [cRR] **2.18, 95% **) ^[523]^B2b. Fingolimod cessation carries similar risk (cRR **2.15, 95% **) ^[523]^B2b. In contrast, the anti-CD20 strategy (interrupting 3 months before conception) confers the best control (cRR **0.38, 95% **) ^[523]^B2b. Natalizumab continuation into the third trimester is associated with mild-to-moderate neonatal hematologic alterations (thrombocytopenia and anemia) and detectable drug in cord blood ^[494]^C4 and breast milk ^[537]^C4. Interferon beta and glatiramer acetate are considered safer during pregnancy (cRR 0.93 and 0.91, respectively) ^[523]^B2b. data are limited, but natalizumab is measurable in breast milk ^[537]^C4; interferon/glatiramer are likely safe. Preconception counseling must include the accelerated elimination protocol for teriflunomide and avoidance of fingolimod, cladribine, and other S1P modulators.

Elderly

Progression independent of relapse activity (PIRA) rises sharply with age: from 1.3% at 20 years to 21.6% at 40 years, 39.0% at 50 years, and 78.7% at 70 years ^[145]^B2b. Comorbidities such as and diabetes are common and may interact with DMT metabolism and infection risk. De-escalation or discontinuation of DMTs should be considered when the benefit-risk ratio shifts unfavorably with aging ^[449]^D5. No age-specific dose modifications are established, but renal function and polypharmacy must inform drug selection ^[15]^A1c^[457]^A1c.

Immunocompromised

Vaccination status must be optimized before initiating immunosuppressive DMTs. ECTRIMS/EAN consensus recommends live-attenuated vaccines be given ≥4-6 weeks before therapy start and inactivated vaccines be scheduled to maximize response ^[439]^A1c. Progressive multifocal leukoencephalopathy risk with natalizumab, fingolimod, and dimethyl fumarate mandates JC virus serology screening and periodic reassessment. No specific dose reductions for DMTs in immunocompromised hosts are provided by the available evidence; individualized risk stratification is advised.

Pearl: For pregnant women with highly active MS, maintaining anti-CD20 therapy until 3 months before conception or continuing natalizumab into the third trimester with short interruption provides the greatest protection against relapse, but each approach requires careful discussion of neonatal risks including hematologic effects and infection.

Pregnancy DMT Management: Relapse Risk and Fetal Considerations

Strategy	cRR (95% CI) vs DMT interruption ^[523]^B2b	Fetal/Neonatal Risk
Anti-CD20 (stop 3 months preconception)	0.38 (0.25-0.52)	Theoretical B-cell depletion; limited data
Natalizumab short interruption	0.80 (0.71-0.90)	Mild-moderate thrombocytopenia/anemia ^[494]^C4; detectable in breast milk ^[537]^C4
Interferon beta continuous	0.93 (0.86-0.99)	Generally safe
Glatiramer acetate continuous	0.91 (0.84-0.99)	Generally safe
Natalizumab prolonged interruption	2.18 (1.76-2.69)	Risk of rebound MS activity; less fetal exposure
Fingolimod cessation	2.15 (1.60-2.93)	Avoid in pregnancy; teratogenic (animal data)

Prevention, Screening & Surveillance

▸Primary prevention of MS remains unproven, but observational data support optimizing vitamin D, avoiding smoking, and maintaining healthy lifestyle habits.
▸Early initiation of high-efficacy DMT improves long-term disability outcomes compared with escalation strategies; comorbidity management is a critical component of secondary prevention.
▸Routine cognitive screening with SDMT and surveillance for subclinical disease activity using MRI and serum neurofilament light chain enable timely therapeutic adjustments.

HY High Yield: The ECTRIMS/EAN 2023 consensus recommends that all MS patients be vaccinated according to national guidelines, with special attention to timing: administer inactivated vaccines before starting immunosuppressive DMTs to maximize immunogenicity [439].

Following the specialized considerations of pregnancy and family planning, the focus shifts to prevention strategies across the disease spectrum, from primary prevention in at-risk individuals to secondary prevention of relapses and disability, and structured surveillance for subclinical disease activity.

Primary Prevention: Modifiable Risk Factors

No intervention has been proven to prevent multiple sclerosis, but observational data identify several modifiable exposures. vaccination is associated with a lower risk of MS (OR 0.67, 95% CI 0.55-0.81) in a systematic review ^[550]^B3a. In contrast, no long-term association exists between hepatitis B, human papillomavirus, or routine vaccines and MS risk ^[560]^B3b; a short-term increase in CNS demyelinating events within 30 days of any vaccination in younger individuals (<50 years) likely reflects acceleration of subclinical autoimmunity rather than causation ^[560]^B3b. Vitamin D supplementation has been hypothesized to reduce MS risk based on the strong geographic gradient and gene-environment interaction with HLA-DRB1*1501, but definitive randomised controlled trial data are lacking ^[553]^D5. Lower serum α-tocopherol levels are found in MS patients compared with controls (SMD -1.17, 95% CI -2.02 to -0.31) ^[112]^B3a, though whether supplementation alters risk is unknown. Lifestyle interventions, including smoking cessation, physical activity, and healthy diet, are recommended based on their association with reduced disease incidence and better outcomes, consistent with WHO guidelines ^[568]^D5.

Secondary Prevention: Preventing Relapses and Disability

Early initiation of high-efficacy disease-modifying therapy (DMT) yields superior long-term outcomes compared with escalation strategies. In a population-based cohort, the 5-year Expanded Disability Status Scale change was lower with early intensive therapy (0.3 vs 1.2; β -0.85, 95% CI -1.38 to -0.32) ^[282]^B2b. Comorbidity burden amplifies disease activity: the presence of three or more comorbidities increases the hazard of evidence of disease activity (aHR 1.14), and two or more cardiometabolic conditions carry aHR 1.21 ^[239]^B2b. of , diabetes, hyperlipidemia, depression, and anxiety is therefore an integral component of secondary prevention. The ECTRIMS/EAN 2023 consensus underscores that vaccination should be optimised before starting immunosuppressive DMTs to maximise vaccine immunogenicity ^[439]^A1c.

Screening and Surveillance for Disease Activity

Structured monitoring for subclinical disease activity is essential. The National MS Society (2018) recommends early baseline cognitive screening with the Symbol Digit Modalities Test (SDMT) in clinically stable patients, followed by annual re-assessment ^[320]^A1c. Serum neurofilament light chain (sNfL) is emerging as a biomarker of ongoing neuroaxonal damage; levels correlate with relapses and MRI activity and can guide treatment response ^[562]^D5. Routine brain MRI surveillance at 12- to 24-month intervals remains standard, though the optimal frequency is individualised. Retinal optical coherence tomography (OCT) measuring inter-eye difference in ganglion cell-inner plexiform layer thickness has shown diagnostic utility (AUROC 0.71) but is not yet recommended for routine screening ^[149]^B2c.

Vaccination Considerations

Vaccination is safe and recommended in people with MS. The ECTRIMS/EAN 2023 consensus provides 53 recommendations ^[439]^A1c: inactivated vaccines can be given without restriction; live attenuated vaccines (e.g., , BCG) are contraindicated during treatment with immunosuppressive DMTs. vaccination does not increase disease activity in radiologically isolated syndrome (conversion rate 6.7% vaccinated vs 8.5% unvaccinated, p>0.9) ^[567]^B2b. A nationwide French cohort found no association between vaccination and hospitalisation for MS flare-ups (AOR 1.00, 95% for all vaccines) ^[558]^B3b.

Patient Education

Patients should be counselled on smoking cessation, regular physical activity, and maintenance of adequate vitamin D levels (target 25-hydroxyvitamin D >30 ng/mL). Screening for osteoporosis is warranted in patients with reduced mobility or glucocorticoid exposure ^[160]^D5. Depression affects up to 50% of patients and is a risk factor for suicide (standardised mortality ratio ~2.0); routine screening with validated tools (e.g., PHQ-9) is recommended ^[161]^D5^[162]^D5.

Pearl: For every newly diagnosed patient, deploy a prevention bundle: vaccinate (influenza, pneumococcal, COVID-19, Tdap) before starting DMT, screen for comorbidities and depression, begin annual SDMT cognitive monitoring, and counsel on smoking cessation and vitamin D supplementation.

References

[1]
Wingerchuk DM, Banwell B, Bennett JL et al.. “International consensus diagnostic criteria for neuromyelitis optica spectrum disorders.” Neurology (2015). PMID: 26092914 ↗
L1GUIDELINECited in: Definition, Classification & Nomenclature, Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG), History and Evolution of Treatment, Special Populations & Pregnancy
[2]
Montalban X, Vermersch P, Arnold DL et al.. “Safety and efficacy of evobrutinib in relapsing multiple sclerosis (evolutionRMS1 and evolutionRMS2): two multicentre, randomised, double-blind, active-controlled, phase 3 trials.” The Lancet. Neurology (2024). PMID: 39307151 ↗
L1RCTCited in: Definition, Classification & Nomenclature, Epidemiology, Etiology & Risk Factors, Severity, Staging & Risk Stratification, History and Evolution of Treatment, Prognosis & Natural History
[3]
Newsome SD, Krzystanek E, Selmaj KW et al.. “Subcutaneous Ocrelizumab in Patients With Multiple Sclerosis: Results of the Phase 3 OCARINA II Study.” Neurology (2025). PMID: 40245351 ↗
L1RCTCited in: Definition, Classification & Nomenclature, Severity, Staging & Risk Stratification, History and Evolution of Treatment, Prognosis & Natural History
[4]
Cerqueira JJ, Berthele A, Cree BAC et al.. “Long-Term Treatment With Ocrelizumab in Patients With Early-Stage Relapsing MS: Nine-Year Data From the OPERA Studies Open-Label Extension.” Neurology (2025). PMID: 39883906 ↗
L2RCTCited in: Definition, Classification & Nomenclature, Long-term & Definitive Management (Evidence Ladder), History and Evolution of Treatment, Disease-Modifying & Immunotherapy Program: Sequencing, Safety Monitoring & De-escalation, Prognosis & Natural History
[5]
Williams MJ, Amezcua L, Cohan SL et al.. “Efficacy of Ofatumumab and Teriflunomide in Patients With Relapsing MS From Racial/Ethnic Minority Groups: ASCLEPIOS I/II Subgroup Analyses.” Neurology (2024). PMID: 39018512 ↗
L2RCTCited in: Definition, Classification & Nomenclature, Epidemiology, Etiology & Risk Factors, Long-term & Definitive Management (Evidence Ladder), History and Evolution of Treatment
[6]
Hartung HP, Benedict RHB, Berger T et al.. “Ocrelizumab in Early-Stage Relapsing-Remitting Multiple Sclerosis: The Phase IIIb ENSEMBLE 4-Year, Single-Arm, Open-Label Trial.” Neurology (2024). PMID: 39626127 ↗
L4TRIAL_NONRANDOMCited in: Definition, Classification & Nomenclature, Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG), Severity, Staging & Risk Stratification, Long-term & Definitive Management (Evidence Ladder), Prognosis & Natural History
[7]
Kowalec K, Fitzgerald KC, Salter A et al.. “Polygenicity of Comorbid Depression in Multiple Sclerosis.” Neurology (2023). PMID: 37290970 ↗
L2SR_OBSCited in: Definition, Classification & Nomenclature, Epidemiology, Etiology & Risk Factors
[8]
Müller J, Cagol A, Lorscheider J et al.. “Harmonizing Definitions for Progression Independent of Relapse Activity in Multiple Sclerosis: A Systematic Review.” JAMA neurology (2023). PMID: 37782515 ↗
L2SR_OBSCited in: Definition, Classification & Nomenclature, Disease-Modifying & Immunotherapy Program: Sequencing, Safety Monitoring & De-escalation
[9]
Beghi E, Carpio A, Forsgren L et al.. “Recommendation for a definition of acute symptomatic seizure.” Epilepsia (2009). PMID: 19732133 ↗
L2SR_OBSCited in: Definition, Classification & Nomenclature, Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG)
[10]
Thacker EL, Mirzaei F, Ascherio A. “Infectious mononucleosis and risk for multiple sclerosis: a meta-analysis.” Annals of neurology (2006). PMID: 16502434 ↗
L2SR_OBSCited in: Definition, Classification & Nomenclature, Epidemiology, Etiology & Risk Factors
[11]
Paradas C, Akman HO, Ionete C et al.. “Branching enzyme deficiency: expanding the clinical spectrum.” JAMA neurology (2014). PMID: 24248152 ↗
L4CASE_REPORTCited in: Definition, Classification & Nomenclature, Clinical Presentation
[12]
Montalban X, Lebrun-Frénay C, Oh J et al.. “Diagnosis of multiple sclerosis: 2024 revisions of the McDonald criteria.” The Lancet. Neurology (2025). PMID: 40975101 ↗
L1REVIEW_NARRATIVECited in: Definition, Classification & Nomenclature, Pathophysiology & Mechanism (Neuroanatomic Localization), Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG)
[13]
Banwell B, Bennett JL, Marignier R et al.. “Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: International MOGAD Panel proposed criteria.” The Lancet. Neurology (2023). PMID: 36706773 ↗
L1REVIEW_NARRATIVECited in: Definition, Classification & Nomenclature, Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG), Prevention, Screening & Surveillance
[14]
Petzold A, Fraser CL, Abegg M et al.. “Diagnosis and classification of optic neuritis.” The Lancet. Neurology (2022). PMID: 36179757 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification & Nomenclature, Clinical Presentation, Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG), History and Evolution of Treatment
[15]
Wattjes MP, Ciccarelli O, Reich DS et al.. “2021 MAGNIMS-CMSC-NAIMS consensus recommendations on the use of MRI in patients with multiple sclerosis.” The Lancet. Neurology (2021). PMID: 34139157 ↗
L1REVIEW_NARRATIVECited in: Definition, Classification & Nomenclature, Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG), Special Populations & Pregnancy
[16]
Barkhof F, Reich DS, Oh J et al.. “2024 MAGNIMS-CMSC-NAIMS consensus recommendations on the use of MRI for the diagnosis of multiple sclerosis.” The Lancet. Neurology (2025). PMID: 40975102 ↗
L1REVIEW_NARRATIVECited in: Definition, Classification & Nomenclature, Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG)
[17]
De Meo E, Portaccio E, Giorgio A et al.. “Identifying the Distinct Cognitive Phenotypes in Multiple Sclerosis.” JAMA neurology (2021). PMID: 33393981 ↗
L4OTHERCited in: Definition, Classification & Nomenclature, Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG), History and Evolution of Treatment, Neurorehabilitation, Symptomatic & Supportive Care
[18]
Müller J, Sharmin S, Lorscheider J et al.. “Standardized Definition of Progression Independent of Relapse Activity (PIRA) in Relapsing-Remitting Multiple Sclerosis.” JAMA neurology (2025). PMID: 40227706 ↗
L2OTHERCited in: Definition, Classification & Nomenclature, Epidemiology, Etiology & Risk Factors, Severity, Staging & Risk Stratification, Prognosis & Natural History
[19]
Wolfova K, Engdahl BL, Horn J et al.. “Maternal Pregnancy Outcomes and Offspring Risk of Adult-Onset Multiple Sclerosis.” JAMA neurology (2026). PMID: 41525064 ↗
L2OTHERCited in: Definition, Classification & Nomenclature, Epidemiology, Etiology & Risk Factors, Special Populations & Pregnancy
[20]
Lim TR, Suthiphosuwan S, Gaitán MI et al.. “Paramagnetic Rim Lesions and Development of Clinical MS in Radiologically Isolated Syndrome.” JAMA neurology (2026). PMID: 41587044 ↗
L2OTHERCited in: Definition, Classification & Nomenclature
[21]
Thompson AJ, Baranzini SE, Geurts J et al.. “Multiple sclerosis.” Lancet (London, England) (2018). PMID: 29576504 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification & Nomenclature, Epidemiology, Etiology & Risk Factors, Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG), Neurorehabilitation, Symptomatic & Supportive Care
[22]
Jakimovski D, Bittner S, Zivadinov R et al.. “Multiple sclerosis.” Lancet (London, England) (2023). PMID: 37949093 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification & Nomenclature, Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG), Neurorehabilitation, Symptomatic & Supportive Care
[23]
Brownlee WJ, Hardy TA, Fazekas F et al.. “Diagnosis of multiple sclerosis: progress and challenges.” Lancet (London, England) (2016). PMID: 27889190 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification & Nomenclature
[24]
Salomon JA, Vos T, Hogan DR et al.. “Common values in assessing health outcomes from disease and injury: disability weights measurement study for the Global Burden of Disease Study 2010.” Lancet (London, England) (2012). PMID: 23245605 ↗
L2OTHERCited in: Definition, Classification & Nomenclature, Prevention, Screening & Surveillance
[25]
Wiles CM. “Physiotherapy and related activities in multiple sclerosis.” Multiple sclerosis (Houndmills, Basingstoke, England) (2008). PMID: 18535020 ↗
L5CASE_REPORTCited in: Definition, Classification & Nomenclature, Pathophysiology & Mechanism (Neuroanatomic Localization), Long-term & Definitive Management (Evidence Ladder), Neurorehabilitation, Symptomatic & Supportive Care
[26]
Kvistad CE, Kråkenes T, Holmøy T et al.. “Intrathecal Mesenchymal Stem Cells in Progressive Multiple Sclerosis: A Randomized, Double-Blind, Placebo-Controlled Trial (SMART-MS).” Neurology (2026). PMID: 42081777 ↗
L1RCTCited in: Definition, Classification & Nomenclature
[27]
Siger M, Hartel M, Majos A et al.. “Revised recommendations of the Polish Medical Society of Radiology and the Polish Neurological Society for a protocol concerning routinely used magnetic resonance imaging in patients with multiple sclerosis.” Neurologia i neurochirurgia polska (2026). PMID: 41983559 ↗
L1GUIDELINECited in: Definition, Classification & Nomenclature
[28]
Bagnato F, Sati P, Hemond CC et al.. “Imaging chronic active lesions in multiple sclerosis: a consensus statement.” Brain : a journal of neurology (2024). PMID: 38226694 ↗
L1REVIEW_NARRATIVECited in: Definition, Classification & Nomenclature
[29]
Lebrun-Frénay C, Okuda DT, Siva A et al.. “The radiologically isolated syndrome: revised diagnostic criteria.” Brain : a journal of neurology (2023). PMID: 36864688 ↗
L5OTHERCited in: Definition, Classification & Nomenclature, Epidemiology, Etiology & Risk Factors, History and Evolution of Treatment, Prognosis & Natural History
[30]
Filippi M, Preziosa P, Banwell BL et al.. “Assessment of lesions on magnetic resonance imaging in multiple sclerosis: practical guidelines.” Brain : a journal of neurology (2019). PMID: 31209474 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification & Nomenclature, Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG)
[31]
Lorscheider J, Buzzard K, Jokubaitis V et al.. “Defining secondary progressive multiple sclerosis.” Brain : a journal of neurology (2016). PMID: 27401521 ↗
L2OTHERCited in: Definition, Classification & Nomenclature
[32]
Takai Y, Misu T, Kaneko K et al.. “Myelin oligodendrocyte glycoprotein antibody-associated disease: an immunopathological study.” Brain : a journal of neurology (2020). PMID: 32412053 ↗
L4OTHERCited in: Definition, Classification & Nomenclature
[33]
Filippi M, Preziosa P, Barkhof F et al.. “The ageing central nervous system in multiple sclerosis: the imaging perspective.” Brain : a journal of neurology (2024). PMID: 39045667 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification & Nomenclature, Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG)
[34]
Scalfari A, Traboulsee A, Oh J et al.. “Smouldering-Associated Worsening in Multiple Sclerosis: An International Consensus Statement on Definition, Biology, Clinical Implications, and Future Directions.” Annals of neurology (2024). PMID: 39051525 ↗
L1REVIEW_NARRATIVECited in: Definition, Classification & Nomenclature, Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG), Complications, Prevention, Screening & Surveillance
[35]
Polman CH, Reingold SC, Banwell B et al.. “Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria.” Annals of neurology (2011). PMID: 21387374 ↗
L5OTHERCited in: Definition, Classification & Nomenclature, Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG)
[36]
Brownlee WJ, Vidal-Jordana A, Shatila M et al.. “Towards a Unified Set of Diagnostic Criteria for Multiple Sclerosis.” Annals of neurology (2024). PMID: 39605172 ↗
L3OTHERCited in: Definition, Classification & Nomenclature, Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG), History and Evolution of Treatment
[37]
Hamzaoui M, Garcia J, Boffa G et al.. “Positron Emission Tomography with [18 F]-DPA-714 Unveils a Smoldering Component in Most Multiple Sclerosis Lesions which Drives Disease Progression.” Annals of neurology (2023). PMID: 37039158 ↗
L2OTHERCited in: Definition, Classification & Nomenclature, Pathophysiology & Mechanism (Neuroanatomic Localization)
[38]
Gaudioso CM, Mar S, Casper TC et al.. “MOG and AQP4 Antibodies among Children with Multiple Sclerosis and Controls.” Annals of neurology (2022). PMID: 36088544 ↗
L3OTHERCited in: Definition, Classification & Nomenclature, Clinical Presentation, Special Populations & Pregnancy
[39]
Demuth S, Faddeenkov I, Paris J et al.. “PRIMUS: a precision medicine platform reusing clinical trials and registry data to support treatment selection in multiple sclerosis.” JAMIA open (2026). PMID: 42131074 ↗
L5TRIAL_NONRANDOMCited in: Definition, Classification & Nomenclature
[40]
Wu Y, Geraldes R, Juryńczyk M et al.. “Double-negative neuromyelitis optica spectrum disorder.” Multiple sclerosis (Houndmills, Basingstoke, England) (2023). PMID: 37740717 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification & Nomenclature
[41]
Hegen H, Arrambide G, Gnanapavan S et al.. “Cerebrospinal fluid kappa free light chains for the diagnosis of multiple sclerosis: A consensus statement.” Multiple sclerosis (Houndmills, Basingstoke, England) (2022). PMID: 36527368 ↗
L1OTHERCited in: Definition, Classification & Nomenclature, Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG)
[42]
Arrambide G, Iacobaeus E, Amato MP et al.. “Aggressive multiple sclerosis (2): Treatment.” Multiple sclerosis (Houndmills, Basingstoke, England) (2020). PMID: 32530366 ↗
L5OTHERCited in: Definition, Classification & Nomenclature
[43]
Kister I, Kantarci OH. “Multiple Sclerosis Severity Score: Concept and applications.” Multiple sclerosis (Houndmills, Basingstoke, England) (2020). PMID: 31965877 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification & Nomenclature, Severity, Staging & Risk Stratification
[44]
Phé V, Pakzad M, Curtis C et al.. “Urinary tract infections in multiple sclerosis.” Multiple sclerosis (Houndmills, Basingstoke, England) (2016). PMID: 26892318 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification & Nomenclature, Acute Management: Neurologic Emergencies & Attack Abortion
[45]
Santana JLS, Themoteo RM, Allioni GA et al.. “Is serum neurofilament light chain accurate enough to guide multiple sclerosis care? Diagnostic performance and optimal cutoff in a systematic review and meta-analysis.” Multiple sclerosis and related disorders (2026). PMID: 42364564 ↗
L1SR_OBSCited in: Definition, Classification & Nomenclature
[46]
Mirmosayyeb O, Panah Yazdan M, Tahmasbi Arashlow F et al.. “Optical coherence tomography measurements between multiple sclerosis and neuromyelitis optica spectrum disorder: A systematic review and meta-analysis.” Multiple sclerosis and related disorders (2026). PMID: 42139966 ↗
L1SR_OBSCited in: Definition, Classification & Nomenclature
[47]
Vagner P, Brayner B, Rauber F et al.. “Ultra-processed food consumption and multiple sclerosis incidence: A prospective cohort study.” Clinical nutrition (Edinburgh, Scotland) (2026). PMID: 42105610 ↗
L2COHORTCited in: Definition, Classification & Nomenclature
[48]
Hauser SL, Bar-Or A, Comi G et al.. “Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis.” The New England journal of medicine (2016). PMID: 28002679 ↗
L1RCTCited in: Pathophysiology & Mechanism (Neuroanatomic Localization), Severity, Staging & Risk Stratification, History and Evolution of Treatment
[49]
Vermersch P, Granziera C, Mao-Draayer Y et al.. “Inhibition of CD40L with Frexalimab in Multiple Sclerosis.” The New England journal of medicine (2024). PMID: 38354138 ↗
L1RCTCited in: Pathophysiology & Mechanism (Neuroanatomic Localization), Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG), Long-term & Definitive Management (Evidence Ladder), History and Evolution of Treatment
[50]
Hauser SL, Waubant E, Arnold DL et al.. “B-cell depletion with rituximab in relapsing-remitting multiple sclerosis.” The New England journal of medicine (2008). PMID: 18272891 ↗
L1RCTCited in: Pathophysiology & Mechanism (Neuroanatomic Localization), Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG), Long-term & Definitive Management (Evidence Ladder), History and Evolution of Treatment
[51]
Montalban X, Arnold DL, Weber MS et al.. “Placebo-Controlled Trial of an Oral BTK Inhibitor in Multiple Sclerosis.” The New England journal of medicine (2019). PMID: 31075187 ↗
L1RCTCited in: Pathophysiology & Mechanism (Neuroanatomic Localization), Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG), Severity, Staging & Risk Stratification, History and Evolution of Treatment, Prognosis & Natural History
[52]
Kappos L, Wiendl H, Selmaj K et al.. “Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis.” The New England journal of medicine (2015). PMID: 26444729 ↗
L1RCTCited in: Pathophysiology & Mechanism (Neuroanatomic Localization), Epidemiology, Etiology & Risk Factors
[53]
Kappos L, Li D, Calabresi PA et al.. “Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial.” Lancet (London, England) (2011). PMID: 22047971 ↗
L1RCTCited in: Pathophysiology & Mechanism (Neuroanatomic Localization), Long-term & Definitive Management (Evidence Ladder), History and Evolution of Treatment
[54]
Conrad N, Misra S, Verbakel JY et al.. “Incidence, prevalence, and co-occurrence of autoimmune disorders over time and by age, sex, and socioeconomic status: a population-based cohort study of 22 million individuals in the UK.” Lancet (London, England) (2023). PMID: 37156255 ↗
L2COHORTCited in: Pathophysiology & Mechanism (Neuroanatomic Localization), Epidemiology, Etiology & Risk Factors, Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG)
[55]
Koch MW, Kaur S, Sage K et al.. “Hydroxychloroquine for Primary Progressive Multiple Sclerosis.” Annals of neurology (2021). PMID: 34590328 ↗
L4TRIAL_NONRANDOMCited in: Pathophysiology & Mechanism (Neuroanatomic Localization), Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG), Prognosis & Natural History, Prevention, Screening & Surveillance
[56]
Zhornitsky S, Yong VW, Weiss S et al.. “Prolactin in multiple sclerosis.” Multiple sclerosis (Houndmills, Basingstoke, England) (2012). PMID: 22933621 ↗
L2SR_OBSCited in: Pathophysiology & Mechanism (Neuroanatomic Localization), Special Populations & Pregnancy
[57]
Steri M, Orrù V, Idda ML et al.. “Overexpression of the Cytokine BAFF and Autoimmunity Risk.” The New England journal of medicine (2017). PMID: 28445677 ↗
L3OTHERCited in: Pathophysiology & Mechanism (Neuroanatomic Localization)
[58]
Lucchinetti CF, Popescu BF, Bunyan RF et al.. “Inflammatory cortical demyelination in early multiple sclerosis.” The New England journal of medicine (2011). PMID: 22150037 ↗
L4OTHERCited in: Pathophysiology & Mechanism (Neuroanatomic Localization)
[59]
Srivastava R, Aslam M, Kalluri SR et al.. “Potassium channel KIR4.1 as an immune target in multiple sclerosis.” The New England journal of medicine (2012). PMID: 22784115 ↗
L3OTHERCited in: Pathophysiology & Mechanism (Neuroanatomic Localization)
[60]
Kuhlmann T, Moccia M, Coetzee T et al.. “Multiple sclerosis progression: time for a new mechanism-driven framework.” The Lancet. Neurology (2022). PMID: 36410373 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism (Neuroanatomic Localization), History and Evolution of Treatment
[61]
Cryan JF, O'Riordan KJ, Sandhu K et al.. “The gut microbiome in neurological disorders.” The Lancet. Neurology (2019). PMID: 31753762 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism (Neuroanatomic Localization), Epidemiology, Etiology & Risk Factors
[62]
Toosy AT, Mason DF, Miller DH. “Optic neuritis.” The Lancet. Neurology (2014). PMID: 24331795 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism (Neuroanatomic Localization), Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG)
[63]
Wingerchuk DM, Lennon VA, Lucchinetti CF et al.. “The spectrum of neuromyelitis optica.” The Lancet. Neurology (2007). PMID: 17706564 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism (Neuroanatomic Localization)
[64]
Aloisi F, Giovannoni G, Salvetti M. “Epstein-Barr virus as a cause of multiple sclerosis: opportunities for prevention and therapy.” The Lancet. Neurology (2023). PMID: 36764322 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism (Neuroanatomic Localization), History and Evolution of Treatment
[65]
Tan CS, Koralnik IJ. “Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis.” The Lancet. Neurology (2010). PMID: 20298966 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism (Neuroanatomic Localization), Clinical Presentation, Disease-Modifying & Immunotherapy Program: Sequencing, Safety Monitoring & De-escalation
[66]
Haghikia A, Schett G, Mougiakakos D. “B cell-targeting chimeric antigen receptor T cells as an emerging therapy in neuroimmunological diseases.” The Lancet. Neurology (2024). PMID: 38760099 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism (Neuroanatomic Localization), Disease-Modifying & Immunotherapy Program: Sequencing, Safety Monitoring & De-escalation
[67]
Pohl D, Alper G, Van Haren K et al.. “Acute disseminated encephalomyelitis: Updates on an inflammatory CNS syndrome.” Neurology (2016). PMID: 27572859 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism (Neuroanatomic Localization), Epidemiology, Etiology & Risk Factors, Clinical Presentation, Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG), Disease-Modifying & Immunotherapy Program: Sequencing, Safety Monitoring & De-escalation, Complications, Prognosis & Natural History, Special Populations & Pregnancy
[68]
Kluger BM, Krupp LB, Enoka RM. “Fatigue and fatigability in neurologic illnesses: proposal for a unified taxonomy.” Neurology (2013). PMID: 23339207 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism (Neuroanatomic Localization), Neurorehabilitation, Symptomatic & Supportive Care
[69]
Schweitzer F, Laurent S, Cortese I et al.. “Progressive Multifocal Leukoencephalopathy: Pathogenesis, Diagnostic Tools, and Potential Biomarkers of Response to Therapy.” Neurology (2023). PMID: 37487750 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism (Neuroanatomic Localization), Clinical Presentation, Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG), Disease-Modifying & Immunotherapy Program: Sequencing, Safety Monitoring & De-escalation, Prognosis & Natural History
[70]
Saucier L, Rossor T, Gorman MP et al.. “Diagnosis and Management of Children With Atypical Neuroinflammation.” Neurology (2025). PMID: 40184590 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism (Neuroanatomic Localization), Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG), Acute Management: Neurologic Emergencies & Attack Abortion, Disease-Modifying & Immunotherapy Program: Sequencing, Safety Monitoring & De-escalation, Special Populations & Pregnancy
[71]
Absoud M, Greenberg BM, Lim M et al.. “Pediatric transverse myelitis.” Neurology (2016). PMID: 27572861 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism (Neuroanatomic Localization), Clinical Presentation, Acute Management: Neurologic Emergencies & Attack Abortion, Special Populations & Pregnancy
[72]
Ciccarelli O, Barkhof F, Calabrese M et al.. “Using the Progression Independent of Relapse Activity Framework to Unveil the Pathobiological Foundations of Multiple Sclerosis.” Neurology (2024). PMID: 38889384 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism (Neuroanatomic Localization), Severity, Staging & Risk Stratification, Complications
[73]
Louis S, Carlson AK, Suresh A et al.. “Impacts of Climate Change and Air Pollution on Neurologic Health, Disease, and Practice: A Scoping Review.” Neurology (2022). PMID: 36384657 ↗
L2REVIEW_NARRATIVECited in: Pathophysiology & Mechanism (Neuroanatomic Localization), Severity, Staging & Risk Stratification
[74]
Tenembaum S, Chitnis T, Ness J et al.. “Acute disseminated encephalomyelitis.” Neurology (2007). PMID: 17438235 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism (Neuroanatomic Localization), Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG), Special Populations & Pregnancy
[75]
Ayroza Galvão Ribeiro Gomes AB, Kulsvehagen L, Lipps P et al.. “Immunoglobulin A Antibodies Against Myelin Oligodendrocyte Glycoprotein in a Subgroup of Patients With Central Nervous System Demyelination.” JAMA neurology (2023). PMID: 37548987 ↗
L3OTHERCited in: Pathophysiology & Mechanism (Neuroanatomic Localization), Clinical Presentation
[76]
Backner Y, Kuchling J, Massarwa S et al.. “Anatomical Wiring and Functional Networking Changes in the Visual System Following Optic Neuritis.” JAMA neurology (2018). PMID: 29297053 ↗
L2OTHERCited in: Pathophysiology & Mechanism (Neuroanatomic Localization)
[77]
Brück W, Gold R, Lund BT et al.. “Therapeutic decisions in multiple sclerosis: moving beyond efficacy.” JAMA neurology (2013). PMID: 23921521 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism (Neuroanatomic Localization)
[78]
Alvermann S, Hennig C, Stüve O et al.. “Immunophenotyping of cerebrospinal fluid cells in multiple sclerosis: in search of biomarkers.” JAMA neurology (2014). PMID: 24818670 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism (Neuroanatomic Localization)
[79]
Marshall O, Lu H, Brisset JC et al.. “Impaired cerebrovascular reactivity in multiple sclerosis.” JAMA neurology (2014). PMID: 25133874 ↗
L3OTHERCited in: Pathophysiology & Mechanism (Neuroanatomic Localization)
[80]
Zipp F, Gold R, Wiendl H. “Identification of inflammatory neuronal injury and prevention of neuronal damage in multiple sclerosis: hope for novel therapies?” JAMA neurology (2013). PMID: 24145957 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism (Neuroanatomic Localization), Prevention, Screening & Surveillance
[81]
Frohman EM, Monaco MC, Remington G et al.. “JC virus in CD34+ and CD19+ cells in patients with multiple sclerosis treated with natalizumab.” JAMA neurology (2014). PMID: 24664166 ↗
L3OTHERCited in: Pathophysiology & Mechanism (Neuroanatomic Localization)
[82]
Zurawski J, Lassmann H, Bakshi R. “Use of Magnetic Resonance Imaging to Visualize Leptomeningeal Inflammation in Patients With Multiple Sclerosis: A Review.” JAMA neurology (2017). PMID: 27893883 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism (Neuroanatomic Localization)
[83]
Brown RB, Traylor M, Burgess S et al.. “Do Cerebral Small Vessel Disease and Multiple Sclerosis Share Common Mechanisms of White Matter Injury?” Stroke (2019). PMID: 31221055 ↗
L2OTHERCited in: Pathophysiology & Mechanism (Neuroanatomic Localization), Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG), Severity, Staging & Risk Stratification
[84]
Qin C, Fan WH, Liu Q et al.. “Fingolimod Protects Against Ischemic White Matter Damage by Modulating Microglia Toward M2 Polarization via STAT3 Pathway.” Stroke (2017). PMID: 29114096 ↗
L5OTHERCited in: Pathophysiology & Mechanism (Neuroanatomic Localization)
[85]
Vogelgesang A, Domanska G, Ruhnau J et al.. “Siponimod (BAF312) Treatment Reduces Brain Infiltration but Not Lesion Volume in Middle-Aged Mice in Experimental Stroke.” Stroke (2019). PMID: 31009359 ↗
L5OTHERCited in: Pathophysiology & Mechanism (Neuroanatomic Localization), Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG), Prognosis & Natural History
[86]
Zhao X, Sun G, Zhang J et al.. “Dimethyl Fumarate Protects Brain From Damage Produced by Intracerebral Hemorrhage by Mechanism Involving Nrf2.” Stroke (2015). PMID: 25977275 ↗
L5OTHERCited in: Pathophysiology & Mechanism (Neuroanatomic Localization)
[87]
Schett G, Mackensen A, Mougiakakos D. “CAR T-cell therapy in autoimmune diseases.” Lancet (London, England) (2023). PMID: 37748491 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism (Neuroanatomic Localization)
[88]
McGinley MP, Cohen JA. “Sphingosine 1-phosphate receptor modulators in multiple sclerosis and other conditions.” Lancet (London, England) (2021). PMID: 34175020 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism (Neuroanatomic Localization)
[89]
Vincent A, Crino PB. “Systemic and neurologic autoimmune disorders associated with seizures or epilepsy.” Epilepsia (2011). PMID: 21542840 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism (Neuroanatomic Localization), Epidemiology, Etiology & Risk Factors, Clinical Presentation
[90]
Lublin FD, Häring DA, Ganjgahi H et al.. “How patients with multiple sclerosis acquire disability.” Brain : a journal of neurology (2022). PMID: 35104840 ↗
L2OTHERCited in: Pathophysiology & Mechanism (Neuroanatomic Localization), Epidemiology, Etiology & Risk Factors, Severity, Staging & Risk Stratification, Long-term & Definitive Management (Evidence Ladder), Disease-Modifying & Immunotherapy Program: Sequencing, Safety Monitoring & De-escalation, Prognosis & Natural History
[91]
Lin J, Zhou J, Xu Y. “Potential drug targets for multiple sclerosis identified through Mendelian randomization analysis.” Brain : a journal of neurology (2023). PMID: 36864689 ↗
L2OTHERCited in: Pathophysiology & Mechanism (Neuroanatomic Localization), Prognosis & Natural History, Prevention, Screening & Surveillance
[92]
Belbasis L, Morris S, van Duijn C et al.. “Mendelian randomization identifies proteins involved in neurodegenerative diseases.” Brain : a journal of neurology (2025). PMID: 40037332 ↗
L2OTHERCited in: Pathophysiology & Mechanism (Neuroanatomic Localization), Severity, Staging & Risk Stratification
[93]
Carotenuto A, Cacciaguerra L, Pagani E et al.. “Glymphatic system impairment in multiple sclerosis: relation with brain damage and disability.” Brain : a journal of neurology (2022). PMID: 34919648 ↗
L2OTHERCited in: Pathophysiology & Mechanism (Neuroanatomic Localization)
[94]
Furlan R, Schaedelin S, Frederiksen JL et al.. “Granulocyte and astrocyte markers distinguish MOG-antibody disease and neuromyelitis optica from multiple sclerosis.” Brain : a journal of neurology (2026). PMID: 40988129 ↗
L2OTHERCited in: Pathophysiology & Mechanism (Neuroanatomic Localization), Severity, Staging & Risk Stratification
[95]
Sun J, Guo M, Chai L et al.. “Distinct virtual histology of grey matter atrophy in four neuroinflammatory diseases.” Brain : a journal of neurology (2024). PMID: 38703370 ↗
L2OTHERCited in: Pathophysiology & Mechanism (Neuroanatomic Localization), Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG)
[96]
Huang J, Tengvall K, Lima IB et al.. “Genetics of immune response to Epstein-Barr virus: prospects for multiple sclerosis pathogenesis.” Brain : a journal of neurology (2024). PMID: 38630618 ↗
L3OTHERCited in: Pathophysiology & Mechanism (Neuroanatomic Localization), Epidemiology, Etiology & Risk Factors, Severity, Staging & Risk Stratification, History and Evolution of Treatment
[97]
Herranz E, Treaba CA, Barletta VT et al.. “Characterization of cortico-meningeal translocator protein expression in multiple sclerosis.” Brain : a journal of neurology (2024). PMID: 38289855 ↗
L2OTHERCited in: Pathophysiology & Mechanism (Neuroanatomic Localization), Severity, Staging & Risk Stratification
[98]
Comi G, Bar-Or A, Lassmann H et al.. “Role of B Cells in Multiple Sclerosis and Related Disorders.” Annals of neurology (2020). PMID: 33091175 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism (Neuroanatomic Localization)
[99]
Greenfield AL, Hauser SL. “B-cell Therapy for Multiple Sclerosis: Entering an era.” Annals of neurology (2018). PMID: 29244240 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism (Neuroanatomic Localization)
[100]
Papadopoulos D, Magliozzi R, Bandiera S et al.. “Accelerated Cellular Senescence in Progressive Multiple Sclerosis: A Histopathological Study.” Annals of neurology (2025). PMID: 39891488 ↗
L3OTHERCited in: Pathophysiology & Mechanism (Neuroanatomic Localization)
[101]
Murphy OC, Sotirchos ES, Kalaitzidis G et al.. “Trans-Synaptic Degeneration Following Acute Optic Neuritis in Multiple Sclerosis.” Annals of neurology (2022). PMID: 36218157 ↗
L2OTHERCited in: Pathophysiology & Mechanism (Neuroanatomic Localization)
[102]
Wollebo HS, White MK, Gordon J et al.. “Persistence and pathogenesis of the neurotropic polyomavirus JC.” Annals of neurology (2015). PMID: 25623836 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism (Neuroanatomic Localization)
[103]
Cohen JA, Chun J. “Mechanisms of fingolimod's efficacy and adverse effects in multiple sclerosis.” Annals of neurology (2011). PMID: 21520239 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism (Neuroanatomic Localization), Complications
[104]
Zhang Y, Atkinson J, Burd CE et al.. “Biological aging in multiple sclerosis.” Multiple sclerosis (Houndmills, Basingstoke, England) (2023). PMID: 37877740 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism (Neuroanatomic Localization), Disease-Modifying & Immunotherapy Program: Sequencing, Safety Monitoring & De-escalation
[105]
Bhargava P, Calabresi PA. “Metabolomics in multiple sclerosis.” Multiple sclerosis (Houndmills, Basingstoke, England) (2016). PMID: 26754801 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism (Neuroanatomic Localization), Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG), Prognosis & Natural History
[106]
Soelberg Sorensen P, Giovannoni G, Montalban X et al.. “The Multiple Sclerosis Care Unit.” Multiple sclerosis (Houndmills, Basingstoke, England) (2018). PMID: 30351211 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism (Neuroanatomic Localization), Disease-Modifying & Immunotherapy Program: Sequencing, Safety Monitoring & De-escalation, Neurorehabilitation, Symptomatic & Supportive Care
[107]
Bergsland N, Dwyer MG, Zivadinov R. “Imaging the Choroid Plexus.” Multiple sclerosis (Houndmills, Basingstoke, England) (2024). PMID: 39658900 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism (Neuroanatomic Localization), Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG)
[108]
Tur C, Montalban X. “Progressive MS trials: Lessons learned.” Multiple sclerosis (Houndmills, Basingstoke, England) (2017). PMID: 29041872 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism (Neuroanatomic Localization), Long-term & Definitive Management (Evidence Ladder), Disease-Modifying & Immunotherapy Program: Sequencing, Safety Monitoring & De-escalation
[109]
Bhargava P, Anthony DC. “Metabolomics in multiple sclerosis disease course and progression.” Multiple sclerosis (Houndmills, Basingstoke, England) (2020). PMID: 31965880 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism (Neuroanatomic Localization)
[110]
Koks F, Reubens F, van der Zee H et al.. “The dual role of mTOR in multiple sclerosis pathophysiology: a systematic review.” Journal of neurology (2026). PMID: 42390760 ↗
L5SR_OBSCited in: Pathophysiology & Mechanism (Neuroanatomic Localization)
[111]
Bartczak J, Gronowski P, Małek M et al.. “Experimental Therapies in Multiple Sclerosis: Epstein-Barr Virus and Potential EBV-Related Therapeutic Strategies-A Systematic Review.” Journal of clinical medicine (2026). PMID: 42278964 ↗
L2SR_OBSCited in: Pathophysiology & Mechanism (Neuroanatomic Localization), Disease-Modifying & Immunotherapy Program: Sequencing, Safety Monitoring & De-escalation, Prevention, Screening & Surveillance
[112]
Abbasi H, Ahmadi B, Sherafati N et al.. “The Association Between Serum α-Tocopherol and Pathogenesis of Multiple Sclerosis: A Systematic Review and Meta-Analysis of Case-Control Studies.” BioMed research international (2026). PMID: 42421296 ↗
L3SR_OBSCited in: Pathophysiology & Mechanism (Neuroanatomic Localization), Prevention, Screening & Surveillance
[113]
Sedighi B, Jafari S, Rahmati S et al.. “The Association between Dairy Consumption and the Risk of Developing Multiple Sclerosis: A Systematic Review and Meta-Analysis.” Iranian journal of public health (2025). PMID: 42428733 ↗
L2SR_OBSCited in: Pathophysiology & Mechanism (Neuroanatomic Localization)
[114]
Mirchi A, Vossough A, Liu GT et al.. “Pearls & Oy-sters: Radiologic Lag in Pediatric-Onset Multiple Sclerosis.” Neurology (2026). PMID: 42320011 ↗
L4CASE_REPORTCited in: Pathophysiology & Mechanism (Neuroanatomic Localization)
[115]
Bernaerts E, De Visscher A, Vanherle S et al.. “Matrix metalloprotease-9 modulates microglial/macrophage responses in murine brain demyelination.” Acta neuropathologica communications (2026). PMID: 42432780 ↗
L5OTHERCited in: Pathophysiology & Mechanism (Neuroanatomic Localization), Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG)
[116]
Lu K, Lu Y, Tang R et al.. “Mechanisms of autophagy-lysosome pathway impairment in Alzheimer's disease.” Journal of Alzheimer's disease : JAD (2026). PMID: 42429504 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism (Neuroanatomic Localization)
[117]
Suhadolc A, Horvat S, Kos J et al.. “Glial Cysteine Cathepsins: From Homeostasis to Neurodegeneration.” Cellular and molecular neurobiology (2026). PMID: 42426293 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism (Neuroanatomic Localization), Clinical Presentation
[118]
Zesiewicz TA, Wilmot G, Kuo SH et al.. “Comprehensive systematic review summary: Treatment of cerebellar motor dysfunction and ataxia [RETIRED]: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology.” Neurology (2018). PMID: 29440566 ↗
L1GUIDELINECited in: Epidemiology, Etiology & Risk Factors, History and Evolution of Treatment, Neurorehabilitation, Symptomatic & Supportive Care
[119]
Torkildsen Ø, Brustad HK, Høgestøl EA et al.. “Rituximab versus Ocrelizumab in Newly Diagnosed Relapsing Multiple Sclerosis.” The New England journal of medicine (2026). PMID: 42384870 ↗
L1RCTCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG), History and Evolution of Treatment, Prognosis & Natural History
[120]
O'Connor P, Wolinsky JS, Confavreux C et al.. “Randomized trial of oral teriflunomide for relapsing multiple sclerosis.” The New England journal of medicine (2011). PMID: 21991951 ↗
L1RCTCited in: Epidemiology, Etiology & Risk Factors, Severity, Staging & Risk Stratification, Long-term & Definitive Management (Evidence Ladder), Disease-Modifying & Immunotherapy Program: Sequencing, Safety Monitoring & De-escalation
[121]
Fox RJ, Miller DH, Phillips JT et al.. “Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis.” The New England journal of medicine (2012). PMID: 22992072 ↗
L1RCTCited in: Epidemiology, Etiology & Risk Factors
[122]
Kappos L, Fox RJ, Burcklen M et al.. “Ponesimod Compared With Teriflunomide in Patients With Relapsing Multiple Sclerosis in the Active-Comparator Phase 3 OPTIMUM Study: A Randomized Clinical Trial.” JAMA neurology (2021). PMID: 33779698 ↗
L1RCTCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG), Severity, Staging & Risk Stratification, Long-term & Definitive Management (Evidence Ladder), History and Evolution of Treatment, Disease-Modifying & Immunotherapy Program: Sequencing, Safety Monitoring & De-escalation
[123]
Cree BAC, Fox E, Hartung HP et al.. “Five Years of Ublituximab in Multiple Sclerosis: ULTIMATE I and II Open-Label Extension Study.” JAMA neurology (2026). PMID: 41697690 ↗
L2RCTCited in: Epidemiology, Etiology & Risk Factors, Long-term & Definitive Management (Evidence Ladder), History and Evolution of Treatment
[124]
Chen Y, Bord E, Tompkins T et al.. “Asymptomatic reactivation of JC virus in patients treated with natalizumab.” The New England journal of medicine (2009). PMID: 19741227 ↗
L4TRIAL_NONRANDOMCited in: Epidemiology, Etiology & Risk Factors, Disease-Modifying & Immunotherapy Program: Sequencing, Safety Monitoring & De-escalation
[125]
Belbasis L, Bellou V, Evangelou E et al.. “Environmental risk factors and multiple sclerosis: an umbrella review of systematic reviews and meta-analyses.” The Lancet. Neurology (2015). PMID: 25662901 ↗
L2SR_OBSCited in: Epidemiology, Etiology & Risk Factors
[126]
Butzkueven H, Ponsonby AL, Stein MS et al.. “Vitamin D did not reduce multiple sclerosis disease activity after a clinically isolated syndrome.” Brain : a journal of neurology (2024). PMID: 38085047 ↗
L2RCTCited in: Epidemiology, Etiology & Risk Factors, History and Evolution of Treatment, Prognosis & Natural History
[127]
Feigin VL, Vos T, Alahdab F et al.. “Burden of Neurological Disorders Across the US From 1990-2017: A Global Burden of Disease Study.” JAMA neurology (2021). PMID: 33136137 ↗
L2SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Complications, Prognosis & Natural History
[128]
Chen H, Kwong JC, Copes R et al.. “Living near major roads and the incidence of dementia, Parkinson's disease, and multiple sclerosis: a population-based cohort study.” Lancet (London, England) (2017). PMID: 28063597 ↗
L2COHORTCited in: Epidemiology, Etiology & Risk Factors
[129]
Traboulsee AL, Knox KB, Machan L et al.. “Prevalence of extracranial venous narrowing on catheter venography in people with multiple sclerosis, their siblings, and unrelated healthy controls: a blinded, case-control study.” Lancet (London, England) (2013). PMID: 24119384 ↗
L3CASE_CONTROLCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG)
[130]
Munk Nielsen N, Corn G, Frisch M et al.. “Multiple sclerosis among first- and second-generation immigrants in Denmark: a population-based cohort study.” Brain : a journal of neurology (2019). PMID: 31081503 ↗
L2COHORTCited in: Epidemiology, Etiology & Risk Factors
[131]
Benedict RHB, Amato MP, DeLuca J et al.. “Cognitive impairment in multiple sclerosis: clinical management, MRI, and therapeutic avenues.” The Lancet. Neurology (2020). PMID: 32949546 ↗
L5CASE_REPORTCited in: Epidemiology, Etiology & Risk Factors, Acute Management: Neurologic Emergencies & Attack Abortion
[132]
Rahimov F, Jacobs BM, Lee JS et al.. “Common Diseases in Clinical Cohorts - Not Always What They Seem.” The New England journal of medicine (2025). PMID: 41124632 ↗
L2OTHERCited in: Epidemiology, Etiology & Risk Factors
[133]
Hafler DA, Compston A, Sawcer S et al.. “Risk alleles for multiple sclerosis identified by a genomewide study.” The New England journal of medicine (2007). PMID: 17660530 ↗
L3OTHERCited in: Epidemiology, Etiology & Risk Factors
[134]
Bloomgren G, Richman S, Hotermans C et al.. “Risk of natalizumab-associated progressive multifocal leukoencephalopathy.” The New England journal of medicine (2012). PMID: 22591293 ↗
L2OTHERCited in: Epidemiology, Etiology & Risk Factors, Disease-Modifying & Immunotherapy Program: Sequencing, Safety Monitoring & De-escalation
[135]
Lebrun-Frenay C, Kantarci O, Siva A et al.. “Radiologically isolated syndrome.” The Lancet. Neurology (2023). PMID: 37839432 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Etiology & Risk Factors, History and Evolution of Treatment
[136]
. “Global, regional, and national burden of neurological disorders, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016.” The Lancet. Neurology (2019). PMID: 30879893 ↗
L2OTHERCited in: Epidemiology, Etiology & Risk Factors, Neurorehabilitation, Symptomatic & Supportive Care, Complications
[137]
. “Global, regional, and national burden of multiple sclerosis 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016.” The Lancet. Neurology (2019). PMID: 30679040 ↗
L2OTHERCited in: Epidemiology, Etiology & Risk Factors
[138]
Miller DH, Chard DT, Ciccarelli O. “Clinically isolated syndromes.” The Lancet. Neurology (2012). PMID: 22265211 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Etiology & Risk Factors, Clinical Presentation
[139]
Cruccu G, Finnerup NB, Jensen TS et al.. “Trigeminal neuralgia: New classification and diagnostic grading for practice and research.” Neurology (2016). PMID: 27306631 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Etiology & Risk Factors, Neurorehabilitation, Symptomatic & Supportive Care
[140]
Hauser SL, Kappos L, Montalban X et al.. “Safety of Ocrelizumab in Patients With Relapsing and Primary Progressive Multiple Sclerosis.” Neurology (2021). PMID: 34475123 ↗
L2OTHERCited in: Epidemiology, Etiology & Risk Factors, History and Evolution of Treatment
[141]
Zhang C, Liu W, Wang L et al.. “Prevalence and Burden of Multiple Sclerosis in China, 1990-2019: Findings From the Global Burden of Disease Study 2019.” Neurology (2024). PMID: 38759127 ↗
L2OTHERCited in: Epidemiology, Etiology & Risk Factors, Complications
[142]
Wallin MT, Culpepper WJ, Campbell JD et al.. “The prevalence of MS in the United States: A population-based estimate using health claims data.” Neurology (2019). PMID: 30770430 ↗
L2OTHERCited in: Epidemiology, Etiology & Risk Factors
[143]
Luna G, Alping P, Burman J et al.. “Infection Risks Among Patients With Multiple Sclerosis Treated With Fingolimod, Natalizumab, Rituximab, and Injectable Therapies.” JAMA neurology (2020). PMID: 31589278 ↗
L2OTHERCited in: Epidemiology, Etiology & Risk Factors, Disease-Modifying & Immunotherapy Program: Sequencing, Safety Monitoring & De-escalation
[144]
Fissolo N, Schaedelin S, Villar LM et al.. “Prognostic Factors for Multiple Sclerosis Symptoms in Radiologically Isolated Syndrome.” JAMA neurology (2025). PMID: 40455494 ↗
L2OTHERCited in: Epidemiology, Etiology & Risk Factors
[145]
Iaffaldano P, Portaccio E, Lucisano G et al.. “Multiple Sclerosis Progression and Relapse Activity in Children.” JAMA neurology (2024). PMID: 38010712 ↗
L2OTHERCited in: Epidemiology, Etiology & Risk Factors, Disease-Modifying & Immunotherapy Program: Sequencing, Safety Monitoring & De-escalation, Special Populations & Pregnancy
[146]
Koch M, Uyttenboogaart M, Polman S et al.. “Seizures in multiple sclerosis.” Epilepsia (2008). PMID: 18336559 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Etiology & Risk Factors, Clinical Presentation, Prognosis & Natural History
[147]
Li EC, Zheng Y, Cai MT et al.. “Seizures and epilepsy in multiple sclerosis, aquaporin 4 antibody-positive neuromyelitis optica spectrum disorder, and myelin oligodendrocyte glycoprotein antibody-associated disease.” Epilepsia (2022). PMID: 35652436 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Etiology & Risk Factors, Severity, Staging & Risk Stratification, Acute Management: Neurologic Emergencies & Attack Abortion, Disease-Modifying & Immunotherapy Program: Sequencing, Safety Monitoring & De-escalation
[148]
Håkansson S, Karlander M, Larsson D et al.. “Potential for improved retention rate by personalized antiseizure medication selection: A register-based analysis.” Epilepsia (2021). PMID: 34245010 ↗
L2OTHERCited in: Epidemiology, Etiology & Risk Factors, History and Evolution of Treatment
[149]
Petzold A, Chua SYL, Khawaja AP et al.. “Retinal asymmetry in multiple sclerosis.” Brain : a journal of neurology (2021). PMID: 33253371 ↗
L2OTHERCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG), Prevention, Screening & Surveillance
[150]
Jacobs BM, Vandebergh M, Maltby VE et al.. “Interplay between genetic and environmental risk factors in multiple sclerosis: what have we learned?” Brain : a journal of neurology (2026). PMID: 41889330 ↗
L5OTHERCited in: Epidemiology, Etiology & Risk Factors
[151]
Akada M, Hata M, Miyake M et al.. “Natural experiment on neuroinflammatory disease incidence and infection links pre- and post-COVID-19.” Brain : a journal of neurology (2026). PMID: 41359492 ↗
L2OTHERCited in: Epidemiology, Etiology & Risk Factors
[152]
Disanto G, Barro C, Benkert P et al.. “Serum Neurofilament light: A biomarker of neuronal damage in multiple sclerosis.” Annals of neurology (2017). PMID: 28512753 ↗
L2OTHERCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG), Severity, Staging & Risk Stratification, Disease-Modifying & Immunotherapy Program: Sequencing, Safety Monitoring & De-escalation
[153]
Brahic M. “Multiple sclerosis and viruses.” Annals of neurology (2010). PMID: 20582990 ↗
L5OTHERCited in: Epidemiology, Etiology & Risk Factors
[154]
Dal Bianco A, Bradl M, Frischer J et al.. “Multiple sclerosis and Alzheimer's disease.” Annals of neurology (2008). PMID: 17924575 ↗
L3OTHERCited in: Epidemiology, Etiology & Risk Factors
[155]
Manouchehrinia A, Fitzgerald KC, Salter A et al.. “Depression Polygenicity and Disease Activity and Disability Worsening in Multiple Sclerosis.” Annals of neurology (2025). PMID: 40772555 ↗
L2OTHERCited in: Epidemiology, Etiology & Risk Factors
[156]
Ascherio A, Munger KL. “Environmental risk factors for multiple sclerosis. Part II: Noninfectious factors.” Annals of neurology (2007). PMID: 17492755 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Etiology & Risk Factors
[157]
Dobson R, Jitlal M, Marshall CR et al.. “Ethnic and Socioeconomic Associations with Multiple Sclerosis Risk.” Annals of neurology (2020). PMID: 31975487 ↗
L3OTHERCited in: Epidemiology, Etiology & Risk Factors
[158]
Ascherio A, Munger KL. “Environmental risk factors for multiple sclerosis. Part I: the role of infection.” Annals of neurology (2007). PMID: 17444504 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Etiology & Risk Factors
[159]
Walton C, King R, Rechtman L et al.. “Rising prevalence of multiple sclerosis worldwide: Insights from the Atlas of MS, third edition.” Multiple sclerosis (Houndmills, Basingstoke, England) (2020). PMID: 33174475 ↗
L4OTHERCited in: Epidemiology, Etiology & Risk Factors, Prevention, Screening & Surveillance
[160]
Hearn AP, Silber E. “Osteoporosis in multiple sclerosis.” Multiple sclerosis (Houndmills, Basingstoke, England) (2010). PMID: 20551086 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG), Complications, Prognosis & Natural History, Prevention, Screening & Surveillance
[161]
Feinstein A, Pavisian B. “Multiple sclerosis and suicide.” Multiple sclerosis (Houndmills, Basingstoke, England) (2017). PMID: 28327056 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Etiology & Risk Factors, Complications, Prevention, Screening & Surveillance
[162]
Feinstein A. “Multiple sclerosis and depression.” Multiple sclerosis (Houndmills, Basingstoke, England) (2011). PMID: 22058085 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Etiology & Risk Factors, Long-term & Definitive Management (Evidence Ladder), Neurorehabilitation, Symptomatic & Supportive Care, Complications, Prognosis & Natural History, Prevention, Screening & Surveillance
[163]
Dobson R, Ramagopalan S, Giovannoni G. “Bone health and multiple sclerosis.” Multiple sclerosis (Houndmills, Basingstoke, England) (2012). PMID: 22740489 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Etiology & Risk Factors, Complications, Prognosis & Natural History
[164]
Freedman DE, Krysko KM, Feinstein A. “Intimate partner violence and multiple sclerosis.” Multiple sclerosis (Houndmills, Basingstoke, England) (2023). PMID: 37732567 ↗
L5OTHERCited in: Epidemiology, Etiology & Risk Factors
[165]
Marrodan M, Alessandro L, Farez MF et al.. “The role of infections in multiple sclerosis.” Multiple sclerosis (Houndmills, Basingstoke, England) (2019). PMID: 30638421 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Etiology & Risk Factors
[166]
. “Corrigendum.” Multiple sclerosis (Houndmills, Basingstoke, England) (2017). PMID: 28608736 ↗
L5OTHERCited in: Epidemiology, Etiology & Risk Factors
[167]
White E, Adanijo A, Papiernik-Berkhauer P et al.. “Effectiveness of non-pharmacological treatments for sexual difficulties in adults with multiple sclerosis: a systematic review and meta-analysis.” Sexual medicine reviews (2026). PMID: 42407255 ↗
L1SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Neurorehabilitation, Symptomatic & Supportive Care
[168]
Hammadeh BM, Sameer S, Alnajjar M et al.. “Efficacy and safety of extended-interval dosing of natalizumab in multiple sclerosis: a systematic review and meta-analysis with subgroup evaluation.” Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology (2026). PMID: 42393408 ↗
L1SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Disease-Modifying & Immunotherapy Program: Sequencing, Safety Monitoring & De-escalation, Prognosis & Natural History
[169]
Horsdal HT, Heitmann B, Boelt SG et al.. “Neonatal vitamin D levels and autoimmune disorders: a Danish population-based cohort study.” European journal of epidemiology (2026). PMID: 42418142 ↗
L2COHORTCited in: Epidemiology, Etiology & Risk Factors
[170]
Maunula A, Laakso SM, Viitala M et al.. “Cancer risk and mortality in patients with multiple sclerosis in Finland: a retrospective population-based cohort study.” Journal of neurology, neurosurgery, and psychiatry (2026). PMID: 42386505 ↗
L2COHORTCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG), Complications
[171]
Paybast S, Asl Fallah E, Sahraian MA et al.. “Pregnancy outcomes in patients with multiple sclerosis with or without exposure to disease-modifying treatment: A retrospective cohort study on Iranian population.” Multiple sclerosis and related disorders (2026). PMID: 42322960 ↗
L2COHORTCited in: Epidemiology, Etiology & Risk Factors, Disease-Modifying & Immunotherapy Program: Sequencing, Safety Monitoring & De-escalation, Special Populations & Pregnancy
[172]
Althobaiti AH, Elrashidy MA, Alabdulhadi AS et al.. “Anti-JCV antibody seroprevalence and testing practices in multiple sclerosis patients considered for natalizumab therapy: a retrospective study from King Saud Medical City, Riyadh, Saudi Arabia.” Multiple sclerosis and related disorders (2026). PMID: 42287857 ↗
L4COHORTCited in: Epidemiology, Etiology & Risk Factors, Disease-Modifying & Immunotherapy Program: Sequencing, Safety Monitoring & De-escalation
[173]
Galus W, Winder M, Owczarek AJ et al.. “Smoking, Comorbidities, and Low Sun Exposure Are Associated with Clinical and Radiological Outcomes in Patients with Multiple Sclerosis-A Four-Year Observational Cohort Study.” Journal of clinical medicine (2026). PMID: 42279131 ↗
L2COHORTCited in: Epidemiology, Etiology & Risk Factors
[174]
Cohen JA, Reingold SC, Polman CH et al.. “Disability outcome measures in multiple sclerosis clinical trials: current status and future prospects.” The Lancet. Neurology (2012). PMID: 22516081 ↗
L5TRIAL_NONRANDOMCited in: Clinical Presentation, Neurorehabilitation, Symptomatic & Supportive Care
[175]
Filippi M, Preziosa P, Meani A et al.. “Prediction of a multiple sclerosis diagnosis in patients with clinically isolated syndrome using the 2016 MAGNIMS and 2010 McDonald criteria: a retrospective study.” The Lancet. Neurology (2017). PMID: 29275979 ↗
L2COHORTCited in: Clinical Presentation
[176]
Otero-Romero S, Sastre-Garriga J, Comi G et al.. “Pharmacological management of spasticity in multiple sclerosis: Systematic review and consensus paper.” Multiple sclerosis (Houndmills, Basingstoke, England) (2016). PMID: 27207462 ↗
L1SR_OBSCited in: Clinical Presentation
[177]
Yousry TA, Major EO, Ryschkewitsch C et al.. “Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy.” The New England journal of medicine (2006). PMID: 16510746 ↗
L4OTHERCited in: Clinical Presentation, Disease-Modifying & Immunotherapy Program: Sequencing, Safety Monitoring & De-escalation
[178]
Renoux C, Vukusic S, Mikaeloff Y et al.. “Natural history of multiple sclerosis with childhood onset.” The New England journal of medicine (2007). PMID: 17582070 ↗
L2OTHERCited in: Clinical Presentation
[179]
Thompson AJ, Banwell BL, Barkhof F et al.. “Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria.” The Lancet. Neurology (2017). PMID: 29275977 ↗
L1REVIEW_NARRATIVECited in: Clinical Presentation, Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG)
[180]
Miller DH, Leary SM. “Primary-progressive multiple sclerosis.” The Lancet. Neurology (2007). PMID: 17884680 ↗
L5REVIEW_NARRATIVECited in: Clinical Presentation
[181]
Cortese R, Prados Carrasco F, Tur C et al.. “Differentiating Multiple Sclerosis From AQP4-Neuromyelitis Optica Spectrum Disorder and MOG-Antibody Disease With Imaging.” Neurology (2022). PMID: 36192175 ↗
L3OTHERCited in: Clinical Presentation
[182]
Cacciaguerra L, Morris P, Tobin WO et al.. “Tumefactive Demyelination in MOG Ab-Associated Disease, Multiple Sclerosis, and AQP-4-IgG-Positive Neuromyelitis Optica Spectrum Disorder.” Neurology (2023). PMID: 36690455 ↗
L3OTHERCited in: Clinical Presentation, Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG)
[183]
Carta S, Cobo Calvo Á, Armangué T et al.. “Significance of Myelin Oligodendrocyte Glycoprotein Antibodies in CSF: A Retrospective Multicenter Study.” Neurology (2022). PMID: 36526426 ↗
L3OTHERCited in: Clinical Presentation, Severity, Staging & Risk Stratification
[184]
Waldman A, Ness J, Pohl D et al.. “Pediatric multiple sclerosis: Clinical features and outcome.” Neurology (2016). PMID: 27572865 ↗
L5REVIEW_NARRATIVECited in: Clinical Presentation, Neurorehabilitation, Symptomatic & Supportive Care
[185]
Dubey D, Pittock SJ, Krecke KN et al.. “Clinical, Radiologic, and Prognostic Features of Myelitis Associated With Myelin Oligodendrocyte Glycoprotein Autoantibody.” JAMA neurology (2019). PMID: 30575890 ↗
L4OTHERCited in: Clinical Presentation
[186]
Hua LH, Solomon AJ, Tenembaum S et al.. “Differential Diagnosis of Suspected Multiple Sclerosis in Pediatric and Late-Onset Populations: A Review.” JAMA neurology (2024). PMID: 39283621 ↗
L5REVIEW_NARRATIVECited in: Clinical Presentation
[187]
Ayrignac X, Carra-Dallière C, Marelli C et al.. “Adult-Onset Genetic Central Nervous System Disorders Masquerading as Acquired Neuroinflammatory Disorders: A Review.” JAMA neurology (2022). PMID: 35969413 ↗
L5REVIEW_NARRATIVECited in: Clinical Presentation
[188]
Andorrà M, Alba-Arbalat S, Camos-Carreras A et al.. “Using Acute Optic Neuritis Trials to Assess Neuroprotective and Remyelinating Therapies in Multiple Sclerosis.” JAMA neurology (2020). PMID: 31566686 ↗
L2OTHERCited in: Clinical Presentation
[189]
Meltzer E, Sguigna PV, Subei A et al.. “Retinal Architecture and Melanopsin-Mediated Pupillary Response Characteristics: A Putative Pathophysiologic Signature for the Retino-Hypothalamic Tract in Multiple Sclerosis.” JAMA neurology (2017). PMID: 28135360 ↗
L3OTHERCited in: Clinical Presentation
[190]
Giovannoni G, James L, Adeniran AA et al.. “The case for targeting latent and lytic Epstein-Barr virus infection in multiple sclerosis.” Brain : a journal of neurology (2025). PMID: 40327539 ↗
L5REVIEW_NARRATIVECited in: Clinical Presentation, Long-term & Definitive Management (Evidence Ladder), Disease-Modifying & Immunotherapy Program: Sequencing, Safety Monitoring & De-escalation
[191]
Cortese R, Battaglini M, Prados F et al.. “Clinical and MRI measures to identify non-acute MOG-antibody disease in adults.” Brain : a journal of neurology (2023). PMID: 36515653 ↗
L3OTHERCited in: Clinical Presentation
[192]
Jurynczyk M, Messina S, Woodhall MR et al.. “Clinical presentation and prognosis in MOG-antibody disease: a UK study.” Brain : a journal of neurology (2017). PMID: 29136091 ↗
L2OTHERCited in: Clinical Presentation
[193]
Longoni G, Brown RA, MomayyezSiahkal P et al.. “White matter changes in paediatric multiple sclerosis and monophasic demyelinating disorders.” Brain : a journal of neurology (2017). PMID: 28334875 ↗
L2OTHERCited in: Clinical Presentation
[194]
Jokubaitis VG, Campagna MP, Ibrahim O et al.. “Not all roads lead to the immune system: the genetic basis of multiple sclerosis severity.” Brain : a journal of neurology (2023). PMID: 36448302 ↗
L2OTHERCited in: Clinical Presentation
[195]
Haider L, Prados F, Chung K et al.. “Cortical involvement determines impairment 30 years after a clinically isolated syndrome.” Brain : a journal of neurology (2021). PMID: 33880511 ↗
L2OTHERCited in: Clinical Presentation
[196]
Zrzavy T, Hametner S, Wimmer I et al.. “Loss of 'homeostatic' microglia and patterns of their activation in active multiple sclerosis.” Brain : a journal of neurology (2017). PMID: 28541408 ↗
L4OTHERCited in: Clinical Presentation
[197]
Cox LM, Maghzi AH, Liu S et al.. “Gut Microbiome in Progressive Multiple Sclerosis.” Annals of neurology (2021). PMID: 33876477 ↗
L3OTHERCited in: Clinical Presentation, Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG), Severity, Staging & Risk Stratification, Disease-Modifying & Immunotherapy Program: Sequencing, Safety Monitoring & De-escalation, Neurorehabilitation, Symptomatic & Supportive Care
[198]
Marrodan M, Calandri IL, Bocancea DI et al.. “Diagnostic MRI Score to Differentiate Susac Syndrome from Primary Angiitis of the Central Nervous System and Multiple Sclerosis.” Annals of neurology (2024). PMID: 39056308 ↗
L3OTHERCited in: Clinical Presentation
[199]
Zrzavy T, Endmayr V, Bauer J et al.. “Neuropathological Variability within a Spectrum of NMDAR-Encephalitis.” Annals of neurology (2021). PMID: 34562035 ↗
L4OTHERCited in: Clinical Presentation
[200]
Knowles S, Middleton R, Cooze B et al.. “Comparing the Pathology, Clinical, and Demographic Characteristics of Younger and Older-Onset Multiple Sclerosis.” Annals of neurology (2023). PMID: 38061895 ↗
L2OTHERCited in: Clinical Presentation
[201]
Fisniku LK, Chard DT, Jackson JS et al.. “Gray matter atrophy is related to long-term disability in multiple sclerosis.” Annals of neurology (2008). PMID: 18570297 ↗
L2OTHERCited in: Clinical Presentation
[202]
Bose G, Healy BC, Lokhande HA et al.. “Early Predictors of Clinical and MRI Outcomes Using Least Absolute Shrinkage and Selection Operator (LASSO) in Multiple Sclerosis.” Annals of neurology (2022). PMID: 35429009 ↗
L2OTHERCited in: Clinical Presentation
[203]
Tremlett H, Waubant E. “Gut microbiome and pediatric multiple sclerosis.” Multiple sclerosis (Houndmills, Basingstoke, England) (2018). PMID: 29307301 ↗
L5REVIEW_NARRATIVECited in: Clinical Presentation, Disease-Modifying & Immunotherapy Program: Sequencing, Safety Monitoring & De-escalation, Special Populations & Pregnancy
[204]
Amezcua L, McCauley JL. “Race and ethnicity on MS presentation and disease course.” Multiple sclerosis (Houndmills, Basingstoke, England) (2020). PMID: 31965878 ↗
L5REVIEW_NARRATIVECited in: Clinical Presentation
[205]
Leibovitch EC, Jacobson S. “Viruses in chronic progressive neurologic disease.” Multiple sclerosis (Houndmills, Basingstoke, England) (2018). PMID: 29307291 ↗
L5REVIEW_NARRATIVECited in: Clinical Presentation
[206]
Kim TB, Lee JY, Brinker A et al.. “Anaphylaxis and glatiramer acetate.” Multiple sclerosis (Houndmills, Basingstoke, England) (2025). PMID: 41139841 ↗
L4OTHERCited in: Clinical Presentation
[207]
Berger JR, Pocoski J, Preblick R et al.. “Fatigue heralding multiple sclerosis.” Multiple sclerosis (Houndmills, Basingstoke, England) (2013). PMID: 23439577 ↗
L3OTHERCited in: Clinical Presentation
[208]
Bennett JL, de Seze J, Lana-Peixoto M et al.. “Neuromyelitis optica and multiple sclerosis: Seeing differences through optical coherence tomography.” Multiple sclerosis (Houndmills, Basingstoke, England) (2015). PMID: 25662342 ↗
L5REVIEW_NARRATIVECited in: Clinical Presentation
[209]
Huang Y, Li W, Wang Y et al.. “Clinical characteristics, diagnosis, treatment, and prognosis of rituximab-induced serum sickness: a retrospective analysis of 39 reported cases.” Frontiers in immunology (2026). PMID: 42051532 ↗
L4SR_OBSCited in: Clinical Presentation
[210]
Chen H, Cortese M, Flores-Torres MH et al.. “Comorbidities and lifestyle changes as predictors of the multiple sclerosis prodrome: A prospective cohort study.” Multiple sclerosis (Houndmills, Basingstoke, England) (2026). PMID: 42267700 ↗
L2COHORTCited in: Clinical Presentation
[211]
Çerçi Kubur Ç, Cengiz Özyurt B, Orak SA et al.. “Clinical, Radiological, and Prognostic Features of Pediatric Clinically Isolated Syndrome and Risk of Conversion to Multiple Sclerosis: A Single-center Cohort Study.” Neuropediatrics (2026). PMID: 42263695 ↗
L2COHORTCited in: Clinical Presentation
[212]
Akkawi N, Mohamed EH, Shatila A. “Ravulizumab for relapse prevention in AQP4-IgG-positive neuromyelitis optica spectrum disorder: a 2-year follow-up case report.” Frontiers in medicine (2026). PMID: 42369157 ↗
L4CASE_REPORTCited in: Clinical Presentation, Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG), Acute Management: Neurologic Emergencies & Attack Abortion
[213]
Mahfouz S, Loutfi T, Jreige W et al.. “Suspected HSV vs. demyelinating transverse myelitis in patient on TNF alpha inhibitor: a case report.” Frontiers in medicine (2026). PMID: 42180712 ↗
L4CASE_REPORTCited in: Clinical Presentation
[214]
Barbiero A, Lilleri D, d'Angelo P et al.. “Possible role of hyperimmunoglobulin in reducing the risk of maternal-fetal transmission of cytomegalovirus in the valacyclovir era: a case series.” Archives of gynecology and obstetrics (2026). PMID: 42045416 ↗
L4CASE_REPORTCited in: Clinical Presentation
[215]
Hauser SL, Bar-Or A, Cohen JA et al.. “Ofatumumab versus Teriflunomide in Multiple Sclerosis.” The New England journal of medicine (2020). PMID: 32757523 ↗
L1RCTCited in: Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG), History and Evolution of Treatment
[216]
Montalban X, Hauser SL, Kappos L et al.. “Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis.” The New England journal of medicine (2016). PMID: 28002688 ↗
L1RCTCited in: Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG), Severity, Staging & Risk Stratification, Long-term & Definitive Management (Evidence Ladder), History and Evolution of Treatment
[217]
Steinman L, Fox E, Hartung HP et al.. “Ublituximab versus Teriflunomide in Relapsing Multiple Sclerosis.” The New England journal of medicine (2022). PMID: 36001711 ↗
L1RCTCited in: Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG), History and Evolution of Treatment
[218]
Polman CH, O'Connor PW, Havrdova E et al.. “A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis.” The New England journal of medicine (2006). PMID: 16510744 ↗
L1RCTCited in: Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG), Severity, Staging & Risk Stratification, History and Evolution of Treatment
[219]
Giovannoni G, Comi G, Cook S et al.. “A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis.” The New England journal of medicine (2010). PMID: 20089960 ↗
L1RCTCited in: Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG), Long-term & Definitive Management (Evidence Ladder), History and Evolution of Treatment
[220]
Chitnis T, Arnold DL, Banwell B et al.. “Trial of Fingolimod versus Interferon Beta-1a in Pediatric Multiple Sclerosis.” The New England journal of medicine (2018). PMID: 30207920 ↗
L1RCTCited in: Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG), Special Populations & Pregnancy
[221]
Lebrun-Frénay C, Siva A, Sormani MP et al.. “Teriflunomide and Time to Clinical Multiple Sclerosis in Patients With Radiologically Isolated Syndrome: The TERIS Randomized Clinical Trial.” JAMA neurology (2023). PMID: 37603328 ↗
L1RCTCited in: Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG), History and Evolution of Treatment, Special Populations & Pregnancy
[222]
Coerver EME, Fung WH, de Beukelaar J et al.. “Discontinuation of First-Line Disease-Modifying Therapy in Patients With Stable Multiple Sclerosis: The DOT-MS Randomized Clinical Trial.” JAMA neurology (2025). PMID: 39652340 ↗
L1RCTCited in: Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG), Long-term & Definitive Management (Evidence Ladder), History and Evolution of Treatment, Disease-Modifying & Immunotherapy Program: Sequencing, Safety Monitoring & De-escalation, Complications, Prognosis & Natural History
[223]
Green AJ, Gelfand JM, Cree BA et al.. “Clemastine fumarate as a remyelinating therapy for multiple sclerosis (ReBUILD): a randomised, controlled, double-blind, crossover trial.” Lancet (London, England) (2017). PMID: 29029896 ↗
L1RCTCited in: Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG), Long-term & Definitive Management (Evidence Ladder), History and Evolution of Treatment, Prognosis & Natural History
[224]
Chataway J, Williams T, Blackstone J et al.. “Effect of repurposed simvastatin on disability progression in secondary progressive multiple sclerosis (MS-STAT2): a phase 3, randomised, double-blind, placebo-controlled trial.” Lancet (London, England) (2025). PMID: 41045938 ↗
L1RCTCited in: Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG), Severity, Staging & Risk Stratification, History and Evolution of Treatment, Prognosis & Natural History
[225]
Atkins HL, Bowman M, Allan D et al.. “Immunoablation and autologous haemopoietic stem-cell transplantation for aggressive multiple sclerosis: a multicentre single-group phase 2 trial.” Lancet (London, England) (2016). PMID: 27291994 ↗
L4RCTCited in: Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG), Severity, Staging & Risk Stratification, Long-term & Definitive Management (Evidence Ladder), Disease-Modifying & Immunotherapy Program: Sequencing, Safety Monitoring & De-escalation, Complications, Prognosis & Natural History
[226]
Lublin F, Miller DH, Freedman MS et al.. “Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial.” Lancet (London, England) (2016). PMID: 26827074 ↗
L1RCTCited in: Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG), Severity, Staging & Risk Stratification, History and Evolution of Treatment
[227]
Kappos L, Freedman MS, Polman CH et al.. “Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study.” Lancet (London, England) (2007). PMID: 17679016 ↗
L1RCTCited in: Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG)
[228]
Petzold A, Balcer LJ, Calabresi PA et al.. “Retinal layer segmentation in multiple sclerosis: a systematic review and meta-analysis.” The Lancet. Neurology (2017). PMID: 28920886 ↗
L1SR_OBSCited in: Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG)
[229]
Hawker K, O'Connor P, Freedman MS et al.. “Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial.” Annals of neurology (2009). PMID: 19847908 ↗
L1RCTCited in: Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG), Severity, Staging & Risk Stratification, History and Evolution of Treatment, Prognosis & Natural History
[230]
Cotter J, Firth J, Enzinger C et al.. “Social cognition in multiple sclerosis: A systematic review and meta-analysis.” Neurology (2016). PMID: 27655736 ↗
L1SR_OBSCited in: Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG), Neurorehabilitation, Symptomatic & Supportive Care
[231]
Bridel C, van Wieringen WN, Zetterberg H et al.. “Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in Neurology: A Systematic Review and Meta-analysis.” JAMA neurology (2019). PMID: 31206160 ↗
L1SR_OBSCited in: Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG), Prognosis & Natural History
[232]
Hegen H, Walde J, Berek K et al.. “Cerebrospinal fluid kappa free light chains for the diagnosis of multiple sclerosis: A systematic review and meta-analysis.” Multiple sclerosis (Houndmills, Basingstoke, England) (2022). PMID: 36453167 ↗
L1SR_OBSCited in: Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG)
[233]
Bennett JL, Costello F, Chen JJ et al.. “Optic neuritis and autoimmune optic neuropathies: advances in diagnosis and treatment.” The Lancet. Neurology (2022). PMID: 36155661 ↗
L5REVIEW_NARRATIVECited in: Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG), Neurorehabilitation, Symptomatic & Supportive Care, Prognosis & Natural History
[234]
Solomon AJ, Arrambide G, Brownlee WJ et al.. “Differential diagnosis of suspected multiple sclerosis: an updated consensus approach.” The Lancet. Neurology (2023). PMID: 37479377 ↗
L1REVIEW_NARRATIVECited in: Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG)
[235]
Cree BAC, Arnold DL, Chataway J et al.. “Secondary Progressive Multiple Sclerosis: New Insights.” Neurology (2021). PMID: 34088878 ↗
L5REVIEW_NARRATIVECited in: Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG)
[236]
Vidal-Jordana A, Rovira A, Calderon W et al.. “Adding the Optic Nerve in Multiple Sclerosis Diagnostic Criteria: A Longitudinal, Prospective, Multicenter Study.” Neurology (2023). PMID: 38165378 ↗
L2OTHERCited in: Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG)
[237]
Roos I, Hughes S, McDonnell G et al.. “Rituximab vs Ocrelizumab in Relapsing-Remitting Multiple Sclerosis.” JAMA neurology (2023). PMID: 37307006 ↗
L2OTHERCited in: Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG), Severity, Staging & Risk Stratification, Long-term & Definitive Management (Evidence Ladder), History and Evolution of Treatment
[238]
Absinta M, Sati P, Masuzzo F et al.. “Association of Chronic Active Multiple Sclerosis Lesions With Disability In Vivo.” JAMA neurology (2019). PMID: 31403674 ↗
L2OTHERCited in: Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG), History and Evolution of Treatment, Disease-Modifying & Immunotherapy Program: Sequencing, Safety Monitoring & De-escalation, Prognosis & Natural History
[239]
Salter A, Lancia S, Kowalec K et al.. “Comorbidity and Disease Activity in Multiple Sclerosis.” JAMA neurology (2024). PMID: 39291661 ↗
L2OTHERCited in: Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG), Severity, Staging & Risk Stratification, Long-term & Definitive Management (Evidence Ladder), Disease-Modifying & Immunotherapy Program: Sequencing, Safety Monitoring & De-escalation, Prevention, Screening & Surveillance
[240]
Jouvenot G, Courbon G, Lefort M et al.. “High-Efficacy Therapy Discontinuation vs Continuation in Patients 50 Years and Older With Nonactive MS.” JAMA neurology (2024). PMID: 38526462 ↗
L2OTHERCited in: Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG), Long-term & Definitive Management (Evidence Ladder)
[241]
Vietzen H, Kühner LM, Berger SM et al.. “Epstein-Barr Virus Antibodies to Differentiate Multiple Sclerosis From Other Neuroinflammatory Diseases.” JAMA neurology (2026). PMID: 41801194 ↗
L2OTHERCited in: Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG)
[242]
Bobinger T, Manaenko A, Burkardt P et al.. “Siponimod (BAF-312) Attenuates Perihemorrhagic Edema And Improves Survival in Experimental Intracerebral Hemorrhage.” Stroke (2019). PMID: 31558140 ↗
L5OTHERCited in: Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG), Severity, Staging & Risk Stratification, History and Evolution of Treatment, Prognosis & Natural History
[243]
Compston A, Coles A. “Multiple sclerosis.” Lancet (London, England) (2008). PMID: 18970977 ↗
L5OTHERCited in: Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG), Disease-Modifying & Immunotherapy Program: Sequencing, Safety Monitoring & De-escalation
[244]
Correale J, Gaitán MI, Ysrraelit MC et al.. “Progressive multiple sclerosis: from pathogenic mechanisms to treatment.” Brain : a journal of neurology (2017). PMID: 27794524 ↗
L5REVIEW_NARRATIVECited in: Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG), Severity, Staging & Risk Stratification, History and Evolution of Treatment, Disease-Modifying & Immunotherapy Program: Sequencing, Safety Monitoring & De-escalation
[245]
Matsumoto Y, Kaneko K, Takahashi T et al.. “Diagnostic implications of MOG-IgG detection in sera and cerebrospinal fluids.” Brain : a journal of neurology (2023). PMID: 37061817 ↗
L2OTHERCited in: Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG)
[246]
Balcer LJ, Miller DH, Reingold SC et al.. “Vision and vision-related outcome measures in multiple sclerosis.” Brain : a journal of neurology (2014). PMID: 25433914 ↗
L5REVIEW_NARRATIVECited in: Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG), History and Evolution of Treatment, Neurorehabilitation, Symptomatic & Supportive Care
[247]
Granziera C, Wuerfel J, Barkhof F et al.. “Quantitative magnetic resonance imaging towards clinical application in multiple sclerosis.” Brain : a journal of neurology (2021). PMID: 33970206 ↗
L5REVIEW_NARRATIVECited in: Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG)
[248]
Bigotte M, Groh AMR, Afanasiev E et al.. “Cerebrospinal fluid-driven ependymal motile cilia defects are implicated in multiple sclerosis.” Brain : a journal of neurology (2025). PMID: 41277219 ↗
L3OTHERCited in: Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG), History and Evolution of Treatment
[249]
Willard C, Puglisi L, Ravi D et al.. “Combined magnetic resonance imaging and serum analysis reveals distinct multiple sclerosis types.” Brain : a journal of neurology (2025). PMID: 41325776 ↗
L2OTHERCited in: Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG)
[250]
Mangioris G, Pittock SJ, Yang B et al.. “Cerebrospinal Fluid Cytokine and Chemokine Profiles in Central Nervous System Sarcoidosis: Diagnostic and Immunopathologic Insights.” Annals of neurology (2024). PMID: 39031103 ↗
L3OTHERCited in: Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG)
[251]
Androdias G, Bernard E, Biotti D et al.. “Multiple sclerosis broke my heart.” Annals of neurology (2017). PMID: 28437859 ↗
L4OTHERCited in: Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG), Acute Management: Neurologic Emergencies & Attack Abortion
[252]
Heming M, Börsch AL, Melnik S et al.. “Atlas of Cerebrospinal Fluid Immune Cells Across Neurological Diseases.” Annals of neurology (2024). PMID: 39665159 ↗
L2OTHERCited in: Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG)
[253]
Bove R, Langdon D, Maciejowski M et al.. “Efficacy and safety of ofatumumab in participants with relapsing multiple sclerosis and breakthrough disease on oral fingolimod or fumarates: results from the ARTIOS study.” Journal of neurology (2026). PMID: 42371147 ↗
L4TRIAL_NONRANDOMCited in: Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG), Severity, Staging & Risk Stratification, Disease-Modifying & Immunotherapy Program: Sequencing, Safety Monitoring & De-escalation, Prognosis & Natural History
[254]
Penner IK, Raselli C, Stöcklin M et al.. “The Fatigue Scale for Motor and Cognitive Functions (FSMC): validation of a new instrument to assess multiple sclerosis-related fatigue.” Multiple sclerosis (Houndmills, Basingstoke, England) (2009). PMID: 19995840 ↗
L3OTHERCited in: Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG), Severity, Staging & Risk Stratification
[255]
. “Corrigendum.” Multiple sclerosis (Houndmills, Basingstoke, England) (2010). PMID: 20123935 ↗
L5OTHERCited in: Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG)
[256]
Tackley G, Kuker W, Palace J. “Magnetic resonance imaging in neuromyelitis optica.” Multiple sclerosis (Houndmills, Basingstoke, England) (2014). PMID: 24829291 ↗
L5REVIEW_NARRATIVECited in: Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG)
[257]
Hochstetler A, Lehtinen MK. “Choroid Plexus as a Mediator of CNS Inflammation in Multiple Sclerosis.” Multiple sclerosis (Houndmills, Basingstoke, England) (2024). PMID: 39503321 ↗
L5REVIEW_NARRATIVECited in: Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG)
[258]
Prineas JW, Parratt JDE. “Multiple sclerosis: Serum anti-CNS autoantibodies.” Multiple sclerosis (Houndmills, Basingstoke, England) (2017). PMID: 28548612 ↗
L3OTHERCited in: Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG)
[259]
Moreno-Bernardino CJ, Treviño-Frenk I, Ortiz-Maldonado JF et al.. “Predictors of early response to cladribine in mexican patients with multiple sclerosis: A real world multicenter retrospective cohort study.” Multiple sclerosis and related disorders (2026). PMID: 42364569 ↗
L2COHORTCited in: Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG)
[260]
Maghbooli Z, Nasir E, Mahdavinasab F et al.. “The HLA paradox across populations in multiple sclerosis progression: a systematic review.” BMC neurology (2026). PMID: 42343278 ↗
L1SR_OBSCited in: Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG)
[261]
Rościszewska-Żukowska I, Popiel M, Perenc A et al.. “Testosterone in Relapsing-Remitting Multiple Sclerosis: A Case-Control Study.” Journal of clinical medicine (2026). PMID: 42355569 ↗
L3CASE_CONTROLCited in: Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG)
[262]
Abdulridha GAO, Fadhel AS, Al-Kinany SQ et al.. “Serum IDO1 and β-catenin levels in patients with multiple sclerosis with and without atherosclerosis: A case-control study.” Journal of neuroimmunology (2026). PMID: 42361476 ↗
L3CASE_CONTROLCited in: Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG)
[263]
Wyse C, Roguski A, Maguire R et al.. “Lifetime exposure to shift work and risk of multiple sclerosis: retrospective and prospective cohort studies in UK Biobank.” Occupational and environmental medicine (2026). PMID: 42431827 ↗
L2OTHERCited in: Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG)
[264]
Comi G, Jeffery D, Kappos L et al.. “Placebo-controlled trial of oral laquinimod for multiple sclerosis.” The New England journal of medicine (2012). PMID: 22417253 ↗
L1RCTCited in: Severity, Staging & Risk Stratification
[265]
Rudick RA, Stuart WH, Calabresi PA et al.. “Natalizumab plus interferon beta-1a for relapsing multiple sclerosis.” The New England journal of medicine (2006). PMID: 16510745 ↗
L1RCTCited in: Severity, Staging & Risk Stratification, Disease-Modifying & Immunotherapy Program: Sequencing, Safety Monitoring & De-escalation
[266]
Feinstein A, Amato MP, Brichetto G et al.. “Cognitive rehabilitation and aerobic exercise for cognitive impairment in people with progressive multiple sclerosis (CogEx): a randomised, blinded, sham-controlled trial.” The Lancet. Neurology (2023). PMID: 37739574 ↗
L1RCTCited in: Severity, Staging & Risk Stratification, History and Evolution of Treatment, Neurorehabilitation, Symptomatic & Supportive Care, Prognosis & Natural History
[267]
Bar-Or A, Dufek M, Budincevic H et al.. “Safety and efficacy of fenebrutinib in relapsing multiple sclerosis (FENopta): a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial and open-label extension study.” The Lancet. Neurology (2025). PMID: 40683275 ↗
L1RCTCited in: Severity, Staging & Risk Stratification, History and Evolution of Treatment, Prognosis & Natural History, Prevention, Screening & Surveillance
[268]
Svenningsson A, Frisell T, Burman J et al.. “Safety and efficacy of rituximab versus dimethyl fumarate in patients with relapsing-remitting multiple sclerosis or clinically isolated syndrome in Sweden: a rater-blinded, phase 3, randomised controlled trial.” The Lancet. Neurology (2022). PMID: 35841908 ↗
L1RCTCited in: Severity, Staging & Risk Stratification, Long-term & Definitive Management (Evidence Ladder), History and Evolution of Treatment, Prognosis & Natural History
[269]
Braley TJ, Ehde DM, Alschuler KN et al.. “Comparative effectiveness of cognitive behavioural therapy, modafinil, and their combination for treating fatigue in multiple sclerosis (COMBO-MS): a randomised, statistician-blinded, parallel-arm trial.” The Lancet. Neurology (2024). PMID: 39424559 ↗
L1RCTCited in: Severity, Staging & Risk Stratification, Long-term & Definitive Management (Evidence Ladder), History and Evolution of Treatment
[270]
Zajicek J, Ball S, Wright D et al.. “Effect of dronabinol on progression in progressive multiple sclerosis (CUPID): a randomised, placebo-controlled trial.” The Lancet. Neurology (2013). PMID: 23856559 ↗
L1RCTCited in: Severity, Staging & Risk Stratification, Neurorehabilitation, Symptomatic & Supportive Care, Complications
[271]
Reilmann R, Anderson KE, Feigin A et al.. “Safety and efficacy of laquinimod for Huntington's disease (LEGATO-HD): a multicentre, randomised, double-blind, placebo-controlled, phase 2 study.” The Lancet. Neurology (2024). PMID: 38280392 ↗
L1RCTCited in: Severity, Staging & Risk Stratification
[272]
Kappos L, Wolinsky JS, Giovannoni G et al.. “Contribution of Relapse-Independent Progression vs Relapse-Associated Worsening to Overall Confirmed Disability Accumulation in Typical Relapsing Multiple Sclerosis in a Pooled Analysis of 2 Randomized Clinical Trials.” JAMA neurology (2020). PMID: 32511687 ↗
L2RCTCited in: Severity, Staging & Risk Stratification, History and Evolution of Treatment, Prognosis & Natural History
[273]
Kappos L, Bar-Or A, Cree BAC et al.. “Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study.” Lancet (London, England) (2018). PMID: 29576505 ↗
L1RCTCited in: Severity, Staging & Risk Stratification, History and Evolution of Treatment, Prognosis & Natural History
[274]
Giovannoni G, Airas L, Bove R et al.. “Efficacy and safety of ocrelizumab in primary progressive multiple sclerosis, including older patients and those with more advanced disease (ORATORIO-HAND): a multicentre, double-blind, randomised, placebo-controlled, phase 3b study.” Lancet (London, England) (2026). PMID: 42208561 ↗
L1RCTCited in: Severity, Staging & Risk Stratification, History and Evolution of Treatment, Prognosis & Natural History
[275]
Hauser SL, Giovannoni G, Montalban X et al.. “Efficacy and safety of a bodyweight-adjusted higher dose of ocrelizumab in relapsing (MUSETTE) and primary progressive (GAVOTTE) multiple sclerosis: two multicentre, randomised, double-blind, parallel-group phase 3b trials.” Lancet (London, England) (2026). PMID: 42208560 ↗
L1RCTCited in: Severity, Staging & Risk Stratification, History and Evolution of Treatment, Prognosis & Natural History
[276]
Goodman AD, Brown TR, Krupp LB et al.. “Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial.” Lancet (London, England) (2009). PMID: 19249634 ↗
L1RCTCited in: Severity, Staging & Risk Stratification, History and Evolution of Treatment, Prognosis & Natural History
[277]
Aktas O, Smith MA, Rees WA et al.. “Serum Glial Fibrillary Acidic Protein: A Neuromyelitis Optica Spectrum Disorder Biomarker.” Annals of neurology (2021). PMID: 33724534 ↗
L1RCTCited in: Severity, Staging & Risk Stratification, History and Evolution of Treatment, Prognosis & Natural History
[278]
Piehl F, Alping P, Virtanen S et al.. “COMBAT-MS: A Population-Based Observational Cohort Study Addressing the Benefit-Risk Balance of Multiple Sclerosis Therapies Compared with Rituximab.” Annals of neurology (2024). PMID: 38923558 ↗
L2COHORTCited in: Severity, Staging & Risk Stratification, Disease-Modifying & Immunotherapy Program: Sequencing, Safety Monitoring & De-escalation
[279]
Kjølhede T, Vissing K, Dalgas U. “Multiple sclerosis and progressive resistance training: a systematic review.” Multiple sclerosis (Houndmills, Basingstoke, England) (2012). PMID: 22760230 ↗
L1SR_OBSCited in: Severity, Staging & Risk Stratification
[280]
Sahi N, Ciccarelli O, Houlden H et al.. “Unlocking Multiple Sclerosis Genetics: From Susceptibility to Severity.” Neurology (2025). PMID: 41004698 ↗
L5REVIEW_NARRATIVECited in: Severity, Staging & Risk Stratification
[281]
Watanabe M, Isobe N, Niino M et al.. “Prevalence of, and Disability Due to, Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder in Japan by the Fifth Nationwide Survey.” Neurology (2024). PMID: 39475688 ↗
L2OTHERCited in: Severity, Staging & Risk Stratification
[282]
Harding K, Williams O, Willis M et al.. “Clinical Outcomes of Escalation vs Early Intensive Disease-Modifying Therapy in Patients With Multiple Sclerosis.” JAMA neurology (2019). PMID: 30776055 ↗
L2OTHERCited in: Severity, Staging & Risk Stratification, Long-term & Definitive Management (Evidence Ladder), Disease-Modifying & Immunotherapy Program: Sequencing, Safety Monitoring & De-escalation, Prognosis & Natural History, Prevention, Screening & Surveillance
[283]
Tur C, Carbonell-Mirabent P, Cobo-Calvo Á et al.. “Association of Early Progression Independent of Relapse Activity With Long-term Disability After a First Demyelinating Event in Multiple Sclerosis.” JAMA neurology (2023). PMID: 36534392 ↗
L2OTHERCited in: Severity, Staging & Risk Stratification
[284]
Phillips Reindel KM, Bell AS, Goldberg EL et al.. “Exploring social moderators of telehealth treatment outcomes for adults with multiple sclerosis: A secondary analysis of a randomized controlled trial.” Rehabilitation psychology (2026). PMID: 42423672 ↗
L1RCTCited in: Severity, Staging & Risk Stratification, History and Evolution of Treatment
[285]
Williams T, Blackstone J, John N et al.. “Evaluating the effectiveness of simvastatin in slowing the progression of disability in secondary progressive multiple sclerosis: a synopsis of MS-STAT2, a multicentre, randomised controlled, double-blind, phase 3 clinical trial.” Health technology assessment (Winchester, England) (2026). PMID: 42370465 ↗
L1RCTCited in: Severity, Staging & Risk Stratification, Long-term & Definitive Management (Evidence Ladder), History and Evolution of Treatment, Disease-Modifying & Immunotherapy Program: Sequencing, Safety Monitoring & De-escalation, Neurorehabilitation, Symptomatic & Supportive Care, Prognosis & Natural History
[286]
Monreal E, Fernández-Velasco JI, Álvarez-Lafuente R et al.. “Serum biomarkers at disease onset for personalized therapy in multiple sclerosis.” Brain : a journal of neurology (2024). PMID: 39101570 ↗
L2OTHERCited in: Severity, Staging & Risk Stratification, Disease-Modifying & Immunotherapy Program: Sequencing, Safety Monitoring & De-escalation
[287]
Cree BAC, Hollenbach JA, Bove R et al.. “Silent progression in disease activity-free relapsing multiple sclerosis.” Annals of neurology (2019). PMID: 30851128 ↗
L2OTHERCited in: Severity, Staging & Risk Stratification, History and Evolution of Treatment, Prognosis & Natural History
[288]
Meuth SG, Wolff S, Mück A et al.. “Different Treatment Outcomes of Multiple Sclerosis Patients Receiving Ocrelizumab or Ofatumumab.” Annals of neurology (2024). PMID: 39582359 ↗
L2OTHERCited in: Severity, Staging & Risk Stratification, Prognosis & Natural History
[289]
Lillo Triguero L, Pilo de la Fuente B, Díaz Díaz J et al.. “Tetrahydrocannabinol/cannabidiol in the treatment of restless legs syndrome.” Journal of neurology (2026). PMID: 42387200 ↗
L4TRIAL_NONRANDOMCited in: Severity, Staging & Risk Stratification, Long-term & Definitive Management (Evidence Ladder), Prognosis & Natural History
[290]
Kobelt G, Thompson A, Berg J et al.. “New insights into the burden and costs of multiple sclerosis in Europe.” Multiple sclerosis (Houndmills, Basingstoke, England) (2017). PMID: 28273775 ↗
L2OTHERCited in: Severity, Staging & Risk Stratification, Neurorehabilitation, Symptomatic & Supportive Care
[291]
Bayoumi A, Hasan KM, Thomas JA et al.. “Glymphatic dysfunction in multiple sclerosis and its association with disease pathology and disability.” Multiple sclerosis (Houndmills, Basingstoke, England) (2024). PMID: 39344166 ↗
L3OTHERCited in: Severity, Staging & Risk Stratification
[292]
Patsopoulos NA, De Jager PL. “Genetic and gene expression signatures in multiple sclerosis.” Multiple sclerosis (Houndmills, Basingstoke, England) (2020). PMID: 31965883 ↗
L5REVIEW_NARRATIVECited in: Severity, Staging & Risk Stratification
[293]
Owen DR, Piccini P, Matthews PM. “Towards molecular imaging of multiple sclerosis.” Multiple sclerosis (Houndmills, Basingstoke, England) (2011). PMID: 21212087 ↗
L5REVIEW_NARRATIVECited in: Severity, Staging & Risk Stratification
[294]
De León-Muñoz A, Rubio-Arias JÁ, Ávila-Gandía V et al.. “Effects of physical exercise on neurofilament light chain in multiple sclerosis and other neurological disorders: A systematic review.” Multiple sclerosis and related disorders (2026). PMID: 42413317 ↗
L1SR_OBSCited in: Severity, Staging & Risk Stratification
[295]
Nabil Y, Mansour A, Mohamed AA et al.. “Comparative effects of pilates-based interventions on functional mobility, balance, fatigue, and quality of life in people with multiple sclerosis: a systematic review and network meta-analysis.” BMC sports science, medicine & rehabilitation (2026). PMID: 42400084 ↗
L1SR_OBSCited in: Severity, Staging & Risk Stratification, Neurorehabilitation, Symptomatic & Supportive Care, Prognosis & Natural History
[296]
Kaveyee H, Etemadifar M, Abhari AP et al.. “Fingolimod for pediatric multiple sclerosis: The Ped-MS group systematic review and meta-analysis.” Multiple sclerosis and related disorders (2026). PMID: 42361660 ↗
L1SR_OBSCited in: Severity, Staging & Risk Stratification, Disease-Modifying & Immunotherapy Program: Sequencing, Safety Monitoring & De-escalation, Complications, Special Populations & Pregnancy, Prevention, Screening & Surveillance
[297]
Nash RA, Hutton GJ, Racke MK et al.. “High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for relapsing-remitting multiple sclerosis (HALT-MS): a 3-year interim report.” JAMA neurology (2015). PMID: 25546364 ↗
L4TRIAL_NONRANDOMCited in: Acute Management: Neurologic Emergencies & Attack Abortion, Neurorehabilitation, Symptomatic & Supportive Care, Complications
[298]
Marrie RA, Tremlett H, Kingwell E et al.. “Disparities in management and outcomes of myocardial infarction in multiple sclerosis: A matched cohort study.” Multiple sclerosis (Houndmills, Basingstoke, England) (2019). PMID: 31517571 ↗
L2SR_OBSCited in: Acute Management: Neurologic Emergencies & Attack Abortion
[299]
Soelberg K, Jarius S, Skejoe H et al.. “A population-based prospective study of optic neuritis.” Multiple sclerosis (Houndmills, Basingstoke, England) (2017). PMID: 28980518 ↗
L2COHORTCited in: Acute Management: Neurologic Emergencies & Attack Abortion
[300]
Lee S, Muccilli A, Schneider R et al.. “Acute central nervous system inflammation following COVID-19 vaccination: An observational cohort study.” Multiple sclerosis (Houndmills, Basingstoke, England) (2023). PMID: 36840605 ↗
L2COHORTCited in: Acute Management: Neurologic Emergencies & Attack Abortion
[301]
Hardy TA, Reddel SW, Barnett MH et al.. “Atypical inflammatory demyelinating syndromes of the CNS.” The Lancet. Neurology (2016). PMID: 27478954 ↗
L5REVIEW_NARRATIVECited in: Acute Management: Neurologic Emergencies & Attack Abortion
[302]
Yamout B, Gouider R, Al-Roughani R et al.. “Consensus Recommendations for the Diagnosis and Treatment of Neuromyelitis Optica Spectrum Disorders (NMOSD): The MENACTRIMS Guidelines.” CNS drugs (2026). PMID: 41591715 ↗
L1GUIDELINECited in: Acute Management: Neurologic Emergencies & Attack Abortion
[303]
Ness JM, Chabas D, Sadovnick AD et al.. “Clinical features of children and adolescents with multiple sclerosis.” Neurology (2007). PMID: 17438237 ↗
L5REVIEW_NARRATIVECited in: Acute Management: Neurologic Emergencies & Attack Abortion
[304]
Wassmer E, Chitnis T, Pohl D et al.. “International Pediatric MS Study Group Global Members Symposium report.” Neurology (2016). PMID: 27572855 ↗
L5REVIEW_NARRATIVECited in: Acute Management: Neurologic Emergencies & Attack Abortion
[305]
Croteau D, Flowers C, Kulick CG et al.. “Acute acalculous cholecystitis: A new safety risk for patients with MS treated with alemtuzumab.” Neurology (2018). PMID: 29602912 ↗
L4REVIEW_NARRATIVECited in: Acute Management: Neurologic Emergencies & Attack Abortion
[306]
Robinson MT, Barrett KM. “Emerging subspecialties in neurology: neuropalliative care.” Neurology (2014). PMID: 24862899 ↗
L5OTHERCited in: Acute Management: Neurologic Emergencies & Attack Abortion
[307]
Marrie RA, Elliott L, Marriott J et al.. “Comorbidity increases the risk of hospitalizations in multiple sclerosis.” Neurology (2014). PMID: 25540309 ↗
L2OTHERCited in: Acute Management: Neurologic Emergencies & Attack Abortion
[308]
Cortese I, Chaudhry V, So YT et al.. “Evidence-based guideline update: Plasmapheresis in neurologic disorders [RETIRED]: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.” Neurology (2011). PMID: 21242498 ↗
L1REVIEW_NARRATIVECited in: Acute Management: Neurologic Emergencies & Attack Abortion
[309]
Deiva K, Absoud M, Hemingway C et al.. “Acute idiopathic transverse myelitis in children: early predictors of relapse and disability.” Neurology (2014). PMID: 25540303 ↗
L2OTHERCited in: Acute Management: Neurologic Emergencies & Attack Abortion
[310]
Banwell B, Kennedy J, Sadovnick D et al.. “Incidence of acquired demyelination of the CNS in Canadian children.” Neurology (2009). PMID: 19153370 ↗
L2OTHERCited in: Acute Management: Neurologic Emergencies & Attack Abortion
[311]
Meier S, Willemse EAJ, Schaedelin S et al.. “Serum Glial Fibrillary Acidic Protein Compared With Neurofilament Light Chain as a Biomarker for Disease Progression in Multiple Sclerosis.” JAMA neurology (2023). PMID: 36745446 ↗
L2OTHERCited in: Acute Management: Neurologic Emergencies & Attack Abortion
[312]
Puthenparampil M, Poggiali D, Causin F et al.. “Cortical relapses in multiple sclerosis.” Multiple sclerosis (Houndmills, Basingstoke, England) (2015). PMID: 25791367 ↗
L4CASE_REPORTCited in: Acute Management: Neurologic Emergencies & Attack Abortion
[313]
Ahrabian D, Neill L, Bell R et al.. “Acute cardiotoxicity associated with alemtuzumab infusion for multiple sclerosis.” Multiple sclerosis (Houndmills, Basingstoke, England) (2020). PMID: 32298216 ↗
L4CASE_REPORTCited in: Acute Management: Neurologic Emergencies & Attack Abortion
[314]
Giorgi L, Marignier R, Pique J et al.. “French guidelines for the diagnosis and management of MOG antibody-associated disease.” Revue neurologique (2025). PMID: 40494723 ↗
L1GUIDELINECited in: Acute Management: Neurologic Emergencies & Attack Abortion
[315]
Keddie S, Smyth D, Keh RYS et al.. “Peripherin is a biomarker of axonal damage in peripheral nervous system disease.” Brain : a journal of neurology (2023). PMID: 37435933 ↗
L3OTHERCited in: Acute Management: Neurologic Emergencies & Attack Abortion, Prognosis & Natural History
[316]
Bellanti R, Keh RYS, Keddie S et al.. “Plasma periaxin is a biomarker of peripheral nerve demyelination.” Brain : a journal of neurology (2025). PMID: 40581376 ↗
L3OTHERCited in: Acute Management: Neurologic Emergencies & Attack Abortion
[317]
Tur C, Susin-Calle S, Otero-Romero S et al.. “Spider-MS: an individualized polyhedral prediction of multiple sclerosis prognosis.” Brain : a journal of neurology (2026). PMID: 42267539 ↗
L2OTHERCited in: Acute Management: Neurologic Emergencies & Attack Abortion
[318]
Hamedani AG, Thibault D, Willis AW. “Seasonal Variation in Neurologic Hospitalizations in the United States.” Annals of neurology (2022). PMID: 36515177 ↗
L2OTHERCited in: Acute Management: Neurologic Emergencies & Attack Abortion
[319]
Tallantyre EC, Vickaryous N, Anderson V et al.. “COVID-19 Vaccine Response in People with Multiple Sclerosis.” Annals of neurology (2021). PMID: 34687063 ↗
L2OTHERCited in: Acute Management: Neurologic Emergencies & Attack Abortion
[320]
Kalb R, Beier M, Benedict RH et al.. “Recommendations for cognitive screening and management in multiple sclerosis care.” Multiple sclerosis (Houndmills, Basingstoke, England) (2018). PMID: 30303036 ↗
L1REVIEW_NARRATIVECited in: Acute Management: Neurologic Emergencies & Attack Abortion, Disease-Modifying & Immunotherapy Program: Sequencing, Safety Monitoring & De-escalation, Neurorehabilitation, Symptomatic & Supportive Care, Prevention, Screening & Surveillance
[321]
Durozard P, Maarouf A, Boutiere C et al.. “Efficacy of rituximab in refractory RRMS.” Multiple sclerosis (Houndmills, Basingstoke, England) (2018). PMID: 29722639 ↗
L2OTHERCited in: Acute Management: Neurologic Emergencies & Attack Abortion
[322]
Roston S, Quick MH, Tisavipat N et al.. “Assessment of increased opening pressure in patients with multiple sclerosis and aquaporin-4-IgG-positive neuromyelitis optica spectrum disorder.” Multiple sclerosis (Houndmills, Basingstoke, England) (2025). PMID: 40415648 ↗
L4OTHERCited in: Acute Management: Neurologic Emergencies & Attack Abortion
[323]
Schwarz T, Otto C, Jones TC et al.. “Preserved T cell responses to SARS-CoV-2 in anti-CD20 treated multiple sclerosis.” Multiple sclerosis (Houndmills, Basingstoke, England) (2022). PMID: 35575234 ↗
L2OTHERCited in: Acute Management: Neurologic Emergencies & Attack Abortion
[324]
Akrivaki A, Giannopapas V, Dimitriadou EM et al.. “Neuropathic Pain in Neuromyelitis Optica Spectrum Disorders: Prevalence and Management Strategies-A Systematic Review and Meta-Analysis.” Journal of clinical medicine (2026). PMID: 41753066 ↗
L1SR_OBSCited in: Acute Management: Neurologic Emergencies & Attack Abortion
[325]
Sredanović M, Bunoza B, Lehman I et al.. “Towards practical management of the Marburg variant of multiple sclerosis.” Multiple sclerosis and related disorders (2025). PMID: 41380461 ↗
L4SR_OBSCited in: Acute Management: Neurologic Emergencies & Attack Abortion
[326]
Craiu D, Dica AD, Pomeran C et al.. “Disease-Modifying Treatment Options in Very Early Onset Multiple Sclerosis-What Choices Are There for Onset Under 5 Years of Age? A Systematic Review.” Journal of clinical medicine (2025). PMID: 41303170 ↗
L5SR_OBSCited in: Acute Management: Neurologic Emergencies & Attack Abortion
[327]
Wang C, Liu Z, Zhou Y et al.. “Exploring the Potential Link Between Autoimmune Diseases and Pan-Cancer: A Multidatabase Mendelian Randomization Analysis.” Journal of immunology research (2025). PMID: 40322556 ↗
L2SR_OBSCited in: Acute Management: Neurologic Emergencies & Attack Abortion
[328]
Yuan S, Hou J, Yang X. “Social Determinants of Health, Nursing Care Quality, and Patient Outcomes in Neurological Disorders: A Systematic Review.” Risk management and healthcare policy (2026). PMID: 42221297 ↗
L2SR_OBSCited in: Acute Management: Neurologic Emergencies & Attack Abortion, Prevention, Screening & Surveillance
[329]
Chen J, Yang K. “Letter to the editor: comment on "primary visual cortex impairment due to trans-synaptic degeneration after optic neuritis: a systematic review of neuroimaging studies".” Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia (2025). PMID: 40845468 ↗
L5SR_OBSCited in: Acute Management: Neurologic Emergencies & Attack Abortion
[330]
Shilash OB, Alqahtani L, Alkhaibary A et al.. “Trigeminal neuralgia management in patients with multiple sclerosis: A systematic review of approaches and outcomes.” Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia (2025). PMID: 40220576 ↗
L5SR_OBSCited in: Acute Management: Neurologic Emergencies & Attack Abortion
[331]
Fox RJ, Bar-Or A, Traboulsee A et al.. “Tolebrutinib in Nonrelapsing Secondary Progressive Multiple Sclerosis.” The New England journal of medicine (2025). PMID: 40202696 ↗
L1RCTCited in: Long-term & Definitive Management (Evidence Ladder), History and Evolution of Treatment, Disease-Modifying & Immunotherapy Program: Sequencing, Safety Monitoring & De-escalation, Prognosis & Natural History
[332]
Cohen JA, Barkhof F, Comi G et al.. “Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis.” The New England journal of medicine (2010). PMID: 20089954 ↗
L1RCTCited in: Long-term & Definitive Management (Evidence Ladder)
[333]
Kappos L, Radue EW, O'Connor P et al.. “A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis.” The New England journal of medicine (2010). PMID: 20089952 ↗
L1RCTCited in: Long-term & Definitive Management (Evidence Ladder)
[334]
Coles AJ, Compston DA, Selmaj KW et al.. “Alemtuzumab vs. interferon beta-1a in early multiple sclerosis.” The New England journal of medicine (2008). PMID: 18946064 ↗
L1RCTCited in: Long-term & Definitive Management (Evidence Ladder), Prognosis & Natural History
[335]
Corboy JR, Fox RJ, Kister I et al.. “Risk of new disease activity in patients with multiple sclerosis who continue or discontinue disease-modifying therapies (DISCOMS): a multicentre, randomised, single-blind, phase 4, non-inferiority trial.” The Lancet. Neurology (2023). PMID: 37353277 ↗
L1RCTCited in: Long-term & Definitive Management (Evidence Ladder), History and Evolution of Treatment, Disease-Modifying & Immunotherapy Program: Sequencing, Safety Monitoring & De-escalation, Prognosis & Natural History
[336]
Kappos L, Hartung HP, Freedman MS et al.. “Atacicept in multiple sclerosis (ATAMS): a randomised, placebo-controlled, double-blind, phase 2 trial.” The Lancet. Neurology (2014). PMID: 24613349 ↗
L1RCTCited in: Long-term & Definitive Management (Evidence Ladder)
[337]
Cree BAC, Cutter G, Wolinsky JS et al.. “Safety and efficacy of MD1003 (high-dose biotin) in patients with progressive multiple sclerosis (SPI2): a randomised, double-blind, placebo-controlled, phase 3 trial.” The Lancet. Neurology (2020). PMID: 33222767 ↗
L1RCTCited in: Long-term & Definitive Management (Evidence Ladder)
[338]
Cohen JA, Comi G, Selmaj KW et al.. “Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial.” The Lancet. Neurology (2019). PMID: 31492652 ↗
L1RCTCited in: Long-term & Definitive Management (Evidence Ladder), Prevention, Screening & Surveillance
[339]
Chataway J, De Angelis F, Connick P et al.. “Efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis (MS-SMART): a phase 2b, multiarm, double-blind, randomised placebo-controlled trial.” The Lancet. Neurology (2020). PMID: 31981516 ↗
L1RCTCited in: Long-term & Definitive Management (Evidence Ladder)
[340]
Comi G, Kappos L, Selmaj KW et al.. “Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial.” The Lancet. Neurology (2019). PMID: 31492651 ↗
L1RCTCited in: Long-term & Definitive Management (Evidence Ladder), Prevention, Screening & Surveillance
[341]
Confavreux C, O'Connor P, Comi G et al.. “Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial.” The Lancet. Neurology (2014). PMID: 24461574 ↗
L1RCTCited in: Long-term & Definitive Management (Evidence Ladder)
[342]
Cortese M, Peng X, Edan G et al.. “Serum Alpha-Linolenic Acid and Long-Term Multiple Sclerosis Activity and Progression.” Neurology (2025). PMID: 40674673 ↗
L2RCTCited in: Long-term & Definitive Management (Evidence Ladder), History and Evolution of Treatment
[343]
Hemmer B, Wiendl H, Roth K et al.. “Efficacy and Safety of Proposed Biosimilar Natalizumab (PB006) in Patients With Relapsing-Remitting Multiple Sclerosis: The Antelope Phase 3 Randomized Clinical Trial.” JAMA neurology (2023). PMID: 36689214 ↗
L1RCTCited in: Long-term & Definitive Management (Evidence Ladder), History and Evolution of Treatment, Prevention, Screening & Surveillance
[344]
Tanasescu R, Tench CR, Constantinescu CS et al.. “Hookworm Treatment for Relapsing Multiple Sclerosis: A Randomized Double-Blinded Placebo-Controlled Trial.” JAMA neurology (2020). PMID: 32539079 ↗
L1RCTCited in: Long-term & Definitive Management (Evidence Ladder), History and Evolution of Treatment, Complications
[345]
Iaci JF, Parry TJ, Huang Z et al.. “Dalfampridine improves sensorimotor function in rats with chronic deficits after middle cerebral artery occlusion.” Stroke (2013). PMID: 23652269 ↗
L5RCTCited in: Long-term & Definitive Management (Evidence Ladder), History and Evolution of Treatment
[346]
Coles AJ, Twyman CL, Arnold DL et al.. “Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial.” Lancet (London, England) (2012). PMID: 23122650 ↗
L1RCTCited in: Long-term & Definitive Management (Evidence Ladder), Disease-Modifying & Immunotherapy Program: Sequencing, Safety Monitoring & De-escalation
[347]
Chataway J, Williams T, Li V et al.. “Clinical trials for progressive multiple sclerosis: progress, new lessons learned, and remaining challenges.” The Lancet. Neurology (2024). PMID: 38365380 ↗
L5TRIAL_NONRANDOMCited in: Long-term & Definitive Management (Evidence Ladder), Disease-Modifying & Immunotherapy Program: Sequencing, Safety Monitoring & De-escalation
[348]
Ontaneda D, Fox RJ, Chataway J. “Clinical trials in progressive multiple sclerosis: lessons learned and future perspectives.” The Lancet. Neurology (2015). PMID: 25772899 ↗
L5TRIAL_NONRANDOMCited in: Long-term & Definitive Management (Evidence Ladder), Disease-Modifying & Immunotherapy Program: Sequencing, Safety Monitoring & De-escalation
[349]
Sormani MP, Bruzzi P. “MRI lesions as a surrogate for relapses in multiple sclerosis: a meta-analysis of randomised trials.” The Lancet. Neurology (2013). PMID: 23743084 ↗
L1SR_OBSCited in: Long-term & Definitive Management (Evidence Ladder)
[350]
Salter A, Lancia S, Kowalec K et al.. “Investigating the Prevalence of Comorbidity in Multiple Sclerosis Clinical Trial Populations.” Neurology (2024). PMID: 38350062 ↗
L2TRIAL_NONRANDOMCited in: Long-term & Definitive Management (Evidence Ladder), History and Evolution of Treatment
[351]
Freedman MS. “Long-term follow-up of clinical trials of multiple sclerosis therapies.” Neurology (2011). PMID: 21205679 ↗
L5TRIAL_NONRANDOMCited in: Long-term & Definitive Management (Evidence Ladder)
[352]
Waubant E, Banwell B, Wassmer E et al.. “Clinical trials of disease-modifying agents in pediatric MS: Opportunities, challenges, and recommendations from the IPMSSG.” Neurology (2019). PMID: 31043474 ↗
L1TRIAL_NONRANDOMCited in: Long-term & Definitive Management (Evidence Ladder)
[353]
Baker D, Herrod SS, Alvarez-Gonzalez C et al.. “Interpreting Lymphocyte Reconstitution Data From the Pivotal Phase 3 Trials of Alemtuzumab.” JAMA neurology (2017). PMID: 28604916 ↗
L4TRIAL_NONRANDOMCited in: Long-term & Definitive Management (Evidence Ladder)
[354]
Okuda DT, Kantarci O, Lebrun-Frénay C et al.. “Dimethyl Fumarate Delays Multiple Sclerosis in Radiologically Isolated Syndrome.” Annals of neurology (2022). PMID: 36401339 ↗
L1RCTCited in: Long-term & Definitive Management (Evidence Ladder), History and Evolution of Treatment, Disease-Modifying & Immunotherapy Program: Sequencing, Safety Monitoring & De-escalation
[355]
Lublin FD, Cofield SS, Cutter GR et al.. “Randomized study combining interferon and glatiramer acetate in multiple sclerosis.” Annals of neurology (2013). PMID: 23424159 ↗
L1RCTCited in: Long-term & Definitive Management (Evidence Ladder)
[356]
Bermel RA, You X, Foulds P et al.. “Predictors of long-term outcome in multiple sclerosis patients treated with interferon β.” Annals of neurology (2013). PMID: 23378325 ↗
L2RCTCited in: Long-term & Definitive Management (Evidence Ladder)
[357]
Goodman AD, Brown TR, Edwards KR et al.. “A phase 3 trial of extended release oral dalfampridine in multiple sclerosis.” Annals of neurology (2010). PMID: 20976768 ↗
L1RCTCited in: Long-term & Definitive Management (Evidence Ladder)
[358]
Gärtner J, Hauser SL, Bar-Or A et al.. “Efficacy and safety of ofatumumab in recently diagnosed, treatment-naive patients with multiple sclerosis: Results from ASCLEPIOS I and II.” Multiple sclerosis (Houndmills, Basingstoke, England) (2022). PMID: 35266417 ↗
L2RCTCited in: Long-term & Definitive Management (Evidence Ladder), History and Evolution of Treatment
[359]
Corboy JR, Fox RJ, Cutter G et al.. “DISCOntinuation of disease-modifying therapies in MS: The DISCOMS extension trial.” Multiple sclerosis (Houndmills, Basingstoke, England) (2025). PMID: 39834328 ↗
L2RCTCited in: Long-term & Definitive Management (Evidence Ladder)
[360]
Bar-Or A, Calabresi PA, Arnold D et al.. “Rituximab in relapsing-remitting multiple sclerosis: a 72-week, open-label, phase I trial.” Annals of neurology (2008). PMID: 18383069 ↗
L4TRIAL_NONRANDOMCited in: Long-term & Definitive Management (Evidence Ladder)
[361]
Mascareñas-García M, Rivero-de-Aguilar A, Candal-Pedreira C et al.. “Distortion in the Communication of Nonsignificant Primary Outcomes: The Spin Strategy in Multiple Sclerosis Trials.” Annals of neurology (2026). PMID: 41586489 ↗
L1SR_OBSCited in: Long-term & Definitive Management (Evidence Ladder)
[362]
Marrie RA, Sormani MP, Apap Mangion S et al.. “Improving the efficiency of clinical trials in multiple sclerosis.” Multiple sclerosis (Houndmills, Basingstoke, England) (2023). PMID: 37555492 ↗
L5TRIAL_NONRANDOMCited in: Long-term & Definitive Management (Evidence Ladder)
[363]
Strijbis E, Mostert J, D'Haeseleer M et al.. “Diminishing returns of disease-modifying treatment in older participants of multiple sclerosis clinical trials.” Multiple sclerosis (Houndmills, Basingstoke, England) (2026). PMID: 41858174 ↗
L2TRIAL_NONRANDOMCited in: Long-term & Definitive Management (Evidence Ladder)
[364]
Gerardi C, Bertele' V, Rossi S et al.. “Preapproval and postapproval evidence on drugs for multiple sclerosis.” Neurology (2018). PMID: 29695598 ↗
L1REVIEW_NARRATIVECited in: Long-term & Definitive Management (Evidence Ladder), History and Evolution of Treatment, Prevention, Screening & Surveillance
[365]
Ghezzi A, Amato MP, Makhani N et al.. “Pediatric multiple sclerosis: Conventional first-line treatment and general management.” Neurology (2016). PMID: 27572869 ↗
L5REVIEW_NARRATIVECited in: Long-term & Definitive Management (Evidence Ladder)
[366]
Scalfari A, Knappertz V, Cutter G et al.. “Mortality in patients with multiple sclerosis.” Neurology (2013). PMID: 23836941 ↗
L5REVIEW_NARRATIVECited in: Long-term & Definitive Management (Evidence Ladder), Complications
[367]
Tur C, Kalincik T, Oh J et al.. “Head-to-head drug comparisons in multiple sclerosis: Urgent action needed.” Neurology (2019). PMID: 31591277 ↗
L5REVIEW_NARRATIVECited in: Long-term & Definitive Management (Evidence Ladder)
[368]
Corboy JR, Weinshenker BG, Wingerchuk DM. “Comment on 2018 American Academy of Neurology guidelines on disease-modifying therapies in MS.” Neurology (2018). PMID: 29685920 ↗
L5REVIEW_NARRATIVECited in: Long-term & Definitive Management (Evidence Ladder)
[369]
Miller AE, Chitnis T, Cohen BA et al.. “Autologous Hematopoietic Stem Cell Transplant in Multiple Sclerosis: Recommendations of the National Multiple Sclerosis Society.” JAMA neurology (2021). PMID: 33104165 ↗
L1REVIEW_NARRATIVECited in: Long-term & Definitive Management (Evidence Ladder)
[370]
Wootla B, Watzlawik JO, Warrington AE et al.. “Naturally Occurring Monoclonal Antibodies and Their Therapeutic Potential for Neurologic Diseases.” JAMA neurology (2015). PMID: 26389734 ↗
L5REVIEW_NARRATIVECited in: Long-term & Definitive Management (Evidence Ladder)
[371]
Zhuang Y, Meng J, Dai X et al.. “Vitamin D for multiple sclerosis as an adjuvant therapy: A network meta-analysis of randomized controlled trials.” Clinical nutrition (Edinburgh, Scotland) (2026). PMID: 42242131 ↗
L1SR_MA_RCTCited in: Long-term & Definitive Management (Evidence Ladder)
[372]
Yang FA, Chen HC, Wu PJ et al.. “Prescribing Resistance Training in Multiple Sclerosis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.” American journal of physical medicine & rehabilitation (2026). PMID: 42155970 ↗
L1SR_MA_RCTCited in: Long-term & Definitive Management (Evidence Ladder)
[373]
Jabbari A, Esmaeili Gouvarchin Ghaleh H, Alimohammadi M et al.. “Effect of vitamin D3 supplementation on systemic inflammation and disease-specific markers in patients with autoimmune diseases: a comprehensive meta-analysis of randomized controlled trials.” Inflammopharmacology (2026). PMID: 41952022 ↗
L1SR_MA_RCTCited in: Long-term & Definitive Management (Evidence Ladder)
[374]
Hogenboom L, Schoof LG, Gelissen LMY et al.. “Individual Variability of CD19+ B-Cell Repopulation in People With Multiple Sclerosis Treated With Extended Interval Dosing of Ocrelizumab.” European journal of neurology (2026). PMID: 42411923 ↗
L2RCTCited in: Long-term & Definitive Management (Evidence Ladder), History and Evolution of Treatment
[375]
Robertson D, Alvarez E, Steinman L et al.. “Disease outcomes with ublituximab in treatment-naïve participants: subpopulation analyses of the phase 3 ULTIMATE I and II studies in participants with relapsing multiple sclerosis.” Frontiers in immunology (2026). PMID: 42292352 ↗
L2RCTCited in: Long-term & Definitive Management (Evidence Ladder), History and Evolution of Treatment, Disease-Modifying & Immunotherapy Program: Sequencing, Safety Monitoring & De-escalation
[376]
Hamedani M, Lombardi G, Boffa G et al.. “Task-oriented virtual reality and brain functional plasticity in progressive multiple sclerosis: A randomized controlled trial on upper limb rehabilitation.” Multiple sclerosis (Houndmills, Basingstoke, England) (2026). PMID: 42265947 ↗
L1RCTCited in: Long-term & Definitive Management (Evidence Ladder), History and Evolution of Treatment, Neurorehabilitation, Symptomatic & Supportive Care
[377]
Tallantyre EC, Planchon SM, Howard H et al.. “Disease-modifying treatment preferences and decision-making in a multiple sclerosis randomized and observational clinical trial (DELIVER-MS).” Multiple sclerosis (Houndmills, Basingstoke, England) (2026). PMID: 42218617 ↗
L1RCTCited in: Long-term & Definitive Management (Evidence Ladder), History and Evolution of Treatment
[378]
Donkers SJ, Lohse KR, Melam GR et al.. “Translingual neural stimulation to improve gait and balance in multiple sclerosis: A randomized controlled trial.” Archives of physical medicine and rehabilitation (2026). PMID: 42150723 ↗
L1RCTCited in: Long-term & Definitive Management (Evidence Ladder)
[379]
Kiropoulos LA, Kilpatrick TJ, Kalincik T et al.. “A tailored cognitive behavioural therapy intervention for depression in those newly diagnosed with multiple sclerosis (ACTION-MS): A randomised, assessor-blinded, active comparator trial.” Journal of affective disorders (2026). PMID: 42134745 ↗
L1RCTCited in: Long-term & Definitive Management (Evidence Ladder)
[380]
Smirnov RA, Cantoni C, Lee K et al.. “Dynamics of Spinal Fluid Immune Cell Alterations Following Cladribine Tablet Treatment in Multiple Sclerosis.” Neurology(R) neuroimmunology & neuroinflammation (2026). PMID: 41990287 ↗
L4RCTCited in: Long-term & Definitive Management (Evidence Ladder)
[381]
Roos I, Leray E, Frascoli F et al.. “Delay from treatment start to full effect of immunotherapies for multiple sclerosis.” Brain : a journal of neurology (2020). PMID: 32947619 ↗
L2OTHERCited in: Long-term & Definitive Management (Evidence Ladder)
[382]
Kalincik T, Cutter G, Spelman T et al.. “Defining reliable disability outcomes in multiple sclerosis.” Brain : a journal of neurology (2015). PMID: 26359291 ↗
L2OTHERCited in: Long-term & Definitive Management (Evidence Ladder), Prevention, Screening & Surveillance
[383]
Moser T, Hitzl W, Lerda-Casaccia T et al.. “Propionic acid in multiple sclerosis: a phase 2b, double-blind, randomized placebo-controlled trial.” Brain : a journal of neurology (2026). PMID: 42402345 ↗
L1OTHERCited in: Long-term & Definitive Management (Evidence Ladder), Neurorehabilitation, Symptomatic & Supportive Care
[384]
Palace J, Lin DY, Zeng D et al.. “Outcome prediction models in AQP4-IgG positive neuromyelitis optica spectrum disorders.” Brain : a journal of neurology (2019). PMID: 30938427 ↗
L2OTHERCited in: Long-term & Definitive Management (Evidence Ladder)
[385]
Abrahamsson SV, Angelini DF, Dubinsky AN et al.. “Non-myeloablative autologous haematopoietic stem cell transplantation expands regulatory cells and depletes IL-17 producing mucosal-associated invariant T cells in multiple sclerosis.” Brain : a journal of neurology (2013). PMID: 23864273 ↗
L4OTHERCited in: Long-term & Definitive Management (Evidence Ladder)
[386]
Cerono G, Cree BAC, Hauser SL et al.. “Comparative Safety Profiles of Ocrelizumab and Rituximab in Multiple Sclerosis Treatment Using Real-World Evidence.” Annals of neurology (2025). PMID: 40919837 ↗
L2OTHERCited in: Long-term & Definitive Management (Evidence Ladder)
[387]
Mowry EM, Krupp LB, Milazzo M et al.. “Vitamin D status is associated with relapse rate in pediatric-onset multiple sclerosis.” Annals of neurology (2010). PMID: 20437559 ↗
L2OTHERCited in: Long-term & Definitive Management (Evidence Ladder)
[388]
Clanet MC, Wolinsky JS, Ashton RJ et al.. “Risk evaluation and monitoring in multiple sclerosis therapeutics.” Multiple sclerosis (Houndmills, Basingstoke, England) (2013). PMID: 24293456 ↗
L5REVIEW_NARRATIVECited in: Long-term & Definitive Management (Evidence Ladder)
[389]
Hartung HP, Aktas O, Boyko AN. “Alemtuzumab: a new therapy for active relapsing-remitting multiple sclerosis.” Multiple sclerosis (Houndmills, Basingstoke, England) (2014). PMID: 25344374 ↗
L5REVIEW_NARRATIVECited in: Long-term & Definitive Management (Evidence Ladder)
[390]
Banwell B. “Pediatric multiple sclerosis: The 2022 ECTRIMS lecture.” Multiple sclerosis (Houndmills, Basingstoke, England) (2023). PMID: 37249099 ↗
L5OTHERCited in: Long-term & Definitive Management (Evidence Ladder)
[391]
Cohen JA, Trojano M, Mowry EM et al.. “Leveraging real-world data to investigate multiple sclerosis disease behavior, prognosis, and treatment.” Multiple sclerosis (Houndmills, Basingstoke, England) (2019). PMID: 31778094 ↗
L5REVIEW_NARRATIVECited in: Long-term & Definitive Management (Evidence Ladder)
[392]
Rød BE, Høgestøl EA, Torkildsen Ø et al.. “Comparative effectiveness of rituximab and cladribine in relapsing-remitting multiple sclerosis: A target trial emulation.” Multiple sclerosis (Houndmills, Basingstoke, England) (2025). PMID: 40415655 ↗
L2OTHERCited in: Long-term & Definitive Management (Evidence Ladder)
[393]
Wingerchuk DM, Noseworthy JH. “Randomized controlled trials to assess therapies for multiple sclerosis.” Neurology (2002). PMID: 11971125 ↗
L5RCTCited in: History and Evolution of Treatment
[394]
Oh J, Arnold DL, Cree BAC et al.. “Tolebrutinib versus Teriflunomide in Relapsing Multiple Sclerosis.” The New England journal of medicine (2025). PMID: 40202623 ↗
L1RCTCited in: History and Evolution of Treatment, Prognosis & Natural History
[395]
Krupp LB, Tardieu M, Amato MP et al.. “International Pediatric Multiple Sclerosis Study Group criteria for pediatric multiple sclerosis and immune-mediated central nervous system demyelinating disorders: revisions to the 2007 definitions.” Multiple sclerosis (Houndmills, Basingstoke, England) (2013). PMID: 23572237 ↗
L5GUIDELINECited in: History and Evolution of Treatment, Special Populations & Pregnancy
[396]
Collongues N, Durand-Dubief F, Lebrun-Frenay C et al.. “Cancer and multiple sclerosis: 2023 recommendations from the French Multiple Sclerosis Society.” Multiple sclerosis (Houndmills, Basingstoke, England) (2024). PMID: 38357870 ↗
L1GUIDELINECited in: History and Evolution of Treatment
[397]
Reich DS, Arnold DL, Vermersch P et al.. “Safety and efficacy of tolebrutinib, an oral brain-penetrant BTK inhibitor, in relapsing multiple sclerosis: a phase 2b, randomised, double-blind, placebo-controlled trial.” The Lancet. Neurology (2021). PMID: 34418400 ↗
L1RCTCited in: History and Evolution of Treatment, Prevention, Screening & Surveillance
[398]
Hartung HP, Gonsette R, König N et al.. “Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial.” Lancet (London, England) (Unknown). PMID: 12504397 ↗
L1RCTCited in: History and Evolution of Treatment
[399]
Hommes OR, Sørensen PS, Fazekas F et al.. “Intravenous immunoglobulin in secondary progressive multiple sclerosis: randomised placebo-controlled trial.” Lancet (London, England) (Unknown). PMID: 15451222 ↗
L1RCTCited in: History and Evolution of Treatment
[400]
Barnes D, Hughes RA, Morris RW et al.. “Randomised trial of oral and intravenous methylprednisolone in acute relapses of multiple sclerosis.” Lancet (London, England) (1997). PMID: 9093250 ↗
L1RCTCited in: History and Evolution of Treatment
[401]
Coles AJ, Wing M, Smith S et al.. “Pulsed monoclonal antibody treatment and autoimmune thyroid disease in multiple sclerosis.” Lancet (London, England) (1999). PMID: 10568572 ↗
L4RCTCited in: History and Evolution of Treatment
[402]
Lorefice L, Pellecchia MT. “Frailty across Neurological Diseases: Why Sex and Gender Matter.” Annals of neurology (2025). PMID: 41267611 ↗
L5SR_OBSCited in: History and Evolution of Treatment
[403]
Siavoshi F, Smith MD, Cassard S et al.. “Fasting Mimicking Diets Reverse Accelerated Biological Aging in Multiple Sclerosis.” Annals of neurology (2025). PMID: 40970462 ↗
L4RCTCited in: History and Evolution of Treatment
[404]
Cree BAC, Freedman MS, Gold M et al.. “Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose Studies to Assess the Safety and Efficacy of Elezanumab when Added to Standard of Care in Relapsing and Progressive Forms of Multiple Sclerosis.” Annals of neurology (2025). PMID: 40698976 ↗
L1RCTCited in: History and Evolution of Treatment
[405]
Hauser SL, Zielman R, Das Gupta A et al.. “Efficacy and safety of four-year ofatumumab treatment in relapsing multiple sclerosis: The ALITHIOS open-label extension.” Multiple sclerosis (Houndmills, Basingstoke, England) (2023). PMID: 37691530 ↗
L2RCTCited in: History and Evolution of Treatment
[406]
Giovannoni G, Soelberg Sorensen P, Cook S et al.. “Safety and efficacy of cladribine tablets in patients with relapsing-remitting multiple sclerosis: Results from the randomized extension trial of the CLARITY study.” Multiple sclerosis (Houndmills, Basingstoke, England) (2017). PMID: 28870107 ↗
L1RCTCited in: History and Evolution of Treatment, Prognosis & Natural History
[407]
Krysko KM, Dobson R, Alroughani R et al.. “Family planning considerations in people with multiple sclerosis.” The Lancet. Neurology (2023). PMID: 36931808 ↗
L5REVIEW_NARRATIVECited in: History and Evolution of Treatment, Disease-Modifying & Immunotherapy Program: Sequencing, Safety Monitoring & De-escalation, Special Populations & Pregnancy
[408]
Okai AF, Howard AM, Williams MJ et al.. “Advancing Care and Outcomes for African American Patients With Multiple Sclerosis.” Neurology (2022). PMID: 35470139 ↗
L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
[409]
Tremlett H, Zhao Y, Rieckmann P et al.. “New perspectives in the natural history of multiple sclerosis.” Neurology (2010). PMID: 20548045 ↗
L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
[410]
Filippi M, Preziosa P, Barkhof F et al.. “Diagnosis of Progressive Multiple Sclerosis From the Imaging Perspective: A Review.” JAMA neurology (2021). PMID: 33315071 ↗
L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
[411]
Rudick R, Polman C, Clifford D et al.. “Natalizumab: bench to bedside and beyond.” JAMA neurology (2013). PMID: 23128399 ↗
L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
[412]
Miller DH, Barkhof F, Frank JA et al.. “Measurement of atrophy in multiple sclerosis: pathological basis, methodological aspects and clinical relevance.” Brain : a journal of neurology (2002). PMID: 12135961 ↗
L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
[413]
Miller DH, Grossman RI, Reingold SC et al.. “The role of magnetic resonance techniques in understanding and managing multiple sclerosis.” Brain : a journal of neurology (1998). PMID: 9549485 ↗
L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
[414]
Filippi M, Horsfield MA, Tofts PS et al.. “Quantitative assessment of MRI lesion load in monitoring the evolution of multiple sclerosis.” Brain : a journal of neurology (1995). PMID: 8595489 ↗
L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
[415]
Hauser SL, Chan JR, Oksenberg JR. “Multiple sclerosis: Prospects and promise.” Annals of neurology (2013). PMID: 23955638 ↗
L5REVIEW_NARRATIVECited in: History and Evolution of Treatment, Disease-Modifying & Immunotherapy Program: Sequencing, Safety Monitoring & De-escalation, Prognosis & Natural History
[416]
Weinshenker BG. “Natural history of multiple sclerosis.” Annals of neurology (1994). PMID: 8017890 ↗
L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
[417]
Noseworthy JH. “Clinical scoring methods for multiple sclerosis.” Annals of neurology (1994). PMID: 8017893 ↗
L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
[418]
Ludwin SK, Rao VTs, Moore CS et al.. “Astrocytes in multiple sclerosis.” Multiple sclerosis (Houndmills, Basingstoke, England) (2016). PMID: 27207458 ↗
L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
[419]
Cheng Q, Cheng XJ, Jiang GX. “Multiple sclerosis in China--history and future.” Multiple sclerosis (Houndmills, Basingstoke, England) (2009). PMID: 19435753 ↗
L4REVIEW_NARRATIVECited in: History and Evolution of Treatment
[420]
Costa SL, Genova HM, DeLuca J et al.. “Information processing speed in multiple sclerosis: Past, present, and future.” Multiple sclerosis (Houndmills, Basingstoke, England) (2016). PMID: 27207446 ↗
L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
[421]
Portaccio E, Amato MP. “Breastfeeding and post-partum relapses in multiple sclerosis patients.” Multiple sclerosis (Houndmills, Basingstoke, England) (2019). PMID: 30793658 ↗
L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
[422]
Carvalho AN, Lim JL, Nijland PG et al.. “Glutathione in multiple sclerosis: more than just an antioxidant?” Multiple sclerosis (Houndmills, Basingstoke, England) (2014). PMID: 24842957 ↗
L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
[423]
Miller DH, Fazekas F, Montalban X et al.. “Pregnancy, sex and hormonal factors in multiple sclerosis.” Multiple sclerosis (Houndmills, Basingstoke, England) (2014). PMID: 24446387 ↗
L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
[424]
Ebers GC. “Natural history of primary progressive multiple sclerosis.” Multiple sclerosis (Houndmills, Basingstoke, England) (2004). PMID: 15218804 ↗
L2REVIEW_NARRATIVECited in: History and Evolution of Treatment
[425]
Atwood LD, Wolf PA, Heard-Costa NL et al.. “Genetic variation in white matter hyperintensity volume in the Framingham Study.” Stroke (2004). PMID: 15143299 ↗
L2OTHERCited in: History and Evolution of Treatment
[426]
Nicoletti A, Sofia V, Biondi R et al.. “Epilepsy and multiple sclerosis in Sicily: a population-based study.” Epilepsia (2003). PMID: 14636354 ↗
L2OTHERCited in: History and Evolution of Treatment
[427]
Vaheb S, Hatef B, Mirani A et al.. “Effects of binaural beats on acute stress recovery and autonomic regulation in multiple sclerosis: a pilot double-blind randomized controlled trial.” Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology (2026). PMID: 42307797 ↗
L1RCTCited in: History and Evolution of Treatment
[428]
Vermersch P, Arnould S, Gold R et al.. “Progression to Wheelchair in Secondary Progressive Multiple Sclerosis and Impact of Siponimod: Post Hoc Analyses From the EXPAND Study.” European journal of neurology (2026). PMID: 42257510 ↗
L2RCTCited in: History and Evolution of Treatment, Neurorehabilitation, Symptomatic & Supportive Care
[429]
Baroni A, Fregna G, Azzolina D et al.. “Motor and cognitive effects of video game training in people with multiple sclerosis: a randomized controlled trial.” European journal of physical and rehabilitation medicine (2026). PMID: 42252956 ↗
L1RCTCited in: History and Evolution of Treatment, Neurorehabilitation, Symptomatic & Supportive Care
[430]
Færk AK, Sellebjerg F, Lund JL et al.. “Cognitively stimulating activities in multiple sclerosis: Results of a randomized controlled trial.” Multiple sclerosis and related disorders (2026). PMID: 42214251 ↗
L1RCTCited in: History and Evolution of Treatment
[431]
Sumowski JF, Levy S, Katz Sand I et al.. “Cognition in multiple sclerosis within the modern diagnostic and treatment era.” Brain : a journal of neurology (2026). PMID: 41293835 ↗
L2OTHERCited in: History and Evolution of Treatment, Disease-Modifying & Immunotherapy Program: Sequencing, Safety Monitoring & De-escalation
[432]
Pisa M, Pansieri J, Yee S et al.. “Anterior optic pathway pathology in CNS demyelinating diseases.” Brain : a journal of neurology (2022). PMID: 35134111 ↗
L4OTHERCited in: History and Evolution of Treatment
[433]
Shams H, Shao X, Santaniello A et al.. “Polygenic risk score association with multiple sclerosis susceptibility and phenotype in Europeans.” Brain : a journal of neurology (2023). PMID: 35253861 ↗
L2OTHERCited in: History and Evolution of Treatment, Prevention, Screening & Surveillance
[434]
De Meo E, Filippi M, Trojano M et al.. “Comparing Natural History of Early and Late Onset Pediatric Multiple Sclerosis.” Annals of neurology (2022). PMID: 35150168 ↗
L2OTHERCited in: History and Evolution of Treatment, Special Populations & Pregnancy
[435]
Rae-Grant A, Day GS, Marrie RA et al.. “Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology.” Neurology (2018). PMID: 29686116 ↗
L1GUIDELINECited in: Disease-Modifying & Immunotherapy Program: Sequencing, Safety Monitoring & De-escalation
[436]
Spain RI, Paz Soldán MM, Freedman MS et al.. “Lipoic Acid for Treatment of Progressive Multiple Sclerosis: A Phase 2 Randomized Clinical Trial.” Neurology (2025). PMID: 41397213 ↗
L1RCTCited in: Disease-Modifying & Immunotherapy Program: Sequencing, Safety Monitoring & De-escalation
[437]
Landmeyer NC, Bürkner PC, Wiendl H et al.. “Disease-modifying treatments and cognition in relapsing-remitting multiple sclerosis: A meta-analysis.” Neurology (2020). PMID: 32430312 ↗
L1SR_OBSCited in: Disease-Modifying & Immunotherapy Program: Sequencing, Safety Monitoring & De-escalation
[438]
He A, Merkel B, Brown JWL et al.. “Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study.” The Lancet. Neurology (2020). PMID: 32199096 ↗
L2COHORTCited in: Disease-Modifying & Immunotherapy Program: Sequencing, Safety Monitoring & De-escalation, Prognosis & Natural History
[439]
Otero-Romero S, Lebrun-Frénay C, Reyes S et al.. “ECTRIMS/EAN consensus on vaccination in people with multiple sclerosis: Improving immunization strategies in the era of highly active immunotherapeutic drugs.” Multiple sclerosis (Houndmills, Basingstoke, England) (2023). PMID: 37293841 ↗
L1SR_OBSCited in: Disease-Modifying & Immunotherapy Program: Sequencing, Safety Monitoring & De-escalation, Special Populations & Pregnancy, Prevention, Screening & Surveillance
[440]
Lindå H, von Heijne A, Major EO et al.. “Progressive multifocal leukoencephalopathy after natalizumab monotherapy.” The New England journal of medicine (2009). PMID: 19741229 ↗
L4CASE_REPORTCited in: Disease-Modifying & Immunotherapy Program: Sequencing, Safety Monitoring & De-escalation
[441]
Wenning W, Haghikia A, Laubenberger J et al.. “Treatment of progressive multifocal leukoencephalopathy associated with natalizumab.” The New England journal of medicine (2009). PMID: 19741228 ↗
L4CASE_REPORTCited in: Disease-Modifying & Immunotherapy Program: Sequencing, Safety Monitoring & De-escalation
[442]
Graves JS, Krysko KM, Hua LH et al.. “Ageing and multiple sclerosis.” The Lancet. Neurology (2022). PMID: 36216015 ↗
L5REVIEW_NARRATIVECited in: Disease-Modifying & Immunotherapy Program: Sequencing, Safety Monitoring & De-escalation
[443]
Benkert P, Meier S, Schaedelin S et al.. “Serum neurofilament light chain for individual prognostication of disease activity in people with multiple sclerosis: a retrospective modelling and validation study.” The Lancet. Neurology (2022). PMID: 35182510 ↗
L2OTHERCited in: Disease-Modifying & Immunotherapy Program: Sequencing, Safety Monitoring & De-escalation
[444]
Chitnis T, Ghezzi A, Bajer-Kornek B et al.. “Pediatric multiple sclerosis: Escalation and emerging treatments.” Neurology (2016). PMID: 27572854 ↗
L5REVIEW_NARRATIVECited in: Disease-Modifying & Immunotherapy Program: Sequencing, Safety Monitoring & De-escalation
[445]
Egan RA, Kawasaki A. “Tadpole pupil.” Neurology (2013). PMID: 23479467 ↗
L5OTHERCited in: Disease-Modifying & Immunotherapy Program: Sequencing, Safety Monitoring & De-escalation, Special Populations & Pregnancy
[446]
Spelman T, Magyari M, Piehl F et al.. “Treatment Escalation vs Immediate Initiation of Highly Effective Treatment for Patients With Relapsing-Remitting Multiple Sclerosis: Data From 2 Different National Strategies.” JAMA neurology (2021). PMID: 34398221 ↗
L2OTHERCited in: Disease-Modifying & Immunotherapy Program: Sequencing, Safety Monitoring & De-escalation
[447]
Frisoni GB, Aho E, Brayne C et al.. “Alzheimer's disease outlook: controversies and future directions.” Lancet (London, England) (2025). PMID: 40997840 ↗
L5REVIEW_NARRATIVECited in: Disease-Modifying & Immunotherapy Program: Sequencing, Safety Monitoring & De-escalation, Neurorehabilitation, Symptomatic & Supportive Care, Complications, Prevention, Screening & Surveillance
[448]
Comi G, Radaelli M, Soelberg Sørensen P. “Evolving concepts in the treatment of relapsing multiple sclerosis.” Lancet (London, England) (2016). PMID: 27889192 ↗
L5REVIEW_NARRATIVECited in: Disease-Modifying & Immunotherapy Program: Sequencing, Safety Monitoring & De-escalation
[449]
Androdias G, Lünemann JD, Maillart E et al.. “De-escalating and discontinuing disease-modifying therapies in multiple sclerosis.” Brain : a journal of neurology (2025). PMID: 39707906 ↗
L5REVIEW_NARRATIVECited in: Disease-Modifying & Immunotherapy Program: Sequencing, Safety Monitoring & De-escalation, Prognosis & Natural History, Special Populations & Pregnancy
[450]
Bosanac T, Hughes RO, Engber T et al.. “Pharmacological SARM1 inhibition protects axon structure and function in paclitaxel-induced peripheral neuropathy.” Brain : a journal of neurology (2021). PMID: 33964142 ↗
L5OTHERCited in: Disease-Modifying & Immunotherapy Program: Sequencing, Safety Monitoring & De-escalation, Prognosis & Natural History
[451]
Scolding NJ, Pasquini M, Reingold SC et al.. “Cell-based therapeutic strategies for multiple sclerosis.” Brain : a journal of neurology (2017). PMID: 29053779 ↗
L5REVIEW_NARRATIVECited in: Disease-Modifying & Immunotherapy Program: Sequencing, Safety Monitoring & De-escalation
[452]
Camara-Lemarroy CR, Metz L, Meddings JB et al.. “The intestinal barrier in multiple sclerosis: implications for pathophysiology and therapeutics.” Brain : a journal of neurology (2018). PMID: 29860380 ↗
L5REVIEW_NARRATIVECited in: Disease-Modifying & Immunotherapy Program: Sequencing, Safety Monitoring & De-escalation
[453]
Brittain G, Roldan E, Alexander T et al.. “The Role of Chimeric Antigen Receptor T-Cell Therapy in Immune-Mediated Neurological Diseases.” Annals of neurology (2024). PMID: 39015040 ↗
L5REVIEW_NARRATIVECited in: Disease-Modifying & Immunotherapy Program: Sequencing, Safety Monitoring & De-escalation
[454]
Fine AJ, Sorbello A, Kortepeter C et al.. “Progressive multifocal leukoencephalopathy after natalizumab discontinuation.” Annals of neurology (2014). PMID: 24242357 ↗
L4OTHERCited in: Disease-Modifying & Immunotherapy Program: Sequencing, Safety Monitoring & De-escalation
[455]
Koralnik IJ. “Progressive multifocal leukoencephalopathy revisited: Has the disease outgrown its name?” Annals of neurology (2006). PMID: 16862584 ↗
L5REVIEW_NARRATIVECited in: Disease-Modifying & Immunotherapy Program: Sequencing, Safety Monitoring & De-escalation
[456]
Berger JR, Houff S. “Opportunistic infections and other risks with newer multiple sclerosis therapies.” Annals of neurology (2009). PMID: 19399841 ↗
L5REVIEW_NARRATIVECited in: Disease-Modifying & Immunotherapy Program: Sequencing, Safety Monitoring & De-escalation, Complications, Prevention, Screening & Surveillance
[457]
Montalban X, Gold R, Thompson AJ et al.. “ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis.” Multiple sclerosis (Houndmills, Basingstoke, England) (2018). PMID: 29353550 ↗
L1OTHERCited in: Disease-Modifying & Immunotherapy Program: Sequencing, Safety Monitoring & De-escalation, Special Populations & Pregnancy
[458]
Sanai SA, Saini V, Benedict RH et al.. “Aging and multiple sclerosis.” Multiple sclerosis (Houndmills, Basingstoke, England) (2016). PMID: 26895718 ↗
L5REVIEW_NARRATIVECited in: Disease-Modifying & Immunotherapy Program: Sequencing, Safety Monitoring & De-escalation
[459]
Abboud H, Hill E, Siddiqui J et al.. “Neuromodulation in multiple sclerosis.” Multiple sclerosis (Houndmills, Basingstoke, England) (2017). PMID: 29115915 ↗
L5REVIEW_NARRATIVECited in: Disease-Modifying & Immunotherapy Program: Sequencing, Safety Monitoring & De-escalation, Neurorehabilitation, Symptomatic & Supportive Care
[460]
Frisell T, Hedberg S, Piehl F. “Comparable Infection Risk of Ocrelizumab and Rituximab in Multiple Sclerosis in a Nationwide Swedish Cohort Study.” Annals of neurology (2026). PMID: 42310849 ↗
L2COHORTCited in: Disease-Modifying & Immunotherapy Program: Sequencing, Safety Monitoring & De-escalation
[461]
Rudick RA, Miller D, Hass S et al.. “Health-related quality of life in multiple sclerosis: effects of natalizumab.” Annals of neurology (2007). PMID: 17696126 ↗
L2RCTCited in: Neurorehabilitation, Symptomatic & Supportive Care, Complications
[462]
Cree BA, Kornyeyeva E, Goodin DS. “Pilot trial of low-dose naltrexone and quality of life in multiple sclerosis.” Annals of neurology (2010). PMID: 20695007 ↗
L2RCTCited in: Neurorehabilitation, Symptomatic & Supportive Care
[463]
Panitch HS, Thisted RA, Smith RA et al.. “Randomized, controlled trial of dextromethorphan/quinidine for pseudobulbar affect in multiple sclerosis.” Annals of neurology (2006). PMID: 16634036 ↗
L1RCTCited in: Neurorehabilitation, Symptomatic & Supportive Care
[464]
Snetselaar LG, Cheek JJ, Fox SS et al.. “Efficacy of Diet on Fatigue and Quality of Life in Multiple Sclerosis: A Systematic Review and Network Meta-analysis of Randomized Trials.” Neurology (2022). PMID: 36257717 ↗
L1SR_OBSCited in: Neurorehabilitation, Symptomatic & Supportive Care, Prognosis & Natural History
[465]
Marrie RA, Miller A, Sormani MP et al.. “Recommendations for observational studies of comorbidity in multiple sclerosis.” Neurology (2016). PMID: 26865523 ↗
L5SR_OBSCited in: Neurorehabilitation, Symptomatic & Supportive Care, Complications
[466]
Cano Porras D, Siemonsma P, Inzelberg R et al.. “Advantages of virtual reality in the rehabilitation of balance and gait: Systematic review.” Neurology (2018). PMID: 29720544 ↗
L2SR_OBSCited in: Neurorehabilitation, Symptomatic & Supportive Care
[467]
Hauser SL. “Advances in Multiple Sclerosis.” The New England journal of medicine (2026). PMID: 42384871 ↗
L5REVIEW_NARRATIVECited in: Neurorehabilitation, Symptomatic & Supportive Care
[468]
Sihvonen AJ, Särkämö T, Leo V et al.. “Music-based interventions in neurological rehabilitation.” The Lancet. Neurology (2017). PMID: 28663005 ↗
L5REVIEW_NARRATIVECited in: Neurorehabilitation, Symptomatic & Supportive Care
[469]
Chiaravalloti ND, DeLuca J. “Cognitive impairment in multiple sclerosis.” The Lancet. Neurology (2008). PMID: 19007738 ↗
L5REVIEW_NARRATIVECited in: Neurorehabilitation, Symptomatic & Supportive Care
[470]
Kluger BM, Hudson P, Hanson LC et al.. “Palliative care to support the needs of adults with neurological disease.” The Lancet. Neurology (2023). PMID: 37353280 ↗
L5REVIEW_NARRATIVECited in: Neurorehabilitation, Symptomatic & Supportive Care, Prevention, Screening & Surveillance
[471]
McKay KA, Manouchehrinia A, Berrigan L et al.. “Long-term Cognitive Outcomes in Patients With Pediatric-Onset vs Adult-Onset Multiple Sclerosis.” JAMA neurology (2019). PMID: 31206130 ↗
L2OTHERCited in: Neurorehabilitation, Symptomatic & Supportive Care
[472]
Feinstein A, Bar-Or A, Benedict RHB et al.. “Is multiple sclerosis-related depression different from depression in general? The data for and against.” Brain : a journal of neurology (2025). PMID: 41251688 ↗
L5REVIEW_NARRATIVECited in: Neurorehabilitation, Symptomatic & Supportive Care
[473]
Rodrigues P, Frare JM, Ruviaro NA et al.. “Advanced oxidation protein products activated TRPA1 in a neuropathic multiple sclerosis model.” Brain : a journal of neurology (2026). PMID: 40819275 ↗
L5OTHERCited in: Neurorehabilitation, Symptomatic & Supportive Care
[474]
Eijlers AJC, van Geest Q, Dekker I et al.. “Predicting cognitive decline in multiple sclerosis: a 5-year follow-up study.” Brain : a journal of neurology (2018). PMID: 30169585 ↗
L2OTHERCited in: Neurorehabilitation, Symptomatic & Supportive Care
[475]
Hobart JC, Riazi A, Thompson AJ et al.. “Getting the measure of spasticity in multiple sclerosis: the Multiple Sclerosis Spasticity Scale (MSSS-88).” Brain : a journal of neurology (2005). PMID: 16280352 ↗
L5OTHERCited in: Neurorehabilitation, Symptomatic & Supportive Care
[476]
de Groot V, Beckerman H, Uitdehaag BM et al.. “The usefulness of evaluative outcome measures in patients with multiple sclerosis.” Brain : a journal of neurology (2006). PMID: 16956906 ↗
L2OTHERCited in: Neurorehabilitation, Symptomatic & Supportive Care
[477]
Pan S, Chan JR. “Clinical Applications of Myelin Plasticity for Remyelinating Therapies in Multiple Sclerosis.” Annals of neurology (2021). PMID: 34402546 ↗
L5REVIEW_NARRATIVECited in: Neurorehabilitation, Symptomatic & Supportive Care
[478]
Petzold A, Mondria T, Kuhle J et al.. “Evidence for acute neurotoxicity after chemotherapy.” Annals of neurology (2010). PMID: 21194151 ↗
L2OTHERCited in: Neurorehabilitation, Symptomatic & Supportive Care
[479]
Kalsi V, Gonzales G, Popat R et al.. “Botulinum injections for the treatment of bladder symptoms of multiple sclerosis.” Annals of neurology (2007). PMID: 17890635 ↗
L4OTHERCited in: Neurorehabilitation, Symptomatic & Supportive Care
[480]
Axthelm MK, Bourdette DN, Marracci GH et al.. “Japanese macaque encephalomyelitis: a spontaneous multiple sclerosis-like disease in a nonhuman primate.” Annals of neurology (2011). PMID: 21674589 ↗
L4OTHERCited in: Neurorehabilitation, Symptomatic & Supportive Care
[481]
Kalb R, Brown TR, Coote S et al.. “Exercise and lifestyle physical activity recommendations for people with multiple sclerosis throughout the disease course.” Multiple sclerosis (Houndmills, Basingstoke, England) (2020). PMID: 32323606 ↗
L1OTHERCited in: Neurorehabilitation, Symptomatic & Supportive Care
[482]
Lavorgna L, Brigo F, Moccia M et al.. “e-Health and multiple sclerosis: An update.” Multiple sclerosis (Houndmills, Basingstoke, England) (2018). PMID: 30231004 ↗
L5REVIEW_NARRATIVECited in: Neurorehabilitation, Symptomatic & Supportive Care
[483]
López-Andaur R, Vásquez-Carrasco E, Guerra-Labbé L et al.. “Effectiveness of Immersive and Non-Immersive Virtual Reality Interventions on Cognitive Function in People with Multiple Sclerosis: A Systematic Review.” Journal of clinical medicine (2026). PMID: 42355702 ↗
L2SR_OBSCited in: Neurorehabilitation, Symptomatic & Supportive Care
[484]
Santamaría G, Jiménez-Callejo E, Rodríguez López N et al.. “Effects of Aquatic Therapy on Fatigue, Mobility, Physical Function, and Quality of Life in People with Multiple Sclerosis: A Systematic Review and Meta-Analysis.” Journal of functional morphology and kinesiology (2026). PMID: 42346748 ↗
L1SR_OBSCited in: Neurorehabilitation, Symptomatic & Supportive Care
[485]
Lagrèze WA, Küchlin S, Ihorst G et al.. “Safety and efficacy of erythropoietin for the treatment of patients with optic neuritis (TONE): a randomised, double-blind, multicentre, placebo-controlled study.” The Lancet. Neurology (2021). PMID: 34800417 ↗
L1RCTCited in: Complications
[486]
Freeman J, Hendrie W, Jarrett L et al.. “Assessment of a home-based standing frame programme in people with progressive multiple sclerosis (SUMS): a pragmatic, multi-centre, randomised, controlled trial and cost-effectiveness analysis.” The Lancet. Neurology (2019). PMID: 31301748 ↗
L1RCTCited in: Complications
[487]
Riva N, Mora G, Sorarù G et al.. “Safety and efficacy of nabiximols on spasticity symptoms in patients with motor neuron disease (CANALS): a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial.” The Lancet. Neurology (2018). PMID: 30554828 ↗
L1RCTCited in: Complications
[488]
Kapoor R, Furby J, Hayton T et al.. “Lamotrigine for neuroprotection in secondary progressive multiple sclerosis: a randomised, double-blind, placebo-controlled, parallel-group trial.” The Lancet. Neurology (2010). PMID: 20621711 ↗
L1RCTCited in: Complications
[489]
Burt RK, Loh Y, Cohen B et al.. “Autologous non-myeloablative haemopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: a phase I/II study.” The Lancet. Neurology (2009). PMID: 19186105 ↗
L4TRIAL_NONRANDOMCited in: Complications
[490]
Sormani MP, Muraro PA, Schiavetti I et al.. “Autologous hematopoietic stem cell transplantation in multiple sclerosis: A meta-analysis.” Neurology (2017). PMID: 28455383 ↗
L1SR_OBSCited in: Complications
[491]
Marrie RA, Maxwell C, Mahar A et al.. “Cancer Incidence and Mortality Rates in Multiple Sclerosis: A Matched Cohort Study.” Neurology (2020). PMID: 33239364 ↗
L3COHORTCited in: Complications
[492]
Learmonth YC, P Herring M, Russell DI et al.. “Safety of exercise training in multiple sclerosis: An updated systematic review and meta-analysis.” Multiple sclerosis (Houndmills, Basingstoke, England) (2023). PMID: 37880997 ↗
L1SR_OBSCited in: Complications
[493]
Stefanou MI, Palaiodimou L, Theodorou A et al.. “Safety of COVID-19 vaccines in multiple sclerosis: A systematic review and meta-analysis.” Multiple sclerosis (Houndmills, Basingstoke, England) (2023). PMID: 36722184 ↗
L1SR_OBSCited in: Complications
[494]
Haghikia A, Langer-Gould A, Rellensmann G et al.. “Natalizumab use during the third trimester of pregnancy.” JAMA neurology (2014). PMID: 24821217 ↗
L4CASE_REPORTCited in: Complications, Special Populations & Pregnancy
[495]
Hession RM, Sharma V, Spiegel DE et al.. “Multiple sclerosis disease progression and paradichlorobenzene: a tale of mothballs and toilet cleaner.” JAMA neurology (2014). PMID: 24343157 ↗
L4CASE_REPORTCited in: Complications
[496]
Kalincik T, Sharmin S, Roos I et al.. “Comparative Effectiveness of Autologous Hematopoietic Stem Cell Transplant vs Fingolimod, Natalizumab, and Ocrelizumab in Highly Active Relapsing-Remitting Multiple Sclerosis.” JAMA neurology (2023). PMID: 37437240 ↗
L3OTHERCited in: Complications
[497]
Maier CM, Yu F, Nishi T et al.. “Interferon-beta fails to protect in a model of transient focal stroke.” Stroke (2006). PMID: 16514094 ↗
L5OTHERCited in: Complications, Prognosis & Natural History
[498]
Rodgers J, Friede T, Vonberg FW et al.. “The impact of smoking cessation on multiple sclerosis disease progression.” Brain : a journal of neurology (2022). PMID: 34623418 ↗
L2OTHERCited in: Complications
[499]
Kalincik T, Sharmin S, Roos I et al.. “Haematopoietic stem cell transplant versus immune-reconstitution therapy in relapsing multiple sclerosis.” Brain : a journal of neurology (2026). PMID: 40755195 ↗
L3OTHERCited in: Complications
[500]
Kingwell E, Leray E, Zhu F et al.. “Multiple sclerosis: effect of beta interferon treatment on survival.” Brain : a journal of neurology (2019). PMID: 30883636 ↗
L3OTHERCited in: Complications
[501]
Tecchio F, Zito G, Zappasodi F et al.. “Intra-cortical connectivity in multiple sclerosis: a neurophysiological approach.” Brain : a journal of neurology (2008). PMID: 18502782 ↗
L4OTHERCited in: Complications
[502]
Hurley MJ, Deacon RMJ, Chan AWE et al.. “Reversal of behavioural phenotype by the cannabinoid-like compound VSN16R in fragile X syndrome mice.” Brain : a journal of neurology (2022). PMID: 34196695 ↗
L5OTHERCited in: Complications
[503]
Scalfari A, Neuhaus A, Degenhardt A et al.. “The natural history of multiple sclerosis: a geographically based study 10: relapses and long-term disability.” Brain : a journal of neurology (2010). PMID: 20534650 ↗
L2OTHERCited in: Complications, Prevention, Screening & Surveillance
[504]
Sabel CE, Pearson JF, Mason DF et al.. “The latitude gradient for multiple sclerosis prevalence is established in the early life course.” Brain : a journal of neurology (2021). PMID: 33704407 ↗
L2OTHERCited in: Complications
[505]
Diebold M, Galli E, Kopf A et al.. “Immunological Predictors of Dimethyl Fumarate-Induced Lymphopenia.” Annals of neurology (2022). PMID: 35170072 ↗
L2OTHERCited in: Complications
[506]
Weiner HL. “The challenge of multiple sclerosis: how do we cure a chronic heterogeneous disease?” Annals of neurology (2009). PMID: 19334069 ↗
L5REVIEW_NARRATIVECited in: Complications
[507]
Khan O, Filippi M, Freedman MS et al.. “Chronic cerebrospinal venous insufficiency and multiple sclerosis.” Annals of neurology (2010). PMID: 20373339 ↗
L5OTHERCited in: Complications
[508]
Witt L, Dost-Kovalsky K, Friedmann N et al.. “Ofatumumab-exposed breastfeeding in multiple sclerosis patients.” Multiple sclerosis (Houndmills, Basingstoke, England) (2025). PMID: 39757874 ↗
L4OTHERCited in: Complications
[509]
Azeem MH, Shakeel R, Hassan D et al.. “Multimodal benefits of VR-based treadmill training in multiple sclerosis: A systematic review.” Multiple sclerosis and related disorders (2026). PMID: 42217431 ↗
L1SR_OBSCited in: Complications, Prevention, Screening & Surveillance
[510]
Avedillo-Salas A, Martínez LB, Fanlo-Villacampa A et al.. “Efficacy and safety of monoclonal antibodies in the treatment of relapsing remitting multiple sclerosis: a systematic review.” Journal of neurology (2026). PMID: 42018029 ↗
L1SR_OBSCited in: Complications
[511]
Grandidge L, Mohamed Abu Baker A, Kennish S et al.. “Suprapubic catheter insertion in people with multiple sclerosis: long-term complications and survival in a retrospective cohort study.” Journal of rehabilitation medicine (2026). PMID: 42237591 ↗
L2COHORTCited in: Complications
[512]
Njohjam MN, Ngoule MO, Niakam TF. “Biological sex differences in neurodegenerative diseases in Africa: a scoping review of evidence and research gaps.” BMC neurology (2026). PMID: 42414949 ↗
L2SR_OBSCited in: Complications
[513]
Moradi A, Ebrahimian A, Talebi M et al.. “The association between depressive symptoms and sleep quality in patients with multiple sclerosis: a systematic review and meta-analysis.” BMC neurology (2026). PMID: 42298462 ↗
L3SR_OBSCited in: Complications
[514]
Kuhle J, Pohl C, Mehling M et al.. “Lack of association between antimyelin antibodies and progression to multiple sclerosis.” The New England journal of medicine (2007). PMID: 17251533 ↗
L2RCTCited in: Prognosis & Natural History
[515]
Metz LM, Li DKB, Traboulsee AL et al.. “Trial of Minocycline in a Clinically Isolated Syndrome of Multiple Sclerosis.” The New England journal of medicine (2017). PMID: 28564557 ↗
L1RCTCited in: Prognosis & Natural History
[516]
Bovis F, Signori A, Carmisciano L et al.. “Expanded disability status scale progression assessment heterogeneity in multiple sclerosis according to geographical areas.” Annals of neurology (2018). PMID: 30179270 ↗
L2SR_OBSCited in: Prognosis & Natural History
[517]
Lublin FD, Reingold SC, Cohen JA et al.. “Defining the clinical course of multiple sclerosis: the 2013 revisions.” Neurology (2014). PMID: 24871874 ↗
L5OTHERCited in: Prognosis & Natural History
[518]
Neyal N, Nathoo N, Cathcart-Rake EJ et al.. “Gender-affirming interventions and prognosis in multiple sclerosis.” Multiple sclerosis (Houndmills, Basingstoke, England) (2025). PMID: 40462266 ↗
L4OTHERCited in: Prognosis & Natural History
[519]
Gafson A, Craner MJ, Matthews PM. “Personalised medicine for multiple sclerosis care.” Multiple sclerosis (Houndmills, Basingstoke, England) (2016). PMID: 27672137 ↗
L5REVIEW_NARRATIVECited in: Prognosis & Natural History
[520]
Leaviss J, Booth A, Coyle D et al.. “Effectiveness of non-pharmacological interventions for fatigue in adults with long-term conditions: a synopsis of the EIFFEL mixed-methods evidence synthesis.” Health technology assessment (Winchester, England) (2026). PMID: 42366788 ↗
L2SR_OBSCited in: Prognosis & Natural History
[521]
Voskuhl RR, Wang H, Wu TC et al.. “Estriol combined with glatiramer acetate for women with relapsing-remitting multiple sclerosis: a randomised, placebo-controlled, phase 2 trial.” The Lancet. Neurology (2015). PMID: 26621682 ↗
L1RCTCited in: Special Populations & Pregnancy
[522]
Goyne C, Fair AE, Yilmaz D et al.. “Epigenetic Aging in Pediatric-Onset Multiple Sclerosis.” Neurology (2025). PMID: 40460354 ↗
L2OTHERCited in: Special Populations & Pregnancy
[523]
Gavoille A, Rollot F, Casey R et al.. “Therapeutic Management During Pregnancy and Relapse Risk in Women With Multiple Sclerosis.” JAMA neurology (2025). PMID: 40758347 ↗
L2OTHERCited in: Special Populations & Pregnancy
[524]
McKay KA, Friberg E, Razaz N et al.. “Long-term Socioeconomic Outcomes Associated With Pediatric-Onset Multiple Sclerosis.” JAMA neurology (2021). PMID: 33616605 ↗
L2OTHERCited in: Special Populations & Pregnancy
[525]
Benallegue N, Rollot F, Wiertlewski S et al.. “Highly Effective Therapies as First-Line Treatment for Pediatric-Onset Multiple Sclerosis.” JAMA neurology (2024). PMID: 38345791 ↗
L2OTHERCited in: Special Populations & Pregnancy
[526]
Mexhitaj I, Nyirenda MH, Li R et al.. “Abnormal effector and regulatory T cell subsets in paediatric-onset multiple sclerosis.” Brain : a journal of neurology (2019). PMID: 30759186 ↗
L3OTHERCited in: Special Populations & Pregnancy
[527]
Eissman JM, Dumitrescu L, Mahoney ER et al.. “Sex differences in the genetic architecture of cognitive resilience to Alzheimer's disease.” Brain : a journal of neurology (2022). PMID: 35552371 ↗
L3OTHERCited in: Special Populations & Pregnancy
[528]
Gaitsch H, Franklin RJM, Reich DS. “Cell-free DNA-based liquid biopsies in neurology.” Brain : a journal of neurology (2023). PMID: 36408894 ↗
L5REVIEW_NARRATIVECited in: Special Populations & Pregnancy
[529]
Hay CM, Mahjoub A, Vidarsson L et al.. “Retinal hyper-reflective foci link retinal and cortical pathology in paediatric multiple sclerosis.” Brain : a journal of neurology (2026). PMID: 42381479 ↗
L4OTHERCited in: Special Populations & Pregnancy
[530]
Kadowaki A, Saga R, Lin Y et al.. “Gut microbiota-dependent CCR9+CD4+ T cells are altered in secondary progressive multiple sclerosis.” Brain : a journal of neurology (2019). PMID: 30770703 ↗
L3OTHERCited in: Special Populations & Pregnancy
[531]
Margoni M, Storelli L, Pagani E et al.. “Subventricular Zone Microstructure in Pediatric-Onset Multiple Sclerosis.” Annals of neurology (2025). PMID: 39825739 ↗
L4OTHERCited in: Special Populations & Pregnancy
[532]
de Mol CL, Jansen PR, Muetzel RL et al.. “Polygenic Multiple Sclerosis Risk and Population-Based Childhood Brain Imaging.” Annals of neurology (2020). PMID: 32162725 ↗
L4OTHERCited in: Special Populations & Pregnancy
[533]
Munger KL, Hongell K, Cortese M et al.. “Epstein-barr virus and multiple sclerosis risk in the finnish maternity cohort.” Annals of neurology (2019). PMID: 31226219 ↗
L3OTHERCited in: Special Populations & Pregnancy
[534]
De Meo E, Bonacchi R, Moiola L et al.. “Early Predictors of 9-Year Disability in Pediatric Multiple Sclerosis.” Annals of neurology (2021). PMID: 33598931 ↗
L2OTHERCited in: Special Populations & Pregnancy
[535]
Fadda G, Banwell B, Elliott C et al.. “Slowly Expanding Lesions Differentiate Pediatric Multiple Sclerosis from Myelin Oligodendrocyte Glycoprotein Antibody Disease.” Annals of neurology (2024). PMID: 39243229 ↗
L3OTHERCited in: Special Populations & Pregnancy
[536]
Yam C, Jokubaitis V, Hellwig K et al.. “MS, pregnancy and COVID-19.” Multiple sclerosis (Houndmills, Basingstoke, England) (2020). PMID: 32924838 ↗
L5REVIEW_NARRATIVECited in: Special Populations & Pregnancy
[537]
Proschmann U, Thomas K, Thiel S et al.. “Natalizumab during pregnancy and lactation.” Multiple sclerosis (Houndmills, Basingstoke, England) (2017). PMID: 28857686 ↗
L4OTHERCited in: Special Populations & Pregnancy
[538]
Szaflik P, Nowakowska-Lipiec K. “Instrumented Timed Up and Go (iTUG): A Systematic Review of Parameters Across Healthy, Older, and Neurological Populations.” Journal of clinical medicine (2026). PMID: 42123041 ↗
L5SR_OBSCited in: Special Populations & Pregnancy
[539]
Buijze MSJ, de Mol CL, Loudon SE et al.. “A systematic review of the clinical utility of retinal optical coherence tomography in childhood acquired demyelinating syndromes.” Multiple sclerosis and related disorders (2026). PMID: 42048775 ↗
L1SR_OBSCited in: Special Populations & Pregnancy
[540]
Ebne-Ali-Heydari Y, Ramezani A, Jozayi A et al.. “Natalizumab for pediatric multiple sclerosis: a systematic review and meta-analysis.” Therapeutic advances in neurological disorders (2026). PMID: 42027697 ↗
L1SR_OBSCited in: Special Populations & Pregnancy
[541]
Najibi A, Bazmi S, Moradi M et al.. “Association between hypertension status and severity and tinnitus: a cross-sectional analysis of the Fasa adult cohort study.” BMJ open (2026). PMID: 42259562 ↗
L4COHORTCited in: Special Populations & Pregnancy, Prevention, Screening & Surveillance
[542]
Amini F, Everett K, Zhu F et al.. “Phenotyping healthcare use before pediatric-onset multiple sclerosis, including by sex and age: A matched cohort study.” Multiple sclerosis (Houndmills, Basingstoke, England) (2026). PMID: 42175615 ↗
L2COHORTCited in: Special Populations & Pregnancy
[543]
Chitnis T, Banwell B, Kappos L et al.. “Safety and efficacy of teriflunomide in paediatric multiple sclerosis (TERIKIDS): a multicentre, double-blind, phase 3, randomised, placebo-controlled trial.” The Lancet. Neurology (2021). PMID: 34800398 ↗
L1RCTCited in: Prevention, Screening & Surveillance
[544]
Zamboni P, Tesio L, Galimberti S et al.. “Efficacy and Safety of Extracranial Vein Angioplasty in Multiple Sclerosis: A Randomized Clinical Trial.” JAMA neurology (2018). PMID: 29150995 ↗
L1RCTCited in: Prevention, Screening & Surveillance
[545]
Comi G, Pulizzi A, Rovaris M et al.. “Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study.” Lancet (London, England) (2008). PMID: 18572078 ↗
L1RCTCited in: Prevention, Screening & Surveillance
[546]
Koch MW, Sage K, Kaur S et al.. “Repurposing Domperidone in Secondary Progressive Multiple Sclerosis: A Simon 2-Stage Phase 2 Futility Trial.” Neurology (2021). PMID: 34038379 ↗
L4TRIAL_NONRANDOMCited in: Prevention, Screening & Surveillance
[547]
Moreno B, Hevia H, Santamaria M et al.. “Methylthioadenosine reverses brain autoimmune disease.” Annals of neurology (2006). PMID: 16786535 ↗
L4RCTCited in: Prevention, Screening & Surveillance
[548]
Khan O, Rieckmann P, Boyko A et al.. “Three times weekly glatiramer acetate in relapsing-remitting multiple sclerosis.” Annals of neurology (2013). PMID: 23686821 ↗
L1RCTCited in: Prevention, Screening & Surveillance
[549]
Comi G, Cohen JA, Arnold DL et al.. “Phase III dose-comparison study of glatiramer acetate for multiple sclerosis.” Annals of neurology (2011). PMID: 21280077 ↗
L1RCTCited in: Prevention, Screening & Surveillance
[550]
Hernán MA, Alonso A, Hernández-Díaz S. “Tetanus vaccination and risk of multiple sclerosis: a systematic review.” Neurology (2006). PMID: 16864810 ↗
L3SR_OBSCited in: Prevention, Screening & Surveillance
[551]
Muraro PA, Zito A, Signori A et al.. “Effectiveness of Autologous Hematopoietic Stem Cell Transplantation versus Alemtuzumab and Ocrelizumab in Relapsing Multiple Sclerosis: A Single Center Cohort Study.” Annals of neurology (2025). PMID: 40251896 ↗
L2COHORTCited in: Prevention, Screening & Surveillance
[552]
Lubetzki C, Zalc B, Williams A et al.. “Remyelination in multiple sclerosis: from basic science to clinical translation.” The Lancet. Neurology (2020). PMID: 32702337 ↗
L5REVIEW_NARRATIVECited in: Prevention, Screening & Surveillance
[553]
Handunnetthi L, Ramagopalan SV, Ebers GC. “Multiple sclerosis, vitamin D, and HLA-DRB1*15.” Neurology (2010). PMID: 20530326 ↗
L5REVIEW_NARRATIVECited in: Prevention, Screening & Surveillance
[554]
Wang Y, Liang J, Fang Y et al.. “Burden of Common Neurologic Diseases in Asian Countries, 1990-2019: An Analysis for the Global Burden of Disease Study 2019.” Neurology (2023). PMID: 37015823 ↗
L2OTHERCited in: Prevention, Screening & Surveillance
[555]
Marriott JJ, Miyasaki JM, Gronseth G et al.. “Evidence Report: The efficacy and safety of mitoxantrone (Novantrone) in the treatment of multiple sclerosis [RETIRED]: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.” Neurology (2010). PMID: 20439849 ↗
L1REVIEW_NARRATIVECited in: Prevention, Screening & Surveillance
[556]
Jain N, Bhatti MT. “Fingolimod-associated macular edema: incidence, detection, and management.” Neurology (2012). PMID: 22371414 ↗
L5REVIEW_NARRATIVECited in: Prevention, Screening & Surveillance
[557]
Solomon AJ, Naismith RT, Cross AH. “Misdiagnosis of multiple sclerosis: Impact of the 2017 McDonald criteria on clinical practice.” Neurology (2018). PMID: 30381369 ↗
L5REVIEW_NARRATIVECited in: Prevention, Screening & Surveillance
[558]
Grimaldi L, Papeix C, Hamon Y et al.. “Vaccines and the Risk of Hospitalization for Multiple Sclerosis Flare-Ups.” JAMA neurology (2023). PMID: 37669073 ↗
L3OTHERCited in: Prevention, Screening & Surveillance
[559]
Brandt AU, Sy M, Bellmann-Strobl J et al.. “Association of a Marker of N-Acetylglucosamine With Progressive Multiple Sclerosis and Neurodegeneration.” JAMA neurology (2021). PMID: 33970182 ↗
L4OTHERCited in: Prevention, Screening & Surveillance
[560]
Langer-Gould A, Qian L, Tartof SY et al.. “Vaccines and the risk of multiple sclerosis and other central nervous system demyelinating diseases.” JAMA neurology (2014). PMID: 25329096 ↗
L3OTHERCited in: Prevention, Screening & Surveillance
[561]
Alsaid HM, Mohammed SS, Fayez ES et al.. “Effect of brain gym on cognition, manual dexterity and bimanual co-ordination in patients with multiple sclerosis.” Multiple sclerosis and related disorders (2026). PMID: 42202496 ↗
L4RCTCited in: Prevention, Screening & Surveillance
[562]
Bittner S, Oh J, Havrdová EK et al.. “The potential of serum neurofilament as biomarker for multiple sclerosis.” Brain : a journal of neurology (2021). PMID: 34180982 ↗
L5REVIEW_NARRATIVECited in: Prevention, Screening & Surveillance
[563]
Arlt FA, Miske R, Appeltshauser L et al.. “Septin multimer autoantibodies in severe motor neuropathy mimicking lower motor neuron disease.” Brain : a journal of neurology (2026). PMID: 42252093 ↗
L3OTHERCited in: Prevention, Screening & Surveillance
[564]
Wentling M, Lopez-Gomez C, Park HJ et al.. “A metabolic perspective on CSF-mediated neurodegeneration in multiple sclerosis.” Brain : a journal of neurology (2019). PMID: 31305892 ↗
L5OTHERCited in: Prevention, Screening & Surveillance
[565]
Sabatino JJ, Cree BAC, Hauser SL. “New Horizons for Multiple Sclerosis Therapy: 2025 and Beyond.” Annals of neurology (2025). PMID: 40474602 ↗
L5REVIEW_NARRATIVECited in: Prevention, Screening & Surveillance
[566]
. “Corrigendum.” Multiple sclerosis (Houndmills, Basingstoke, England) (2011). PMID: 22194215 ↗
L5OTHERCited in: Prevention, Screening & Surveillance
[567]
Cohen M, Thomel-Rocchi O, Siva A et al.. “Impact of COVID-19 vaccination or infection on disease activity in a radiologically isolated syndrome cohort: The VaxiRIS study.” Multiple sclerosis (Houndmills, Basingstoke, England) (2023). PMID: 37322880 ↗
L2OTHERCited in: Prevention, Screening & Surveillance
[568]
Tamondong-Lachica DR, Villanueva CAG, Roxas-Timonera M et al.. “Philippine Clinical Practice Guidelines for Periodic Health Examination: Lifestyle Interventions for Adults and Adolescents.” Acta medica Philippina (2026). PMID: 42382939 ↗
L5GUIDELINECited in: Prevention, Screening & Surveillance

Quick Reference

Overview and Recommendations

Background

Evaluation

Management

Board Review — High Yield

Deep Dive — Evidence Details

Definition, Classification & Nomenclature

Disease Phases and Stages

Classification of MS Types

Clinical Significance

Pathophysiology & Mechanism (Neuroanatomic Localization)

The Immune Cascade: From Periphery to CNS

Neuroanatomic Localization of Injury

Accelerated Aging and Cellular Senescence

Epidemiology, Etiology & Risk Factors

Established Risk Factors

Negative and Protective Factors

Special Populations

Clinical Presentation

Presenting Symptoms

Neurological Examination Findings

Phenotypic Variants

Red Flags

Atypical Presentations

Diagnosis & Workup (Neuroimaging, CSF, Evoked Potentials)

MRI Protocol and Lesion Criteria

Cerebrospinal Fluid Analysis

Evoked Potentials and Optical Coherence Tomography

Diagnostic Algorithm

Differential Diagnosis

Controversies and Guideline Disagreement

Severity, Staging & Risk Stratification

Progression Independent of Relapse Activity (PIRA)

Serum Biomarkers: sNfL and sGFAP

Imaging and Genetic Risk Factors

Composite Stratification and Treatment Thresholds

Acute Management: Neurologic Emergencies & Attack Abortion

Step 1: Triage and Classification of the Acute Event

Step 2: First-Line Attack Abortion, High-Dose Corticosteroids

Step 3: Second-Line Therapy, Plasma Exchange for Severe or Steroid-Refractory Attacks

Step 4: Escalation for Aggressive and Atypical Syndromes

Step 5: Transition to Maintenance Therapy

What NOT to Do

Controversies and Guideline Disagreement

Long-term & Definitive Management (Evidence Ladder)

Step 1: Risk Stratification and Treatment Goal

Step 2: First-Line DMT Selection - Early High-Efficacy vs Escalation

Step 3: Selecting Therapy by MS Subtype

Step 4: Monitoring, Switching, and Treatment Failure

Step 5: Discontinuation of DMT in Older, Stable Patients

Symptomatic and Adjunctive Therapies

Controversies and Guideline Disagreement

History and Evolution of Treatment

The Pre-DMT Era and Natural History

First Generation: Interferons and Glatiramer Acetate (1990s)

Second Generation: Natalizumab, Oral Therapies, and Induction (2000s)

Third Generation: Anti-CD20 Therapies (2010s)

Targeting Progressive MS: Siponimod, Tolebrutinib, and Failed Candidates

Emerging and Investigational Therapies

Lessons on De-escalation and Personalization

Disease-Modifying & Immunotherapy Program: Sequencing, Safety Monitoring & De-escalation

Step 1: Initial Treatment Selection, Early High-Efficacy vs Escalation

Step 2: Safety Monitoring Before and During Therapy

Step 3: Switching and Escalation for Breakthrough Disease

Step 4: De-escalation and Discontinuation

Controversies and Guideline Disagreement

Neurorehabilitation, Symptomatic & Supportive Care

Symptomatic Pharmacotherapy

Rehabilitation: Exercise, Physical Therapy, and Virtual Reality

Cognitive Rehabilitation and Screening

Psychosocial Support and Mood

Sexual Dysfunction

Complications

Respiratory Complications

Autonomic Dysfunction

Venous Thromboembolism Prophylaxis

Pain Management

Falls and Fractures

Pain